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1. Bipolar disorder 
Bipolar disorder (BD) is a chronic mental illness that affects 1%-3% of the global 
population and is one of the major causes of disability worldwide (Goodwin and 
Jamison, 2007). It is characterized by recurrent episodes of depression and mania or 
hypomania (Abrial et al., 2015). BD can be mainly subdivided into BD-I and BD-II, in 
which BD-I is characterized by episodes of mania and depression and BD-II is 
characterized by episodes of hypomania and depression. The manic episodes in BD-
I are periods of abnormally and persistently elevated, expansive, or irritable mood and 
increased goal-directed activity or energy. The same applies for hypomania in BD-II. 
However, the manic episode lasts at least one week and is present most of the day, 
nearly every day, while the hypomanic episode lasts at least four consecutive days 
and is present most of the day, nearly every day. Three (or more) of the following 
symptoms are present to a significant degree and denote a noticeable change from 
usual behavior in both mania and hypomania: inflated self-esteem or grandiosity; 
decreased need for sleep; talkativeness or pressure to keep talking; flight of ideas; 
distractibility; increase in goal-directed activity or psychomotor agitation; excessive 
involvement in activities that have a high potential for painful consequences. However, 
in hypomania, the episode is not severe enough to cause significant impairment in 
social or occupational functioning or to necessitate hospitalization (American 
Psychiatry Association, 2013).  
The major depressive episodes present in BD-I or BD-II consist of five (or more) 
of the following symptoms present for a two-week period with changes in normal 
functioning (and at least one of the symptoms must be depressed mood or loss of 
interest/pleasure (anhedonia)): depressed mood most of the day, nearly every day; 
markedly diminished interest or pleasure in all, or almost all, activities most of the day, 
nearly every day; significant weight loss or weight gain; insomnia or hypersomnia 
nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss 
of energy; feelings of worthlessness or excessive or inappropriate guilt; diminished 
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ability to think or concentrate, or indecisiveness; recurrent thoughts of death or 
recurrent suicidal ideation (American Psychiatry Association, 2013). 
Other forms of BD include: cyclothymic disorder, which is a chronic, fluctuating 
mood disturbance with many periods of hypomanic and depressive symptoms, for at 
least two years; mixed episodes, in which mania or hypomanic episodes occur with 
depressive features; substance/medication-induced BD, when induced by substances 
such as alcohol or psychostimulants, such as amphetamine; other specified BD, when 
full criteria for other subtypes of BD are not met; rapid cycling, in which there are, at 
least, four mood episodes in the previous twelve months; and BD with psychotic 
features, consisting of delusions or hallucinations that are present at any time in the 
episodes (American Psychiatry Association, 2013). 
According to Nivoli (2011) and Judd et al. (2008), bipolar patients spend 
approximately 2/3 of their lives in depressed mood and 1/3 in other types of mood 
(manic, hypomanic or euthymic). Thus, greater attention is directed towards the 
depressive stages of the disorder and not so much towards the manic phase. 
However, just as the depressive symptoms, the manic symptoms also affect 
significantly the well-being of patients and are associated to several social and 
personal losses, significant distress or impairment in social and occupational 
functioning (American Psychiatry Association, 2013; Müller-Oerlinghausen et al., 
2002). Suicidal behavior is frequent in patients with BD, as between 20 and 60% of 
them attempt suicide at least once in their lifetime, and between 4 and 19% of them 
end up committing suicide (Dome et al., 2019). In BD, the risk of death by suicide can 
be 30% higher than of the general population (Bauer et al., 2018). In addition, although 
there are several drugs for the treatment of the depressive stages, there are fewer 
pharmacological options for the management of the manic phases, which show many 
limitations regarding their clinical use, such as intolerance to several side effects or 
refractoriness to treatment (Cipriani et al., 2011; Keck, 2003). Also, even when the 
treatment strategies are adequate, the course of BD involves high rates of recurrent 
manic and depressive episodes, relapses and hospitalizations (Souza, 2011) and 
even with the remission of mood swings, subsyndromal symptoms can still persist in 
a large number of patients (Knapp and Isolan, 2005). The great number of side effects 
results in low medication adherence (Castro-Costa e Silva, 2011; Miklowitz and 
Johnson, 2006; Sajatovic et al., 2004), which contributes to medication nonresponse 
(Osterberg and Blaschke, 2005), increases in relapses (Gutiérrez-Rojas et al., 2010), 
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suicide and suicide attempts (Pompili et al., 2009), hospitalizations (Hong et al., 2011) 
and involvement with criminal justice (Robertson et al., 2014). 
Among the main pharmacological treatments available for the treatment of BD, 
mood stabilizers such as lithium and sodium valproate are the main ones (Chiu et al., 
2013; Miklowitz and Johnson, 2006). Antipsychotics such as risperidone, olanzapine, 
quetiapine, lurasidone, ziprasidone, paliperidone, asenapine, clozapine and 
aripiprazole, and anticonvulsants such as lamotrigine, carbamazepine and 
oxcarbazepine, have also been approved for the treatment of BD, also in combination 
with antidepressants (Bai et al., 2019; Bauer et al., 2019). Antipsychotics act on 
dopamine and serotonin receptors. Second-generation (atypical) antipsychotics have 
less affinity to D2 receptors than first-generation antipsychotics, and more affinity to 5-
HT2A receptors (Jauhar and Young, 2019). An advantage of second-generation 
antipsychotics is the decreased propensity of causing movement disorders in 
comparison to first-generation antipsychotics (Carbon et al., 2017). The main adverse 
effects involved in the use of antipsychotics are extrapyramidal symptoms, weight 
gain, effects on glucose metabolism, sedation and sexual dysfunction (Young et al., 
2015). Antidepressant monotherapy for acute bipolar depression is not recommended 
due to the possibility of manic switch or induction of rapid cycling (Bauer et al., 2012). 
Thus, antidepressants (such as tricyclics or serotonin/norepineprhine reuptake 
inhibitors) are combined with mood stabilizers (lithium or anticonvulsants) or 
antipsychotics for the management of BD (Bauer et al., 2012; Malhi et al., 2012).   
The biochemical abnormalities underlying the pathophysiology of this disorder 
remain to be fully elucidated (Szabo et al., 2009). However, as will be discussed below, 
studies indicate in particular the involvement of increased brain oxidative stress, as 
well as increased activity of the enzymes glycogen synthase kinase 3β (GSK3β) and 
protein kinase C (PKC) in the pathophysiology of BD. 
 
2. Oxidative stress 
Studies show that among many other factors, increased oxidative stress is 
involved in the pathophysiology of BD, as there is increased production of free radicals 
and depletion of antioxidant enzymes and molecules in BD (Berk et al., 2011). One of 
the main processes involved in the generation of free radicals, reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) is oxidative phosphorylation. Among the 
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ROS, the most relevant are the singlet oxygen (1O2), hydrogen peroxide (H2O2), ozone 
(O3), hypochlorous acid (HOCl) and the free radicals superoxide anion (O2-) and the 
hydroxyl radical (OH-). Some examples of RNS are nitric oxide (NO) and the free 
radical peroxynitrite (ONOO-) (Kohen and Nyska, 2002). ROS and RNS are capable 
of reacting with practically every biomolecule, including DNA, RNA, proteins, 
carbohydrates and lipids, causing damage to these molecules (Diplock et al., 1998). 
The endogenous antioxidant defense system protects the cells from damage caused 
by free radicals, ROS and RNS. One of the most important antioxidant molecules in 
the prevention of oxidative damage is reduced glutathione (GSH), which is able to 
reduce proteins with oxidated sulphydryl groups and to also reduce the levels of O2- 
and H2O2, with the co-activity of other enzymes, such as glutathione peroxidase (GPx), 
glutathione reductase (GR), glutathione-S-transferase (GST) and catalase (CAT) 
(Rosa et al., 2014). Studies show that there are alterations in the levels of antioxidant 
enzymes in mania and BD. The GR and GST activities are increased in BD patients 
in late stages, when compared to BD patients in early stages (Andreazza et al., 2009). 
Studies demonstrate the consistent increase in lipid peroxidation (LPO) by free 
radicals and ROS and alterations in the levels of antioxidant enzymes in BD patients, 
independently of their stage (Berk et al., 2011; Andreazza et al., 2007; Machado-Vieira 
et al., 2007; Ozcan et al., 2004).  
 Brüning et al. (2012), in an animal model of mania, demonstrated the positive 
correlation between hyperlocomotion and increased LPO levels in rats. Valvassori et 
al. (2020) showed that intracerebroventricular (i.v) injection of lithium, tamoxifen or 
other drugs which can inhibit PKC prevented manic-like behaviors, such as crossings, 
rearings and groomings in the open-field test, induced by intraperitoneal (i.p.) 
administration of methamphetamine, a model of mania, in rats. In addition, these drugs 
also prevented methamphetamine-induced oxidative stress, by regulating oxidative 
parameters such as GPx, GR, 4-hydroxy-2-nonenal (4-HNE), 8-isoprostane (8-ISO), 
carbonyl groups and 3-nitrotyrosine (3-NT) levels in the frontal cortex, hippocampus 
and striatum of rats.  
 
3. GSK3β, p-GSK3β and PKC 
Pathways in which the enzyme GSK3β acts as a key regulator have been 
implicated in the development of many psychiatric diseases, including BD and that an 
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increase in GSK3β activity is linked to the occurrence of manic-like behaviors in 
animals (Prickaerts et al., 2006; Gould et al., 2004a).  
The enzyme GSK3 is a serine/threonine kinase that regulates various signaling 
pathways (Prickaerts et al., 2006), including metabolic, signaling and structural 
proteins related to the modulation of G-coupled-, hormone- and ionotropic receptors 
and receptor trafficking (Beurel et al., 2016; Enman and Unterwald, 2012). GSK3 has 
two isoforms: GSK3 and GSK3β, which are serine/threonine kinases associated with 
regulation of glycogen synthesis in response to insulin (Dandekar et al., 2018; Frame 
and Cohen, 2001). It is well documented that GSK3β is generally pro-apoptotic (Rowe 
et al., 2007). GSK3β phosphorylates over 100 substrates and regulates multiple 
signaling pathways, involved in several cellular processes, such as gene expression, 
neurogenesis, neuronal death or survival and circadian rhythms (Jope and Roh, 2006). 
Impaired neurogenesis and neuronal plasticity are suggested to be crucial 
mechanisms in mood disorders and GSK3β is known to regulate both processes in 
the brain (Li and Jope, 2010). 
GSK3β is a component of the Wnt signaling pathway, which is essential for 
embryonic development and also plays important roles in protein synthesis, cell 
proliferation and differentiation, microtubule dynamics and cell adhesion, for example 
(Frame and Cohen, 2001). GSK3β forms part of a β-catenin destruction complex that 
phosphorylates and thus facilitates the degradation of β-catenin, which is a protein 
related to the transcription of anti-apoptotic proteins (Serrano et al., 2014). In the 
absence of Wnt ligands, GSK3β, the transcriptional co-activator β-catenin and the 
tumor suppressor adenomatous polyposis coli (APC) bind directly to the scaffolding 
protein Axin in a complex that facilitates phosphorylation of β-catenin by GSK3β, which 
targets β-catenin for proteasome-dependent degradation (Valvezan and Klein, 2012). 
The pathway is activated by the binding of Wnt to a Frizzled family receptor, which 
passes the biological signal to the Dishevelled protein inside the cell (Zhang et al., 
2010), inducing phosphorylation of the essential co-receptors low density lipoprotein 
receptor-related protein 5 (LRP5) and LRP6, which results in GSK3β inhibition and β-
catenin stabilization, which is prevented from degradation and accumulates in the 
cytoplasm and nucleus. Stabilized β-catenin enters the nucleus and interacts with the 
lymphocyte enhancer factor/T-cell factor (LEF/TCF) family of transcription factors to 
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activate gene transcription (Valvezan and Klein, 2012; MacDonald et al., 2009; 
Clevers, 2006).  
 Evidence from pharmacological interventions and genetic models suggest the 
involvement of GSK3β in BD. For example, GSK3β knockout or GSK3β inhibitor-
treated mice exhibited antidepressive- and antimanic-like behaviors, which suggests 
that GSK3β inhibition may be involved in the mechanism of mood-improving therapies 
(Gould et al., 2004b; O’Brien et al., 2004). Prickaerts et al. (2006) suggested that the 
use of transgenic mice with overexpression of GSK3β may be an animal model of 
mania, as these animals show manic-like behaviors, such as hyperlocomotion.  
Lithium, the prototype mood stabilizer is both a direct and indirect inhibitor of 
GSK3β (Cole, 2013). In rat models of mania, specific GSK3β inhibitors reproduce 
behaviors mimicking the effects of lithium. Overexpression of GSK3β annuls the 
ameliorative behavioral effects caused by lithium treatment in mice. Polymorphisms in 
the GSK3β promoter region, in humans, are linked to earlier age of onset of BD, and 
therapeutic sensitivity to lithium (Polter et al., 2010). GSK3β is linked both to manic-
like and depressive-like behaviors, and serine-9 (Ser9) phosphorylation of GSK3β is 
the major regulatory mechanism inhibiting GSK3β (Polter et al., 2010). 
The phosphorylation of GSK3 at an N-terminal serine residue (Ser21 at the -
isoform and Ser9 at the β-isoform) creates a pseudosubstrate motif that inhibits GSK-
3, allowing activation of downstream effectors such as glycogen synthase and mTOR 
(Proud, 2006). Of note, Ser9-inhibition is on a pool of free GSK-3 that is not related to 
the Dishevelled/β-catenin complex. Proteins capable of phosphorylating GSK3β are 
widespread and include, for the Ser9 site, protein kinase A (PKA) and protein kinase 
B (Akt) (Rowe et al., 2007). Disabling the inhibitory serine-phosphorylation of GSK3β 
can promote manic-like behavioral disturbances in animals, and serine-
phosphorylation of GSK3β is reduced during manic states in animals and bipolar 
patients (Polter et al., 2010). 
One of the actions of the mood stabilizer lithium is to inhibit GSK3β activity by 
either directly competitively inhibiting Mg2+ binding to the active site of the enzyme 
(Ryves and Harwood, 2001) or indirectly by stimulating the phosphoinositide 3-kinase 
(PI3K)/Akt pathway and enhancing phosphorylation of GSK3β at Ser9 residues (Chiu 
et al., 2013; Kitagishi, 2012), which is associated with inhibition of GSK3β activity, and 
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this action is shared by agents such as valproate and antipsychotic drugs (Kozlovsky 
et al., 2006; DeSarno et al., 2002; Chalecka-Franaszek and Chuang, 1999).  
Manic bipolar patients show higher levels of GSK3β compared to healthy 
controls (Li and Jope, 2010). Inhibitory serine-phosphorylation of GSK3β is lower in 
peripheral blood mononuclear cells of symptomatic bipolar cases as compared to 
healthy controls (Polter et al., 2010). Transgenic mice overexpressing GSK3β by 
substituting alanine by serine at position 9 show increased locomotor activity, 
modeling mania-like behavior (Polter et al., 2010). The 
phosphorylated/unphosphorylated GSK3β ratio (p-Ser9-GSK3β/GSK3β ratio) can be 
an index of GSK3β activity and can correlate with behavioral aspects (Grabinski and 
Kanaan, 2016; De Sousa et al., 2015). 
Another enzyme involved in the pathophysiology of BD is PKC. PKC is a family 
of, at least, 10 serine/threonine kinases, subdivided in three subfamilies, namely 
conventional (or classical) PKC (cPKC: , I, II, ; regulated by phospholipids, 
calcium ions and diacylglycerol (DAG)), novel PKC (nPKC: , , , ; regulated by 
phospholipids and DAG), and atypical PKC (aPKC: , , ; regulated by phospholipids 
but not by calcium ions or DAG), that are involved in intracellular signaling pathways 
(Saxena et al., 2017; Way et al., 2000). The activation of a variety of subtypes of Gq-
coupled receptors stimulates phospholipase C (PLC), which, when activated, 
catalyzes the conversion of phosphatidylinositol 4,5-biphosphate (PIP2) in two second 
messengers: triphosphate inositol (IP3) and DAG. IP3 stimulates the mobilization of 
intracellular calcium ions, whereas DAG activates PKC (Manji et al., 2001). Once 
activated, PKC migrates from the cytosol to the cellular membrane, as the enzyme 
bound to the membrane represents the active form of the enzyme, which is capable 
of phosphorylating its substrates properly (Parker and Murray-Rust, 2004). 
PKC can be found in different cell types in different organs and its activity is 
related to the type of receptor activated and the cell type involved (Parker and Murray-
Rust, 2004). PKC is highly expressed in the central nervous system (CNS) and most 
isoforms of PKC can be found in different brain areas, such as the hippocampus and 
the prefrontal cortex (PFC), and are involved in mood regulation (Abrial et al., 2011; 
Wetsel et al., 1992). PKC signaling is involved in processes that are altered in BD, 
such as neuroinflammation (Suganthy et al., 2016), oxidative stress (Hadley et al., 
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2014), neuronal excitability (Pahl et al., 2014) and apoptotic pathway activation (Nam 
et al., 2015). 
Studies show that manic patients have a higher membrane:cytosol PKC ratio in 
platelets, which is normalized after treatment with lithium (Friedman et al., 1993). Post-
mortem studies show that there is increased expression, activity and translocation of 
PKC and PKC in the brains of bipolar patients, when compared to control individuals, 
with no psychiatric disorders (Wang and Friedman, 1996). Drugs used in the 
therapeutic management of BD, such as lithium and valproate, are capable of 
regulating PKC activity. Manji and Lenox (1999) showed that chronic (but not acute) 
treatment with lithium leads to an isoform-selective reduction of PKC and PKC in 
the PFC and hippocampus, with no significant alterations in the    or  isoforms. 
Both acute and chronic administration of amphetamine induces increased PKC activity 
and increased membrane:cytosol ratio, and increased growth associated protein-43 
(GAP-43) phosphorylation, a substrate of PKC, leading to long term alterations in 
neurotransmission, which are linked to manic-like behavior (Einat et al., 2007). Chronic 
lithium administration was shown to decrease the levels of both cytosolic and 
membrane-bound PKC in platelets of BD patients (Soares et al., 2000). 
 
4. Lithium 
Lithium has been the cornerstone of maintenance treatment in BD since the 
1960s (Jauhar and Young, 2019). Lithium regulates cell membrane transport, ion 
distribution and neurotransmitter regulation, as it inhibits excitatory neurotransmission 
by decreasing dopaminergic neurotransmission; and through its modulation of 
glutamatergic neurotransmission by downregulating NMDA receptors. Lithium 
regulates intracellular signaling and enzymes such as GSK3β, with inhibition of Akt 
phosphorylation and activation of neuroprotective pathways (Alda et al., 2015). Lithium 
inhibits GSK3β by regulating its inhibitory phosphorylation at Ser9 residues (Malhi et 
al., 2013). GSK3β is activated under conditions of chronic stress, such as excessive 
dopaminergic neurotransmission during mania and has been shown to cause 
hyperactivity in animals (Prickaerts et al., 2006; Beaulieu et al., 2004). Lithium 
treatment antagonizes the development of dopamine-dependent locomotor behaviors 
in rodents by interfering with the regulation of Akt-GSK3β signaling pathway by D2 
receptors (Beaulieu et al., 2009). These results might indicate that the inactivation of 
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GSK3β could be one mechanism for the therapeutic response of lithium in BD patients 
(Dandekar et al., 2018). 
 Lithium also inhibits PKC by interfering with the phosphoinositol cycle (Malhi et 
al., 2013). After Gq-coupled receptor stimulation, PLC mediates the hydrolysis of PIP2 
to the secondary messengers DAG and IP3. Inositol monophosphatase (IMPase) and 
inositol polyphosphate phosphatase (IPPase) facilitate the recycling of IP3 back into 
myoinositol, which allows the phosphoinositol cycle to continue. Lithium inhibits the 
phosphoinositol cycle, as it inhibits the reuptake of inositol, and by direct inhibition of 
IMPase and IPPase. Therefore, with lithium-induced depletion of IP3, there is less 
activation of PKC (Malhi et al., 2013). Lithium also directly inhibits MARCKS, a 
downstream target of PKC, that is responsible for neurotransmitter release (Machado-
Vieira et al., 2009). 
However, treatment with lithium involves the occurrence of many important side 
effects, such as nausea, vomiting, weight gain, xerostomia, polydipsia, polyuria, renal 
failure, thyroidal dysfunctions, somnolence, insulin resistance, and so on (Bai et al., 
2019; Kemp et al., 2014; Chiu et al., 2013; Price and Marzani-Nissen, 2012; Souza, 
2011; Müller-Oerlinghausen et al., 2002). Öhlund et al., 2018 showed that 44% of the 
patients with BD taking lithium discontinued the treatment due to side effects or 
perceived lack of effectiveness.  
 The inhibitory activity of lithium over GSK3β is believed to be one the main 
responsible factors for its antimanic action (Chiu et al., 2013). Many studies indicate 
that GSK3β is an interesting target for BD and that GSK3β inhibitors might possess 
antimanic-like properties. Kozikowski et al. (2007) affirm that the research regarding 
the therapeutic efficacy of GSK3β inhibitors as possible antimanic agents is of great 
importance. Valvassori et al. (2020) affirm that PKC and oxidative stress are also 
involved in BD and that PKC inhibition is strongly implied in the antioxidant and 
antimanic effects of several PKC inhibitors, such as lithium or tamoxifen. Thus, the 
search for other GSK3β- or PKC inhibitors in the context of mania in BD is of great 
relevance. 
 
5. GSK3β or PKC inhibitors 
Inhibition of GSK3β has beneficial effects and intensive efforts have been made 
in the search for and design of selective GSK3β inhibitors. These include inhibitors 
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isolated from natural sources, cations or small synthetic molecules, such as ATP-
competitive inhibitors, non-ATP-competitive inhibitors or substrate-competitive 
inhibitors (Eldar-Finkelman and Martinez, 2011). Kalinichev and Dawson (2011) 
evaluated the antimanic-like properties of the GSK3β inhibitors indirubin, 
alsterpaullone, SB-627772, TDZD-8, AR-A014418, among others. The study showed 
that these drugs were capable of inhibiting the amphetamine-induced hyperlocomotion 
in rats, just like lithium, sodium valproate and other drugs that are employed in the 
pharmacotherapy of BD. GSK3β inhibitors such as CHIR99021, 6-BIO, SB216763 and 
alsterpaullone decreased amphetamine-induced hyperlocomotion (Muneer, 2017). 
Enman and Unterwald (2012) showed that valproic acid and the GSK3β inhibitor 
SB216763 markedly reduced amphetamine-induced hyperlocomotion and stereotypy.  
Valvassori et al. (2017) showed that lithium and valproate act on GSK3β to reverse 
the manic-like behavior in an ouabain-administration model of mania. 
PKC inhibitors have also been shown to possess antimanic-like effects in 
preclinical studies. Chelerythrine, an alkaloid that inhibits PKC, was shown to prevent 
manic phenotypes induced by amphetamine administration (Abrial et al., 2013). 
Armani et al. (2012) showed that treatment with lithium, tamoxifen, which is actually 
an estrogen receptor modulator with inhibitory activity over PKC, or their combination 
prevented manic-like behavior after sleep deprivation (SD), an animal model of mania. 
Zarate et al. (2007) showed that tamoxifen administration for three weeks in BD 
patients led to an improvement of their symptoms. Myricitrin, another PKC inhibitor, 
prevented the increase in ultrasonic vocalizations (USVs) after amphetamine 
administration (Pereira et al., 2014). Monotherapy with endoxifen, a metabolite of 
tamoxifen, which also inhibits PKC, was shown to be as effective as valproate in 
reducing manic symptoms (Ahmad et al., 2016). 
 In addition to its inhibitory activity over PKC, it is believed that the antimanic 
effect of lithium is also related to its inhibitory activity over GSK3β, as well as to its 
antioxidant properties (Chiu et al., 2013; Malhi et al., 2013; Valvassori et al., 2020). 
Thus, research on drugs with inhibitory activity over the enzymes GSK3β and/or PKC 






   
 
6. Andrographolide 
The diterpene andrographolide (ANDRO) is known to be an inhibitor of GSK3β 
(Serrano et al., 2014). This compound is the major bioactive constituent of the plant 
Andrographis paniculata, which has been used for centuries in the Traditional Chinese 
Medicine, as well as in the Traditional Thai Medicine, Japan, Scandinavia and 
Indonesia over the centuries (Lu et al., 2019; Jayakumar et al., 2013). The plant 
expands to a height of 30-110 cm, mostly in moist shady places with glabrous leaves, 
and white flowers with rose purple spots on the petals (Kandanur et al., 2019). The 
whole plant has medicinal value, but the leaves contain the highest levels of ANDRO 
(Sareer et al., 2014).  
ANDRO is a labdane diterpenoid lactone, which was first reported in the Indian 
Gazette in 1951, as an active constituent of A. paniculata. But it was not until 1984 
that ANDRO was first described as a potential therapeutic agent for liver injury 
(Choudhury and Poddar, 1984). Many therapeutic effects for several ailments are 
reported for ANDRO: anti-diarrheal, anti-viral, anti-malarial, antioxidant, anti-
inflammatory, hepatoprotective, for sexual dysfunctions, for cardiovascular disorders, 
to treat carbuncles, ulcers, colitis, herpes and venomous snake bites (Lim et al., 2012; 
Bharati et al., 2011). The plant is used in more than twenty-five Ayurvedic formulas for 
the management of diarrhea, sore throat, tonsilitis, jaundice, liver disorders, 
dermatological diseases, among others. It is very relevant in the Indian Pharmacopeia 
(Pandey et al., 2019). The herb A. paniculata is present in the United States 
Pharmacopeia as a dietary supplement (Aromdee et al., 2014).  
 The main pharmacological properties of ANDRO are mostly related to its anti-
inflammatory and antioxidant properties. Mittal et al. (2016) showed that ANDRO 
exhibited protective effects against H2O2-induced cell death, ROS and LPO in HepG2 
cells. The authors indicate that ANDRO administration led to inhibition of GSK3β, 
which led to retention of Nrf2 in the nucleus as well as sustained expression of HO-1 
by binding to its antioxidant response elements (Are). Several data have reported the 
antioxidant properties of ANDRO in in vitro and in vivo models. They involve ROS 
scavenging, protective effects of ANDRO on mitochondria, inhibition of free radical-
producing enzymes, such as NADPH oxidase and xanthine oxidase, as well as 
activation of antioxidant systems involving superoxide dismutase (SOD), CAT and 
GPx (Mussard et al., 2019). 
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Besides its antioxidant property, another pivotal mechanism of action of 
ANDRO involves its anti-inflammatory properties. For example, Pan et al. (2017) 
demonstrated that the hepatoprotective effects of ANDRO are linked to its anti-
inflammatory and antioxidant properties, as it was capable of improving liver histology, 
decreasing the levels of aspartate transaminase (AST), alanine transaminase (ALT), 
myeloperoxidase (MPO), MDA, IL-1β, TNF- and ROS levels. Li et al. (2017) showed 
that ANDRO possesses a beneficial effect in models of rheumatoid arthritis, due to its 
anti-inflammatory properties. ANDRO decreased the severity of arthritis and joint 
destruction in collagen-induced arthritis mouse model by inhibiting the MAPK signaling 
pathway, by decreasing IL-6, IL-1β, TNF-, expression in the serum and reducing the 
phosphorylation of p38 MAPK and ERK1/2 expression. Tan et al. (2016) showed that 
ANDRO reversed pulmonary immune cell infiltration and pro-inflammatory cytokine 
production (TNF-, IL-1β, and CXCL1, for example) in an animal model of lung 
inflammation in mice.  
Also, treatment with ANDRO showed promising results in neurodegenerative 
disorders, such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) (Rivera et 
al., 2016; Zhang et al., 2014). Rivera et al. (2016) showed that ANDRO treatment 
resulted in recovery of synaptic basal transmission and partial or complete protection 
of certain synaptic proteins in animal models of cognitive impairment. Serrano et al. 
(2014) showed that ANDRO has the capacity to induce a protection of long-term 
potentiation (LTP) and synaptic proteins against Aβ oligomers in an Alzheimer’s 
animal model and that ANDRO has the property to inhibit the long-term depression 
(LTD) in a concentration-dependent manner, showing an accumulation of β-catenin 
and a reduction in the active state of GSK3β. 
ANDRO was shown to inhibit the enzyme GSK3β possibly by directly interacting 
with the GSK3β binding site. ANDRO activates the Wnt/β-catenin and induces the 
transcription of Wnt genes and the phosphorylation of GSK3β at Ser9, leading to its 
inactivation thus stimulating Akt-dependent GSK3β signaling (Tapia-Rojas et al., 
2015). Serrano et al. (2014) showed that ANDRO was capable of increasing the levels 
of the inactive form of GSK3β and also increasing the levels of anti-apoptotic β-
catenin. 
Currently, ANDRO and A. paniculata extracts are taken orally by the general 
population (Tan et al., 2017). ANDRO is being tested clinically for several disorders. 
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For example, A. paniculata was tested in a double-blind, placebo-controlled study for 
the treatment of acute upper respiratory tract infection (Gabrielian et al., 2002). Also, 
A. Paniculata composition Paractin(R) showed promising beneficial effects in a phase 
2 clinical study by reducing the levels of rheumatoid factor, IgA and C4 in a randomized 
placebo-controlled clinical trial of rheumatoid arthritis (Clinical Trial Identifier: 
NCT00749645),  
Natural products have been the primary source of a diversity of biologically 
active molecules, driving pharmaceutical discoveries for centuries (Kandanur et al., 
2019). Taking into consideration that ANDRO has an inhibitory activity over the 
enzyme GSK3β, as the antimanic drug lithium does, it is therefore relevant to evaluate 
if ANDRO may also have an antimanic-like activity by testing its effects in animal 
models of mania/BD. 
 
7. Quercetin 
Quercetin is the most widely distributed flavonoid in nature. This flavonoid can 
be found in plants as aglicones or in their glycosylated form (Lakhanpal and Rai, 2007). 
Quercetin-type flavonols can be found in apples, berries, grapes, onions, tomatoes, 
potatoes, orange, lettuce, eggplant, black and green teas, as well as in many seeds, 
nuts, flowers and leaves of, for example, Ginkgo biloba and Hypericum perforatum (Li 
et al., 2016). Quercetin is a brilliant yellow needle crystal, insoluble in cold water and 
poorly soluble in hot water (Li et al., 2016). The solubility can be changed by alterations 
in the attached glycosyl group (quercetin glycoside) (Li et al., 2016). Although its 
antioxidant properties are its most studied and elucidated pharmacological effects, 
quercetin possesses several other therapeutic properties still in investigation. It is 
hypothesized that its therapeutic properties are linked to its interaction with proteins 
from intracellular signaling cascades, such as Akt, MAPK, PI-3K and PKC (Dajas, 
2012; Williams et al., 2004; Agullo et al., 1997).  
Quercetin appears to be one of the most powerful flavonoids to protect against 
ROS produced by the normal metabolism or induced by damage (De Groot, 1994). 
The antioxidant properties of quercetin are related to the presence of several OH 
groups and conjugating pi bond orbital, which act as electron or proton donors and 
H2O2 scavengers (Alrawaiq and Abdullah, 2014). Several studies demonstrate other 
biological effects of quercetin, rather than its antioxidant properties, such as 
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antinociceptive (Filho et al., 2008), anti-inflammatory (Comalada et al., 2005), 
anxiolytic, antidepressant (Bhutada et al., 2010), neuroprotective (Dajas et al., 2015), 
antiproliferative (Russo et al., 2012), antibacterial (Rigano et al., 2007), and anti-
ulcerative (De La Lastra et al., 1994), among other properties. 
 In an in vitro study, for example, quercetin inhibited neuroinflammation in 
astrocytes and pure neuronal cultures by inhibiting the release of IL-6, IL-8 and ROS 
production (Sharma et al., 2007), displaying a neuroprotective effect. Maurya and 
Vinayak (2015) show that PKC activation partially depends on ROS signaling. Thus, 
quercetin treatment reduced the total ROS level and downregulated PKC activity in 
ascite cells of Dalton’s lymphoma-bearing mice.  In an animal model of AD, quercetin 
administration reduced Aβ production in the hippocampus of APP/PS1 mice, reversing 
spatial learning deficit by stimulating the CREB/BDNF signaling pathway (Hou et al., 
2010). In an animal model of PD induced by intracisternal 6-OHDA administration, 
quercetin treatment diminished striatal dopamine depletion, inhibiting GSH depletion 
through its antioxidant properties and improving neuronal survival (Haleagrahara et 
al., 2013). Sriraksa et al. (2012) showed that quercetin treatment improved spatial 
memory in rats by inhibiting acetylcholinesterase (AChE) activity and diminishing 
neuronal damage due to oxidative stress after 6-OHDA administration in rats. 
Quercetin administration was shown to attenuate myeloperoxidase activity, 
diminishing neutrophil infiltration and restoring GSH levels in a model of traumatic 
brain injury in rats (Graham et al., 2000). The neuroprotective properties of quercetin 
were demonstrated by Jiang et al. (2016), who showed that pre-treatment with 5 or 10 
mol/L quercetin in HT22 hippocampal neurons protected the cells against okadaic 
acid-induced neuronal injury, decreasing the levels of MDA and increasing the levels 
of SOD and GPx, and increasing the levels of p-Ser9-GSK3β, the inactive 
phosphorylated form of the enzyme, and stimulating Akt.  
 Taking into account that quercetin exerts an inhibitory activity over the enzyme 
PKC and that it possesses antioxidant effects, as the antimanic drug lithium does, it is 
worthy to evaluate if quercetin may also have an antimanic-like activity by testing its 






   
 
8. Animal models of BD 
Animal models of BD must be employed in order to evaluate the possible 
antimanic-like effects of drugs. Animal models of human diseases should meet three 
sets of criteria: construct validity, face validity, and predictive validity. Construct validity 
refers to commonalities between the mechanism of the model and the human disorder. 
Face validity refers to commonalities between the features of the model and of the 
symptoms of human disorder, whereas predictive validity refers to the efficacy of 
treatment drugs used for human disease for the phenotype of the animal model (Kato 
et al., 2007). To date, several putative animal models of mania or depression have 
been reported. They are classified into different categories: pharmacological models, 
nutritional models, environmental models, and genetic models (Kato et al., 2007). One 
of the reasons for the lack of successful drug development in BD is the absence of an 
established animal model and difficulty in assessing the prophylactic effect of mood 
stabilizers (Kato et al., 2007). 
The administration of ouabain, a Na+/K+ ATPase inhibitor, is a model of mania, 
as rats display hyperactivity after ouabain administration (Decker et al., 2000). 
Nutritional models of mania/BD can also be employed, such as homocysteine 
administration or n-3 polyunsaturated fatty acids deprivation, yet also leading to 
behaviors such as aggressiveness (DeMar et al., 2006; Levine et al., 2005). 
Environmental models are also applied, such as SD (Gessa et al., 1995), as 
aberrations of the sleep-wake cycle and circadian rhythms belong to primary 
symptoms of patients suffering from BD and are used as diagnostic criteria (Gonzalez 
et al., 2014). Genetic models, such as usage of specific animal strains can be 
employed (Einat, 2007). CLOCK knockout mice or transgenic mice overexpressing 
GSK3β showed hyperactivity (Roybal et al., 2007; Prickaerts et al., 2006) and 
mutPOLG transgenic mice display manic-like behavior (Kubota et al., 2006). However, 
the most commonly used model of mania is the single administration of 
psychostimulants such as amphetamine (Frey et al., 2006), metamphetamine (Gould 
et al., 2001) or lisdexamfetamine (LDX) dimesylate (Macêdo et al., 2013). They cause 
hyperactivity and these models have been used to test the efficacy of antimanic 





   
 
9. Methylphenidate-induced manic-like behavior 
The administration of psychostimulants, such as methylphenidate, affects 
several neurotransmitter systems, which is in line with the fact that many 
neurotransmitters are affected in patients with BD (Beyer and Freund, 2017). The 
catecholaminergic system is mainly involved in mania-like symptoms, as elevated 
levels of dopamine or norepinephrine are observed in patients with BD (Berk et al., 
2007). Psychostimulants increase synaptic dopamine and norepinephrine through 
inhibition or reversing the corresponding reuptake mechanisms (Berk et al., 2007). 
Psychostimulants not only induces mania-like behavior in animals but also cause 
manic symptoms in healthy humans and BD patients, such as decreased need for 
sleep, elevated mood, hypersexuality, affecting sensorimotor function, learning and 
memory, for example (Corp et al., 2014; Cousins et al., 2009; Berk et al., 2007; Asghar 
et al., 2003; Jacobs and Silverstone, 1986). Psychostimulants can also precipitate 
manic episodes in patients with BD (Young et al., 2011). Lithium and valproate can 
attenuate the amphetamine mania-relevant behavior (Frey et al., 2006; Flemenbaum 
et al., 1974) 
Psychostimulant-induced hyperlocomotion is the most frequently used animal 
model of mania (Einat, 2006). This pharmacological induction of manic-like behavior 
is reliable and shows face, construct and predictive validity (Einat, 2006; Machado-
Vieira et al., 2004). To measure hyperlocomotion, the number of crossings in the open-
field can be analyzed as an index of locomotor activity. The blocking or attenuation of 
hyperlocomotion after methylphenidate administration is indicative of an antimanic-like 
effect, at doses that do not impair locomotor activity per se (Gould et al., 2001; Sabioni 
et al., 2008). 
 
10. Sleep deprivation (SD)-induced manic-like behavior 
The SD model of mania is also widely used, as SD often precedes manic 
episodes (Kato et al., 2007). After SD, animals show insomnia, hyperactivity, irritability, 
aggressiveness, hypersexuality, and stereotypy (Gessa et al., 1995). These 
behavioral changes were improved by haloperidol and prevented by lithium (Gessa et 
al., 1995). The objective of the protocol is that, when animals standing in platforms 
surrounded by water for 24h, 72h or 96h, reach REM sleep, they display muscle 
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relaxation, falling into the water and, thus, having their sleep interrupted (Machado-
Vieira et al., 2004). After this period of SD, animals show some behaviors such as 
hyperlocomotion and an increase in appetitive USVs, which can be correlated with 
manic-like behaviors (Wendler et al., 2019; Gessa et al., 1995). 
 The SD model involves several neurochemical alterations, such as down-
regulation of the expression of the enzyme tyrosine hydroxylase in the substantia nigra 
pars compacta, as well as the decrease of dopaminergic neurotransmission in 
substantia nigra pars compacta and striatum (Lima et al., 2012), an increase of the 
expression of D2 receptors in the striatum (Lima et al., 2007), as well as 
supersensibility of dopaminergic receptors (Tufik et al., 1978).  
This non-pharmacological induction of manic-like behavior is reliable and 
shows face, construct and predictive validity (Einat, 2006; Gessa et al., 1995). 
 
11. Lisdexamfetamine (LDX)-induced increases in 50-kHz USVs 
The administration of the psychostimulant LDX dimesylate is another model of 
mania. LDX dimesylate is a long-acting d-amphetamine pro-drug employed in the 
therapeutic management of attention deficit/hyperactivity disorder (ADHD) (Ermer et 
al., 2016). It was developed to improve the therapeutic effects of stimulants such as 
d-amphetamine or methylphenidate, which are long-established treatments for ADHD, 
but of which the effects are not long lasting (Swanson et al., 2011). In the LDX 
molecule, a peptide links the amino group of d-amphetamine to the carboxyl group of 
L-lysine. After absorption in the small intestine, enzymatic hydrolysis by an unknown 
erythrocyte peptidase of this peptide bond releases the active d-amphetamine and the 
byproduct L-lysine (Ermer et al., 2016). D-amphetamine acts primarily by increasing 
the synaptic levels of dopamine and norepinephrine (Ward and Citrome, 2018). In 
adults with ADHD, the half-life of LDX is 0.5 hours, and the half-life of the d-
amphetamine released is 17 hours, which allows a single daily dose (Adler et al., 
2017).  
As psychostimulant administration is a model of mania, LDX administration has 
also been used to mimic manic-like behavior in animals. Bristot et al. (2019) showed 
that 10 mg/kg once daily for 14 days LDX administration caused hyperlocomotion, 
which was reversed by a 7-day pre-treatment with 47.5 mg/kg lithium. Eger et al. 
(2016) used LDX administration as a model of mania to induce hyperlocomotion and 
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oxidative imbalance in rats, which were reversed by chronic pre-treatment with 
simvastatin. In addition to hyperlocomotion, Souza et al. (2015) showed that LDX 
administration led to oxidative stress, by causing depletion of GSH and induction of 
LPO in the PFC and striatum of rats, which were prevented or reversed by valproate.  
Another parameter that can be analyzed in order to evaluate changes in 
behavior is alterations in the emission of USVs by the animal. Wendler et al. (2016) 
used LDX administration as model of mania to induce increases in 50-kHz USVs in 
rats. Studies show that psychostimulants and SD induce increases in 50-kHz USVs in 
rats, which can be inhibited by drugs used in the management of BD, such as 
antipsychotics and lithium (Wendler et al., 2019; Wendler et al., 2016; Barker et al., 
2015; Rippberger et al., 2015; Pereira et al., 2014). Therefore, the evaluation of the 
effects of drugs on psychostimulant (e.g., LDX)-induced increases in 50-kHz USVs is 
of great relevance in the research for antimanic drugs. 
Rodents can spontaneously emit USVs that occur above the range of human 
hearing (> 20 kHz) in positive and negative contexts to express emotional states or for 
communication with other rodents (Brudzynski, 2015; Burgdorf et al., 2011; Knutson 
et al., 2002). Adult rats emit high-frequency 50-kHz USVs in appetitive situations, such 
as playing with other rats, mating or due to psychostimulant administration (Burgdorf 
et al., 2011) Under aversive situations, such as painful or stressful stimuli, rats emit 
low-frequency 22-kHz USVs (Wöhr and Schwarting, 2013). Therefore, both appetitive 
50-kHz and aversive 22-kHz USVs represent different affective and behavioral 
aspects of rats (Wöhr and Schwarting, 2013). Different types of USVs occur at different 
ages, with 40-kHz USVs predominating during infancy, and 22-kHz and 50-kHz USVs 
occurring during adolescence and into adulthood and then waning in frequency with 
senescence (Knutson et al., 2002). 
40-kHz USVs have been most extensively documented in rat pups that have 
been separated from their mothers, and they range from 80 to 140 ms (Knutson et al., 
2002). Although they have an average of 40-kHz, they can range from 30 to 65-kHz in 
frequency. Longer 22-kHz USV which are emitted by juvenile and adult rats during 
exposure to predators, aversive conditions, exposure to pain or threat cues are longer 
(ranging from 300 to 3000 ms) and lower in sound frequency (ranging from 18 to 32-
kHz, with a typically narrow bandwidth of 1 to 6-kHz) (Brudzynski et al., 1993). The 
emitted shorter and higher-pitched 50-kHz USVs of juvenile and adult rats during 
playful activities, “rough-and-tumble" play, male and female social exploration 
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(Brudzynski and Pniak, 2002), locomotor activity, and rearing and exploration (Fu and 
Brudzynski, 1994), are short in length, range from 20 to 80 ms, and have a higher in 
sound frequency (ranging from 35 to 70-kHz with a bandwidth of 1 to 6-kHz) 
(Blanchard et al., 1993). 
Based in frequency profile and call duration, three subtypes of appetitive calls 
(50-kHz USVs) have been described so far: flat calls, frequency modulated (which can 
be subdivided into step and mixed calls) and trill calls (Brudzynski, 2015), which can 
be seen in Figures 1 and 2. Both flat and frequency modulated remain within the same 
peak frequency range but differ in the sonographic profile and duration (Brudzynski, 
2015). Flat 50-kHz calls appear to be a contact call, occurring at higher rates during 
non-positive affective social interactions (Burgdorf et al., 2008), however, frequency-
modulated 50-kHz calls seem to be selective for positive affective social interactions 
(Burgdorf et al., 2011). Step calls are two adjoining frequencies with a jump (or step) 
between them (Grant et al., 2018). Trills, representing fast sin wave-like oscillations of 
the call frequency, were regarded as expressions of the highest state of arousal and 
motivation (Burgdorf et al., 2008). Repeated application of amphetamine causes 
sensitization with increased emission of trill-type 50-kHz USVs but not for flat 50-kHz 
calls (Ahrens et al., 2009). 
 
 




   
 
 
Fig. 2: Spectrograms of flat, trill and step 50-kHz USVs. Adapted from: Trein, 2017 
 
Highly arousing aversive stimuli such as predatory odor, foot shock and bright 
light, decrease rates of 50-kHz USV emission, whereas rewarding stimuli increases 
rates of 50-kHz calls (Knutson et al., 2002, Burgdorf et al., 2011). The discovery that 
50-kHz USVs reflect a positive state in rats allows these measures to be used 
effectively to monitor hedonic states in animal models of various psychiatric disorders 
(Burgdorf et al., 2011). The increased emission of 50-kHz induced by amphetamine 
administration is usually parallel to hyperlocomotion (Ahrens et al., 2013). Other 
psychostimulants, which strongly affect catecholamine release, such as cocaine, also 
increase 50-kHz USV emission rates (Wright et al., 2012). Peripheral or central 
administration of amphetamine unconditionally increases emission of 50-kHz USVs in 
a dose-dependent manner (Wintink and Brudzynski, 2001; Burgdorf et al., 2001). This 
effect can be reversed by peripheral injection of the dopamine antagonist haloperidol 
(Wintink and Brudzynski, 2001).  
 Rippberger et al. (2015) showed that d-amphetamine administration led to an 
increase in all subtypes of 50-kHz USVs. Drugs used in the management of BD, such 
as antipsychotics (e.g., risperidone and haloperidol), lithium and tamoxifen were 
shown to inhibit the increases in 50-kHz USVs induced by d-amphetamine or LDX 
(Wendler et al., 2016; Barker et al., 2015; Rippberger et al., 2015; Pereira et al., 2014). 
Pereira et al. (2014) studied the effects of the antimanic drugs lithium, the PKC-
inhibitor tamoxifen and the nitric oxide inhibitor myricitrin on amphetamine-induced 
increases in 50-kHz USVs and hyperlocomotion in adult male rats. Lithium, tamoxifen 
and myricitrin abolished amphetamine-induced increases in 50-kHz USVs and 
reversed amphetamine-induced hyperlocomotion.  
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Aim and Outline of the Thesis 
The aim of the thesis was to investigate the possible antimanic-like effect of 
chronic treatment with ANDRO and quercetin in animals submitted to different models 
of mania. 
Chapter 2 is a review regarding the effects of ANDRO in disorders of the 
Central Nervous System, focusing on the effects of ANDRO in psychiatric disorders, 
in particular anxiety and mood. It was noted that ANDRO had not been tested for 
possible antimania effects yet, though it is evident that ANDRO has therapeutic 
potential for the treatment of BD. Therefore, ANDRO was tested in three models of BD 
(chapter 3 and 4). Besides ANDRO, quercetin is an interesting compound, which 
already attracted attention as a possible antimania drug. Therefore, we further 
investigated this compound in two models of BD (chapters 5 and 6). To briefly 
summarize the experiments: 
In chapter 3, the results are shown of the experiments involving the chronic 
treatment with ANDRO in mice subjected to the SD- and methylphenidate-
administration models of mania. The read-out effects of ANDRO were on SD- and 
methylphenidate-induced hyperlocomotion as well as on the levels of GSK3β and p-
Ser9-GSK3β in samples of PFC and striatum. 
In chapter 4, the effects are evaluated of chronic treatment with ANDRO on the 
increase of 50-kHz USVs and hyperlocomotion elicited by administration of LDX as a 
rat model of mania. 
In chapter 5, findings are described regarding the effects of quercetin on SD-
induced hyperlocomotion and oxidative stress parameters (GSH and LPO levels) in 
the PFC, hippocampus and striatum of mice. 
In chapter 6, results are shown regarding the effects of quercetin on 
methylphenidate-induced hyperlocomotion and oxidative stress parameters (GSH and 






   
 
REFERENCES 
Abrial, E.; Bétourné, A.; Etiévant, A.; Lucas, G.; Scarna, H.; Lambás-eñas, L.; 
Haddjeri, N. Protein kinase C inhibition rescues manic-like behaviors and hippocampal 
cell proliferation deficits in the sleep deprivation model of mania. International 
Journal of Neuropsychopharmacology. 18(2); pii: pyu031, 2015. 
Abrial, E.; Etiévant, A.; Bétry, C.; Scarna, H.; Lucas, G.; Haddjeri, N.; Lambás-Señas, 
L. Protein kinase C regulates mood-related behaviors and adult hippocampal cell 
proliferation in rats. Progress in Neuro-Psychopharmacology & Biological 
Psychiatry. v. 43; 40 – 48, 2013. 
Abrial, E.; Lucas, G.; Scarna, H.; Haddjeri, N.; Lambás-Señas, L. A role for the PKC 
signaling system in the pathophysiology and treatment of mood disorders: involvement 
of a functional imbalance? Molecular Neurobiology. v. 44; 407 – 419, 2011. 
Adler, L. A.; Alperin, S.; Leon, T.; Faraone, S. V. Pharmacokinetic and 
pharmacodynamic properties of lisdexamfetamine in adults with attention-
deficit/hyperactivity disorder. Journal of Child and Adolescent 
Psychopharmacology. v. 27(2); 196 – 199, 2017. 
Agullo, G.; Gamet-Payrastre, L.; Manenti, S.; Viala, C.; Rémésy, C.; Chap, H.; 
Payrastre, B. Relationship between flavonoid structure and inhibition of 
phosphatidylinositol-3-kinase: a comparison with tyrosine kinase and protein kinase C 
inhibition. Biochemical Pharmacology. v. 53; 1649 – 1657, 1997. 
Ahmad, A.; Sheikh, S.; Shah, T.; Reddy, M. S.; Prasad, B.; Verma, K. K.; Chandrakant, 
B. B.; Paithankar, M.; Kale, P.; Solanki, R. V.; Patel, R.; Barkate, H.; Ahmad, I. 
Endoxifen, a new treatment option for mania: a double-blind, active-controlled trial 
demonstrates the antimanic efficacy of endoxifen. Clinical and Translational 
Science. v. 9(5); 252 – 259, 2016. 
Ahrens, A. M.; Nobile, C. W.; Page, L. E.; Maier, E. Y.; Duvauchelle, C. L.; Schallert, 
T. Individual differences in the conditioned and unconditioned rat 50-kHz ultrasonic 
vocalizations elicited by repeated amphetamine exposure. Psychopharmacology. v. 
229(4); 687 – 700, 2013. 
Ahrens, A. M.; Ma, S. T.; Maier, E. Y.; Duvauchelle, C. L.; Schallert, T. Repeated 
intravenous amphetamine exposure: rapid and persistent sensitization of 50-kHz 
ultrasonic trill calls in rats. Behavioural Brain Research. v. 197(1); p. 205-209, 2009. 
Alrawaiq, N. S.; Abdullah, A. A review of flavonoid quercetin: metabolism, bioactivity 
and antioxidant properties. International Journal of PharmTech Research. v. 6; 933 
– 941, 2014. 
American Psychiatry Association. Diagnostic and statistical manual of mental 
disorders. 5th ed (DSM-5). Washington: American Psychiatric Publishing. 2013. 
Alda, M. Lithium in the treatment of bipolar disorder: pharmacology and 
pharmacogenetics. Molecular Psychiatry. v. 20; p. 661-670, 2015. 
Andreazza, A. C.; Kapczinski, F.; Kauer-Sant'anna, M.; Walz, J. C.; Bond, D. J.; 
Gonçalves, C. A.; Young, L. T.; Yatham, L. N. 3-Nitrotyrosine and glutathione 
antioxidant system in patients in the early and late stages of bipolar disorder. Journal 
of Psychiatry & Neuroscience. 34 (4); 263 – 271, 2009 
30 
 
   
 
Andreazza, A. C.; Cassini, C.; Rosa, A. R.; Leite, M. C.; De Almeida, L. M.; Nardin, P.; 
Cunha, A. B.; Ceresér, K. M.; Santin, A.; Gottfried, C.; Salvador, M.; Kapczinski, F.; 
Gonçalves, C. A. Serum 100B and antioxidant enzymes in bipolar patients. Journal 
of Pyschiatric Research. 41 (6); 523 – 9, 2007. 
Armani, F.; Andersen, M. L.; Andreatini, R.; Frussa-filho, R.; Tufik, S.; Galduroz, J. C. 
Succesful combined therapy with tamoxifen and lithium in a paradoxical sleep 
deprivation-induced mania model. CNS Neuroscience & Therapeutics. v. 18; 119 – 
125, 2012. 
Aromdee, C. Andrographolide: progression in its modifications and applications – a 
patent review (2012-2014). Expert Opinions on Therapeutic Patents. v. 24(10); p. 
1129-1138, 2014. 
Asghar, S. J.; Tanay, V. A. M. I.; Baker, G. B.; Greenshaw, A.; Silverstone, P. H. 
Relationship of plasma amphetamine levels to physiological subjective, cognitive and 
biochemical measures in healthy volunteers. Human Psychopharmacology: 
Clinical & Experimental. v. 18(4): 291-299, 2003. 
Bai, Y.; Liu, T.; Xu, A.; Yang, H.; Gao, K. Comparison of common side effects from 
mood stabilizers and antipsychotics between pediatric and adult patients with bipolar 
disorder: a systematic review of randomized, double-blind, placebo-controlled trials. 
Expert Opinion on Drug Safety. v. 18(8): 703-717, 2019. 
Barker, D. J.; Simmons, S. J.; West, M. O. Ultrasonic vocalizations as a measure of 
affect in preclinical models of drug abuse: a review of current findings. Current 
Neuropharmacology. v. 13(2); p. 193-210, 2015. 
Bauer, M.; Glenn, T.; Alda, M.; Bauer, R.; Grof, P.; Marsh, W.; Moneith, S.; Munoz, R.; 
Rasgon, N.; Sagduyu, K.; Whybrow, P. C. Trajectories to adherence to mood 
stabilizers in patients with bipolar disorder. International Journal of Bipolar 
Disorders. v. 7(1); 2019 
Bauer, M.; Andreassen, O. A.; Geddes, J. R.; Vedel Kessing, L.; Lewitzka, U.; Schulze, 
T. G.; Vieta, E. Areas of uncertainties and unmet needs in bipolar disorders: clinical 
and research perspectives. Lancet Psychiatry. v. 5(11); p. 930-939, 2018. 
Bauer, M.; Ritter, P.; Grunze, H.; Pfennig, A. Treatment options for acute depression 
in bipolar disorder. Bipolar Disorders. v. 14(2); p. 37-50, 2012. 
Beaulieu, J. M.; Gainetdinov, R. R.; Caron, M. G. Akt/GSK3 signaling in the action of 
psychotropic drugs. Annual Review of Pharmacology and Toxicology. v. 49; 327 – 
347, 2009. 
Beaulieu, J. M.; Sotnikova, T. D.; Yao, W. D.; Kockeritz, L.; Woodgett, J. R.; 
Gainetdinov, R. R.; Caron, M. G. Lithium antagonizes dopamine-dependent behaviors 
mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proceedings of 
the National Academy of Sciences of the USA. v. 101(14); p.5099-5104, 2004. 
Berk, M.; Kapczinski, F.; Andreazza, A. C.; Dean, O. M.; Giorlando, F.; Maes, M.; 
Yücel, M.; Gama, C. S.; Dodd, S.; Dean, B.; Magalhães, P. V. S.; Amminger, P.; 
Mcgorry, P.; Malhi, G. S. Pathways underlying neuroprogression in bipolar disorder: 
focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience and 
Biobehavioral Reviews. 35; 804-817, 2011. 
31 
 
   
 
Berk, M.; Dodd, S.; Kauer-sant'anna, M.; Malhi, G. S.; Bourin, M.; Kapczinski, F.; 
Norman, T. Dopamine dysregulation syndrome: implications for a dopamine 
hypothesis of bipolar disorder. Acta Psychiatrica Scandinavica Supplementum. v. 
434: 41-9, 2007. 
Beurel, E.; Grieco, S. F.; Jope, R. S. Glycogen synthase kinase-3 (GSK-3): regulation, 
actions, and diseases. Pharmacology &amp; Therapeutics. v. 0: 114-131, 2016. 
Beyer, D. K. E.; Freund, N. Animal models for bipolar disorder: from bedside to the 
cage. International Journal of Bipolar Disorders. v. 5(1); 2017. 
Bharati, B. D.; Sharma, P. K.; Kumar, N.; Dudhe, R.; Bansal, V. Pharmacological 
activity of Andrographis paniculata: a brief review. Pharmacologyonline 2. v. 10, 
2011. 
Bhutada, P.; Mundhada, Y.; Bansod, K.; Ubgade, A.; Quazi, M.; Umathe, S.; 
Mundhada, D. Reversal by quercetin of corticotrophin releasing factor induced anxiety- 
and depression-like effect in mice. Progress in Neuro-psychopharmacology & 
Biological Psychiatry. 34; 955 – 960, 2010. 
Blanchard, R. J.; Yudko, E. B.; Blanchard, D. C.; Taukulis, H. K. High-frequency (35-
70 kHz) ultrasonic vocalizations in rats confronted with anesthetized conspecifics: 
effects of geripone, ethanol and diazepam. Pharmacology, Biochemistry and 
Behavior. v. 44(2): 313-319, 1993 
Bristot, G.; Ascoli, B. M.; Scotton, E.; Géa, L. P.; Pfaffenseller, B.; Kauer-sant'anna, 
M. Effects of lithium on inflammatory and neurotrophic factors after an immune 
challenge in a lisdexamfetamine animal model of mania. Brazilian Journal of 
Psychiatry. v. 41(5); 2019. 
Brudzynski, S. M. Pharmacology of ultrasonic vocalizations in adult rats: significance, 
call classification and neural substrate. Curr. Neuropharmacol. v.13(2): 180-192, 
2015. 
Brudzynski, S. M.; Pniak, A. Social contacts and production of 50-kHz short ultrasonic 
calls in adult rats. Journal of Comparative Psychology. v. 116(1), p. 73-82, 2002.  
Brudzynski, S. M.; Bihari, F.; Ociepa, D.; Fu, X. W. Analysis of 22 kHz ultrasonic 
vocalization in laboratory rats: long and short calls. Physiology & Behavior. v. 54(2): 
215-221, 1993. 
Brüning, C. A.; Prigol, M.; Luchese, C.; Pinton, S.; Nogueira, C. W. Diphenyl diselenide 
ameliorates behavioral and oxidative parameters in an animal model of mania induced 
by ouabain. Progress in Neuropsychopharmacology and Biological Psychiatry. 
38; 168-174, 2012. 
Burgdorf, J.; Panksepp, J.; Moskal, J. R. Frequency-modulated 50 kHz ultrasonic 
vocalizations: a tool for uncovering the molecular substrates of positive affect. 
Neurosci Biobehav. Rev. v. 35(9): 1831-1836, 2011. 
Burgdorf, J.; Kroes, R. A.; Moskal, J. R.; Pfaus, J. G.; Brudzynski, S. M.; Panksepp, J. 
Ultrasonic vocalizations of rats (Rattus norvegicus) during mating, play, and 
aggression: behavioral concomitants, relationship to reward, and self-administration 
of playback. Journal of Comparative Psychology. v. 122(4), p. 357-367, 2008. 
32 
 
   
 
Burgdorf, J.; Knutson, B.; Panksepp, J.; Ikemoto, S. Nucleus accumbens 
amphetamine microinjections unconditionally elicit 50-kHz ultrasonic vocalizations in 
rats. Behavioral Neuroscience. v.115(4); 940 – 944, 2001. 
Carbon, M.; Hsieh, C. H.; Kane, J. M.; Correll, C. U. Tardive dyskinesia prevalence in 
the period of second-generation antipsychotic use: a meta-analysis. Journal of 
Clinical Psychiatry. v. 78(3), p. 264-278, 2017. 
Castro-Costa, E.; Silva, A. G. A adesão terapêutica no transtorno bipolar. Revista 
Debates em Psiquiatria. 1 (5); 5, 2011. 
Chalecka-Franaszek, E.; Chuang, D. M. Lithium activates the serine/threonine kinase 
Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neuros. 
Proceedings of the National Academy of Sciences of the United States of 
America. v. 96(15): 8745-8750, 1999. 
Chiu, C. T.; Wang, Z.; Hunsberger, J. G.; Chuang, D. M. Therapeutic potential of mood 
stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacological 
Reviews. 65; 105-142, 2013. 
Choudhury, B. R.; Poddar, M. K. Andrographolide and kalmegh (Andrographis 
paniculata) extract: in vivo and in vitro effect on hepatic lipid peroxidation. Methods 
and Findings in Experimental and Clinical Pharmacology. v. 6(9):481-5, 1984. 
Cipriani, A.; Barbui, C.; Salanti, G.; Rendell, J.; Brown, R.; Stockton, S.; Purgato, M.; 
Spineli, L. M.; Goodwin, G. M.; Geddes, J. R. Comparative efficacy and acceptability 
of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 378 
(9799); 1306-15, 2011. 
Clevers, H. Wnt/beta-catenin signaling in development and disease. Cell. v. 127(3); 
p. 469-480, 2006. 
Cole, A. R. Glycogen synthase kinase 3 substrates in mood disorders and 
schizophrenia. FEBS Journal. v. 280(2); p. 5213-5227, 2013. 
Comalada, M.; Camuesco, D.; Sierra, S.; Ballester, I.; Xaus, J.; Gálvez, J.; Zarzuelo, 
A. In vivo quercitrin anti-inflammatory effect involves release of quercetin, which 
inhibits inflammation through down-regulation of the NF-kB pathway. European 
Journal of Immunology. 35; 584 – 592, 2005. 
Corp, S. A.; Gitlin, M. J.; Altshuler, L. L. A review of the use of stimulants and stimulant 
alternatives in treating bipolar depression and major depressive disorder. Journal of 
Clinical Psychiatry. v. 75(9): 1010-1018, 2014. 
Cousins, D. A.; Butts, K.; Young, A. H. The role of dopamine in bipolar disorder. 
Bipolar Disorders. v. 11: 787-806, 2009. 
Dajas, F. Abin-carriquiry, J. A.; Arredondo, F.; Blasina, F.; Echeverry, C.; Martínez, 
M.; Rivera, F.; Vaamonde, L. Quercetin in brain diseases: potential and limits. 
Neurochemistry International. 89; 140-148, 2015. 
Dajas, F. Life or death: neuroprotective and anticancer effects of quercetin. Journal 
of Ethnopharmacology. 143; 383 – 96, 2012. 
33 
 
   
 
Dandekar, M. P.; Valvassori, S. S.; Dal-pont, G. C.; Quevedo, J. Glycogen synthase 
kinase-3 as a putative target for bipolar disorder. Current Drug Metabolism. v. 19(8), 
663 – 673, 2018. 
Decker, S.; Grider, G.; Cobb, M.; Li, X. P.; Huff, M. O.; El-mallakh, R. S.; Levy, R. S. 
Open field is more sensitive than automated activity monitor in documenting ouabain-
induced hyperlocomotion in the development of an animal model for bipolar illness. 
Progress in Neuropsychopharmacology & Biological Psychiatry. v. 24(3); p. 455-
462, 2000. 
De Groot, H. Reactive oxygen species in tissue injury. Hepatogastroenterology. 
41(4); 328-332, 1994. 
De La Lastra, C. A.; Calero, M. J. M.; Motilva, V. Antiulcer and Gastroprotective Effects 
of Quercetin: A Gross and Histologic Study. Pharmacology. 48; 56 – 62, 1994. 
DeMar, J. C.; Ma, K.; Bell, J. M.; Igarashi, M.; Greenstein, D.; Rapoport, S. I. One 
generation of n-3 polyunsaturated fatty acid deprivation increases depression and 
aggression test score in rats. Journal of Lipid Research. v. 61(4); p. 172-180, 2006. 
DeSarno, P.; Li, X.; Jope, R. S. Regulation of Akt and glycogen synthase kinase-3 
beta phosphorylation by sodium valproate and lithium. Neuropharmacology. v. 43; 
p. 1158-1164, 2002. 
DeSousa, R. T.; Zanetti, M. V.; Talib, L. L.; Serpa, M. H.; Chaim, T. M.; Carvalho, A. 
F.; Brunoni, A. R.; Busatto, G. F.; Gattaz, W. F.; Machado-vieira, R. Lithium increases 
platelet serine-9 phosphorylated GSK-3b levels in drug-free bipolar disorder during 
depressive episodes. Journal of Psychiatric Research. v. 62: p. 78-83, 2015. 
Diplock, A. T.; Charleux, J. L.; Crozier-willi, G.; Kok, F. J.; Rice-evans, C.; Roberfroid, 
M.; Stahl, W.; Viña-ribes, J. Functional food science and defence against reactive 
oxidative stress. British Journal of Nutrition. 80 (1); S77 – 112, 1998 
Dome, P.; Rihmer, Z.; Gonda, X. Suicide risk in bipolar disorder: a brief review. 
Medicina (Kaunas). v. 55(8); pii: E403, 2019. 
Eger, G. A.; Ferreira, V. V.; Batista, C. R.; Bonde, H.; De Lima, D. D.; Wyse, A. T. S.; 
Da Cruz, J. N.; Rodrigues, A. F.; Dal Magro, D. D.; Da Cruz, J. G. P. Antioxidant effect 
of simvastatin through oxidative imbalance caused by lisdexamfetamine dimesylate. 
Annals of the Brazilian Academy of Sciences. v. 88(1); 335 – 348, 2016. 
Einat, H. Estabilshment of a battery of simple models for facets of bipolar disorder: a 
practical approach to achieve increased validity, better screening and possible insights 
into endophenotypes of disease. Behavior Genetics. v. 37(1); p. 244-255, 2007.  
Einat, H. Modelling facets of mania – new directions related to the notion of 
endophenotypes. Journal of Psychopharmacology. 20 (5); 714 – 22, 2006. 
Eldar-Finkelman, H.; Martinez, A. GSK-3 inhibitors: preclinical and clinical focus on 
CNS. Frontiers in Molecular Neuroscience. v. 4(32), 2011. 
Enman, N. M.; Unterwald, E. M. Inhibition of GSK3 attenuates amphetamine-induced 
hyperactivity and sensitization in the mouse. Behavioural Brain Research. v. 231(1); 
p. 217-225, 2012. 
34 
 
   
 
Ermer, J. C.; Pennick, M.; Frick, G. Lisdexamfetamine dimesylate: prodrug delivery, 
amphetamine exposure and duration of efficacy. Clinical Drug Investigation. v. 36; 
341 – 356, 2016. 
Filho, A. W.; Filho, V. C.; Olinger, L.; De Souza, M. M. Quercetin: further investigation 
of its antinociceptive properties and mechanisms of action. Archives of Pharmacal 
Research. 31 (6); 713 – 721, 2008. 
Flemenbaum, A. Does lithium block the effects of amphetamine? A report of three 
cases. American Journal of Psychiatry. v. 131(7); p. 820-821, 1974. 
Frame, S.; Cohen, P. GSK3 takes centre stage more than 20 years after its discovery. 
Biochemical Journal. v. 359 (Pt 1), 1 – 16, 2001. 
Frey, B. N.; Valvassori, S. S.; Réus, G. Z.; Martins, M. R.; Petronilho, F. C.; Bardini, 
K.; Dal-pizzol, F.; Kapczinski, F.; Quevedo, J. Effects of lithium and valproate on 
amphetamine-induced oxidative stress generation in an animal model of mania. 
Journal of Psychiatry & Neuroscience. v. 31(5); p. 326-332, 2006. 
Friedman, E.; Wang, H. Y.; Levinson, D.; Connell, T. A.; Singh, H. Altered platelet 
protein kinase C activity in bipolar affective disorder, manic episode. Biological 
Psychiatry. 33; 520 – 525, 1993. 
Fu, X. W.; Brudzynski, S. M. High-frequency ultrasonic vocalization induced by 
intracerebral glutamate in rats. Pharmacology, Biochemistry and Behavior. v. 
49(4); p. 835-841, 1994. 
Gabrielian, E. S.; Shukarian, A. K.; Goukasova, G. I.; Chandanian, G. L.; Panossian, 
A. G.; Wikman, G.; Wagner, H. A double-blind, placebo-controlled study of 
Andrographis paniculata fixed combination Kan Jang in the treatment of acute upper 
respiratory tract infections including sinusitis. Phytomedicine. v. 9(7); p. 589-597, 
2002.  
Gessa, G. L.; Pani, L.; Fadda, P.; Fratta, W. Sleep deprivation in the rat: an animal 
model of mania. European Neuropsychopharmacology. v. 5 Suppl: 89-93, 1995. 
Gonzalez, R.; Tamminga, C. A.; Tohen, M.; Suppes, T. The relationship between 
affective state and rhythmicity of activity in bipolar disorder. Journal of Clinical 
Psychiatry. v. 75(4); p. 317-322, 2014. 
Goodwin, F. K.; Jamison, K. R. Manic-Depressive Illness: Bipolar and Recurrent 
Unipolar Disorders. Oxford University Press, New York. 2007. 
Gould, T. D.; Zarate, C. A.; Manji, H. K. Glycogen synthase kinase-3: a target for novel 
bipolar disorder treatments. Journal of Clinical Psychiatry. v. 65(1): 10 – 21, 2004a. 
Gould, T. D.; Einat, H.; Bhat, R.; Manji, H. K. AR-A014418, a selective GSK-3 inhibitor, 
produces antidepressant-like effects in the forced swimming test. International 
Journal of Neuropsychopharmacology. v. 7(4); p.387-390, 2004b. 
Gould, T. J.; Keith, R. A.; Bhat, R. V. Differential sensitivity to lithium’s reversal of 
amphetamine-induced open-field activity in two inbred strains of mice. Behavioural 
Brain Research. 118; 95 – 105, 2001.  
35 
 
   
 
Grabinski, T.; Kanaan, N. M. Novel non-phosphorylated serine 9/21 GSK-3b/a 
antibodies: expanding the tools for studying GSK-3 regulation. Frontiers In Molecular 
Neuroscience. v. 9, 2016. 
Graham, D.; Raghupathi, R.; Saatman, K.; Meaney, D.; Mcintosh, T. Tissue tears in 
the white matter after lateral fluid percussion brain injury in the rat: relevance to human 
brain injury. Acta Neuropathologica. v. 99; 117 - 124, 2000.  
Grant, L. M.; Barth, K. J.; Muslu, C.; Kelm-Nelson, C. A.; Bakshi, V. P.; Ciucci, M. R. 
Noradrenergic receptor modulation influences the acoustic parameters of pro-social 
rat ultrasonic vocalizations. Behavioral Neuroscience. v. 132(4); p. 269-283, 2018. 
Gutiérrez-rojas, L.; Jurado, D.; Martínez-ortega, J. M.; Gurpegui, M. Poor adherence 
to treatment associated with a high recurrence in bipolar disorder outpatient sample. 
Journal of Affective Disorders. v. 127(1-3); p. 77-83, 2010. 
Hadley, S. H.; Bahia, P. K.; Taylor-Clark, T. E. Sensory nerve terminal mitochondrial 
dysfunction induces hyperexcitability in airway nociceptors via protein kinase C. 
Molecular Pharmacology. v. 85(6); 839 – 848, 2014. 
Haleagrahara, N.; Siew, C. J.; Ponnusamy, K. Effect of quercetin and desferrioxamine 
on 6-hydroxydopamine (6-OHDA) induced neurotoxicity in striatum of rats. Journal of 
Toxicological Sciences. v. 38; 25 – 33, 2013. 
Hong, J.; Reed, C.; Novick, D.; Haro, J. M.; Aguado, J. Clinical and economic 
consequences of medication non-adherence in the treatment of patients with a 
manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar 
Longitudinal Evaluation of Medication (EMBLEM) study. Psychiatry Research. v. 
190(1); p. 110-114, 2011. 
Hou, Y.; Aboukhatwa, M. A.; Lei, D. L.; Manaye, K.; Khan, I.; Luo, Y. Anti-depressant 
natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of 
double TgAD mice. Neuropharmacology. v. 58; 911 – 920, 2010. 
Jacobs, D.; Silverstone, T. Dextroamphetamine-induced arousal in human subjects as 
a model of mania. Psychological Medicine. v. 16(2); p. 323-329, 1986, 
Jauhar, S.; Young, A. H. Controversies in bipolar disorder: role of second-generation 
antipsychotic for maintenance therapy. International Journal of Bipolar Disorders. 
v. 7(1), 2019. 
Jayakumar, T.; Hsieh, C. Y.; Lee, J. J.; Sheu, J. R. Experimental and clinical 
pharmacology of Andrographis paniculata and its major bioactive phytoconstituent 
andrographolide. Evidence-Based Complementary And Alternative Medicine, 
2013. 
Jiang, W.; Luo, T.; Li, S.; Zhou, Y.; Shen, X. Y.; He, F.; Xu, J.; Wang, H. Q. Quercetin 
protects against okadaic acid-induced injury via MAPK and PI3K/Akt/GSK3β signaling 
pathways in HT22 hippocampal neurons. PLoS One. v. 11(4). 2016. 
Jope, R. S.; Roh, M. S. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases 
and therapeutic interventions. Current Drug Targets. v. 7(11); p. 1421-1434, 2006. 
Judd, L. L.; Schetler, P. J.; Akiskal, H. S.; Coryell, M.; Leon, A. C.; Maser, J. D.; 
Solomon, D. A. Residual symptom recovery from major affective episodes in bipolar 
36 
 
   
 
disorders and rapid episode relapse/recurrence. Archives of General Psychiatry. 65 
(4); 386 – 394, 2008. 
Kalinichev, M.; Dawson, L. A. Evidence for antimanic efficacy of glycogen synthase 
kinase-3 (GSK-3) inhibitors in a strain-specific model of acute mania. International 
Journal of Neuropsychopharmacology. v. 14(80): 1051-67, 2011. 
Kandanur, S. G. S.; Tamang, N.; Golakoti, N. R.; Nanduri, S. Andrographolide: a 
natural product template for the generation of structurally and biologically diverse 
diterpenes. European Journal of Medicinal Chemistry. v. 176, p. 513-533, 2019. 
Kato, T.; Kubota, M.; Kasahara, T. Animal models of bipolar disorder. Neuroscience 
and Biobehavioral Reviews. v. 31(6); p. 832-842, 2007. 
Keck, P. E. Jr. The management of acute mania. British Medical Journal. 327 
(7422); 1002 – 1003, 2003. 
Kemp, D. E.; Sylvia, L. G.; Calabrese, J. R.; et al. General medical burden in bipolar 
disorder: findings from the LiTMUS comparative effectiveness trial. Acta Psychiatrica 
Scandinavica. 129(1); 24-34, 2014. 
Kisko, T. M.; Braun, M. D.; Michels, S.; Witt, S. H.; Rietschel, M.; Culmsee, C.; 
Schwarting, R. K. W.; Wöhr, M. Cacna1c haploinsufficiency leads to pro-social 50-kHz 
ultrasonic communication deficits in rats. Disease Models & Mechanisms. v. 11(6). 
2018. 
Kitagishi, Y.; Kobayashi, M.; Kikuta, K.; Matsuda, S. Roles of PI3K/AKT/GSK3/mTOR 
Pathway in Cell Signaling of Mental Illnesses. Depress Res Treat. 2012: 752563, 
2012. 
Knapp, P.; Isolan, L. Abordagens psicoterápicas no transtorno bipolar. Revista de 
Psiquiatria Clínica. 32 (1); 98 – 104, 2005. 
Knutson, B.; Burgdorf, J.; Panksepp, J. Ultrasonic vocalizations as indices of affective 
states in rats. Psychological Bulletin. v. 128(6); p. 961-977, 2002.  
Kohen, R.; Nyska, A. Oxidation of biological systems: oxidative stress phenomena, 
antioxidants, redox reactions, and methods for their quantification. Toxicologic 
Pathology. v. 30(6); 620 – 650, 2002. 
Kozlovsky, N.; Amar, S.; Belmaker, R. H.; Agam, G. Psychotropic drugs affect Ser9-
phosphorylated GSK-3beta protein levels in rodent frontal cortex. International 
Journal of Neuropsychopharmacology. v. 9; p.337-342, 2006. 
Kozikowski, A. P.; Gaisina, I. N.; Yuan, H.; Petukhov, P. A.; Blond, S. Y.; Fedolak, A.; 
Caldarone, B.; Mcgonigle, P. Structure-based design leads to the identification of 
lithium mimetics that block mania-like effects in rodents. Possible new GSK3beta 
therapies for bipolar disorders. Journal of the American Chemical Society. v. 129: 
8328-8332, 2007. 
Kubota, M.; Kasahara, T.; Nakamura, T.; Ishiwata, M.; Miyauchi, T.; Kato, T. Abnormal 
Ca2+ dynamics in transgenic mice with neuron-specific mitochondrial DNA defects. 
Journal of Neuroscience. v.26 (47); p.12314-12324, 2006. 
Lakhanpal, P.; Rai, D. K. Quercetin: a versatile flavonoid. Internet Journal of Medical 
Update. 2 (2); 22 – 37, 2007. 
37 
 
   
 
Levine, J.; Sela, B. A.; Osher, Y.; Belmaker, R. H. High homocysteine serum levels in 
young male schizophrenia and bipolar patients and in an animal model. Progress in 
Neuro-psychopharmacology & Biological Psychiatry. v. 29(7); p. 1181-1191, 
2005. 
Li, Z. Z.; Tan, J. P.; Wang, L. L.; Li, Q. H. Andrographolide benefits rheumatoid arthritis 
via inhibiting MAPK pathways. Inflammation. v. 40(5); p. 1599-1605, 2017.  
Li, X.; Jope, R. S. Is glycogen synthase kinase-3 a central modulator in mood 
regulation? Neuropsychopharmacology. v. 35(11); p. 2143-2154, 2010. 
Lim, J. C.; Chan, T. K.; Ng, D. S.; Sagineedu, S. R.; Stanslas, J.; Wong, W. S. 
Andrographolide and its analogues: versatile bioactive molecules for combating 
inflammation and cancer. Clinical and Experimental Pharmacology & Physiology. 
v. 39(3); p.300-310, 2012. 
Lima, M. M. S.; Andersen, M. L.; Reksidler, A. B.; Ferraz, A. C.; Vital, M. A. B. F.; Tufik, 
S. Paradoxical sleep deprivation modulates tyrosine hydroxylase expression in the 
nigrostriatal pathway and attenuates motor deficits induced by dopaminergic 
depletion. CNS & Neurological Disorders – Drug Targets. 11(4); 359 – 368, 2012. 
Lima, M. M. S.; Andersen, M. L.; Reksidler, A. B.; Vital, M. A. B. F.; Tufik, S. The role 
of the substantia nigra pars compacta in regulating sleep patterns in rats. PLoS ONE. 
2(6): e513, 2007. 
Lu, J.; Ma, Y.; Wu, J.; Huang, H.; Wang, X.; Chen, Z.; Chen, J.; He, H.; Huang, C. A 
review for the neuroprotective effects of andrographolide in the central nervous 
system. Biomedicine & Pharmacotherapy. v. 117:109078, 2019. 
Macdonald, B. T.; Tamai, K.; He, X. Wnt/b-catenin signaling: components, 
mechanisms, and diseases. Developmental Cell. v. 17(1); p. 9-26, 2009. 
Macêdo, D. S.; De Lucena, D. F.; Queiroz, A. I. G.; Cordeiro, R. C.; Araújo, M. M.; 
Sousa, F. C.; Vasconcelos, S. M.; Hyphantis, T. N.; Quevedo, J.; Mcintyre, R. S.; 
Carvalho, A. F. Effects of lithium on oxidative stress and behavioral alterations induced 
by lisdexamfetamine dimesylate: revelance as an animal model of mania. Progress 
in Neuro-Psychopharmacology and Biological Psychiatry. v. 43, p. 230-237, 
2013. 
Machado-Vieira, R.; Manji, H. K.; Zarate Jr, C. A. The role of lithium in the treatment 
of bipolar disorder: convergent evidence for neurotrophic effects as a unifying 
hypothesis. Bipolar Disorders. v. 11; 92 – 109, 2009. 
Machado-Vieira, R.; Andreazza, A. C.; Viale, C. I.; Zanatto, V.; Ceresér, V. Jr.; Da 
Silva Vargas, R.; Kaczinski, F.; Portela, L. V.; Souza, D. O.; Salvador, M.; Gentil, V. 
Oxidative stress parameters in unmedicated and treated bipolar subjects during initial 
manic episode: a possible role for lithium antioxidant effects. Neuroscience Letters. 
421 (1); 33 – 6, 2007. 
Machado-Vieira, R.; Kapczinski, F.; Soares, J. C. Perspectives for the development of 
animal models of bipolar disorder. Progress in Neuro-Psychopharmacology & 
Biological Psychiatry. 28(2); 209 – 224, 2004. 
Malhi, G. S.; Tanious, M.; Das, P.; Coulston, C. M.; Berk, M. Potential mechanisms of 
action of lithium in bipolar disorder. CNS Drugs. v. 27; 135-153, 2013. 
38 
 
   
 
Malhi, G. S.; Bargh, D. M.; Mcintyre, R.; Gitlin, M.; Frye, M. A.; Bauer, M.; Berk, M. 
Balanced efficacy, safety, and tolerability recommendations for the clinical 
management of bipolar disorder. Bipolar Disorders. v. 14(Suppl. 2): 1-21, 2012. 
Manji, H. K.; Moore, G. J.; Chen, G. Bipolar disorder: leads from the molecular and 
cellular mechanisms of action of mood stabilisers. British Journal of Psychiatry. 178 
(41); 107 – 119, 2001. 
Manji, H. K.; Lenox, R. H. Protein kinase C signaling in the brain: molecular 
transduction of mood stabilization in the treatment of bipolar disorder. Biological 
Psychiatry. 46; 1328 – 1351, 1999. 
Maurya, A. K.; Vinayak, M. Modulation of PKC signaling and induction of apoptosis 
through suppression of reactive oxygen species and tumor necrosis factor receptor 1 
(TNFR1): key role of quercetin in cancer prevention. Tumor Biology. v. 36(11); 8913 
– 8924, 2015. 
Mittal, S. P. K.; Khole, S.; Jagadish, N.; Ghosh, D.; Gadgil, V.; Sinkar, V.; Ghaskadbi, 
S. S. Andrographolide protects liver cells from H2O2 induced cell death by 
upregulation of Nrf-2/HO-1 mediated via adenosine A2a receptor signalling. 
Biochimica et Biophysica Acta. v. 1860(11 Pt A): 2377-90, 2016. 
Müller-Oerlinghausen, B.; Berghöfer, A.; Bauer, M. Bipolar disorder. Lancet. 359; 241-
247, 2002. 
Muneer, A. Wnt and GSK3 signaling pathways in bipolar disorder: clinical and 
therapeutic implications. Clinical Psychopharmacology and Neuroscience. 
v.15(2): 100-114, 2017. 
Mussard, E.; Cesaro, A.; Lespessailles, E.; Legrain, B.; Berteina-raboin, S.; Toumi, H. 
Andrographolide, a natural antioxidant: an update. Antioxidants. v. 8(12), 2019. 
Nam, Y.; Wie, M. B.; Shin, E. J.; Nguyen, T. T.; Nah, S. Y.; Ko, S. K.; Jeong, J. H.; 
Jang, C. G.; Kim, H. C. Ginsenoside Re protects methamphetamine-induced 
mitochondrial burdens and proapoptosis via genetic inhibition of protein kinase C δ in 
human neuroblastoma dopaminergic SH-SY5Y cell lines. Journal of Applied 
Toxicology. v. 35(8); 927 – 944, 2015. 
Nivoli, A. M.; Colom, F.; Murru, A.; Pacchiarotti, I.; Castro-loli, P.; González-pinto, A.; 
Fountoulakis, K. N.; Vieta, E. New treatment guidelines for acute bipolar depression: 
a systematic review. Journal of Affective Disorders. 129 (1-3); 14-26, 2011. 
O’Brien, W. T.; Harper, A. D.; Jové, F.; Woodgett, J. R.; Maretto, S.; Piccolo, S.; Klein, 
P. S. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and 
molecular effects of lithium. Journal of Neuroscience. v. 24(30); 6791 – 6798, 2004. 
Öhlund, L.; Ott, M.; Oja, S.; Bergqvist, M.; Lundqvist, R.; Sandlund, M.; Renberg, E. 
S.; Werneke, U. Reasons for lithium discontinuation in men and women with bipolar 
disorder: a retrospective cohort study. BMC Psychiatry. v.18 (37), 2018. 
Osterberg, L.; Blaschke, T. Adherence to medication. New England Journal of 
Medicine. v. 353, p. 487-497, 2005. 
Ozcan, M. E.; Gulec, M.; Ozerol, E.; Polat, R.; Akyol, O. Antioxidant enzyme activities 
and oxidative stress in affective disorders. International Clinical 
Psychopharmacology. 19 (2); 89 – 95, 2004 
39 
 
   
 
Pahl, S.; Tapken, D.; Haering, S. C.; Hollmann, M. Trafficking of kainate receptors. 
Membranes. v. 4(3); 565 – 595, 2014. 
Pan, C. W.; Yang, S. X.; Pan, Z. Z.; Zheng, B.; Wang, J. Z.; Lu, G. R.; Xue, Z. X.; Xu, 
C. L. Andrographolide ameliorates d-galactosamine/lipopolysaccharide-induced acute 
liver injury by activating Nrf2 signaling pathway. Oncotarget. v. 8(25):41202-41210, 
2017. 
Pandey, A.; Gulati, S.; Gupta, A.; Tripathi, Y. C. Variation in andrographolide content 
among different accessions of Andrographis paniculata. The Pharma Innovation 
Journal. v. 8(4); p. 140-144, 2019. 
Parker, J. P.; Murray-rust, J. PKC at a glance. Journal of Cell Science. 117; 131 – 
132, 2004. 
Pereira, M.; Andreatini, R.; Schwarting, R. K. W.; Brenes, J. C. Amphetamine-induced 
appetitive 50-kHz calls in rats: a marker of affect in mania? Psychopharmacology. v. 
231(13): 2567 – 2577, 2014. 
Polter, A.; Beurel, E.; Yang, S.; Garner, R.; Song, L.; Miller, C. A.; Sweatt, J. D.; 
Mcmahon, L.; Bartolucci, A. A.; Li, X.; Jope, R. S. Deficiency in the inhibitory serine-
phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood 
disturbances. Neuropsychopharmacology. v. 35: 1761 – 1774, 2010. 
Pompili, M.; Rihmer, Z.; Innamorati, M.; Lester, D.; Girardi, P.; Tatarelli, R. 
Assessment and treatment of suicide risk in bipolar disorders. Expert Review of 
Neurotherapeutics. v 9(1), p. 109-136, 2009. 
Price, A. L.; Marzani-nissen, G. R. Bipolar disorders: a review. American Family 
Physician. 85(5); 483-493, 2012. 
Prickaerts, J.; Moechars, D.; Cryns, K.; Lenaerts, I.; Van Craenendonck, H.; Goris, I.; 
Daneels, G.; Bouwknecht, J. A.; Steckler, T. Transgenic mice overexpressing 
glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. Journal 
of Neuroscience. v. 26(35):9022-9, 2006. 
Proud, C. G. Regulation of protein synthesis by insulin. Biochemical Society 
Transactions. v. 34(2); p. 213-216, 2006. 
Rigano, D. Formisano, C.; Basile, A.; Lavitola, A.; Senatore, F.; Rosselli, S.; Bruno, M. 
Antibacterial activity of flavonoids and phenylpropanoids from Marrubium globosum 
ssp. Libanoticum. Phytotherapy Research. 21 (4); 395 – 7, 2007. 
Rippberger, H.; Van Gaalen, M. M.; Schwarting, R. K. W.; Wöhr, M. Environmental 
and pharmacological modulation of amphetamine-induced 50-kHz ultrasonic 
vocalizations in rats. Curr Neuropharmacol. v. 13: 220 – 232, 2015. 
Rivera, D. S.; Lindsay, C.; Codocedo, J. F.; Morel, I.; Pinto, C.; Cisternas, P.; 
Bozinovic, F.; Inestrosa, N. C. Andrographolide recovers cognitive impairment in a 
natural model of Alzheimer’s disease (Octodon degus). Neurobiology of Aging. v. 
46: 204-20, 2016. 
Robertson, A. G.; Swanson, J. F.; Frisman, L. K.; Lin, H.; Swartz, M. S. Patterns of 
justice involvement among adults with schizophrenia and bipolar disorder: key risk 
factors. Psychiatric Services. v. 65(7): 931-938, 2014. 
40 
 
   
 
Rosa, A. R.; Singh, N.; Whitaker, E.; De Brito, M.; Lewis, A. M.; Vieta, E.; Churchill, G. 
C.; Geddes, J. R.; Goodwin, G. M. Altered plasma glutathione levels in bipolar disorder 
indicates higher oxidative stress; a possible risk factor for illness onset despite normal 
brain-derived neurotrophic factor (BDNF) levels. Psychological Medicine. 44; 2409 
– 18, 2014. 
Rowe, M. K.; Wiest, C.; Chuang, D. M. GSK-3 is a viable potential target for therapeutic 
intervention in bipolar disorder. Neuroscience and Biobehavioral Reviews. 31 (6); 
920 – 931, 2007. 
Roybal, K.; Theobold, D.; Graham, A.; Dinieri, J. A.; Russo, S. J.; Krishnan, V.; 
Chakravarty, S.; Peevey, J.; Oehrlein, N.; Birnbaum, S.; Vitaterna, M. H.; Orsulak, P.; 
Takahashi, J. S.; Nestler, E. J.; Carlezon Jr, W. A.; Mcclung, C. A. Mania-like behavior 
induced by disruption of CLOCK. PNAS. v. 104(15); p. 6406-6411, 2007. 
Russo, M.; Spagnuolo, C.; Tedesco, I.; Bilotto, S.; Russo, G. L. The flavonoid 
quercetin in disease prevention and therapy: facts and fancies. Biochemical 
Pharmacology. 83 (1); 6 – 15, 2012. 
Ryves, W. J.; Harwood, A. J. Lithium inhibits glycogen synthase kinase-3 by 
competition for magnesium. Biochem Biophys Res Commun. 280: 720–725, 2001. 
Sabioni, P.; Baretta, I. P.; Ninomiya, E. M.; et al. The antimanic-like effect of tamoxifen: 
behavioral comparison with other PKC-inhibiting and antiestrogenic drugs. Progress 
in Neuropsychopharmacology and Biological Psychiatry. 32(8); 1927-1931, 
2008. 
Sajatovic, M.; Davies, M.; Hrouda, D. R. Enhancement of treatment adherence among 
patients with bipolar disorder. Psychiatric Services. 55(3); 264-269, 2004. 
Sareer, O.; Ahmad, S.; Umar, S. Andrographis paniculata: a critical appraisal of 
extraction, isolation and quantification of andrographolide and other constituents. 
Natural Product Research. v. 28(23); p. 2081-2101, 2014. 
Saxena, A.; Scaini, G.; Bavaresco, D. V.; Leite, C.; Valvassori, S. S.; Carvalho, A. F.; 
Quevedo, J. Role of protein kinase C in bipolar disorder: a review of the current 
literature. Molecular Neuropsychiatry. v. 3(2); 108-124, 2017. 
Serrano, F. G.; Tapia-Rojas, C.; Carvajal, F. J.; Hancke, J.; Cerpa, W.; Inestrosa, N. 
C. Andrographolide reduces cognitive impairment in young and mature AbPPswe/PS-
1 mice. Molecular Neurodegeneration. v. 9:61, 2014. 
Sharma, V.; Mishra, M.; Ghosh, S.; Tewari, R.; Basu, A.; Seth, P.; Sen, E. Modulation 
of interleukin-1b mediated inflammatory response in human astrocytes by flavonoids: 
implications in neuroprotection. Brain Research Bulletin. v. 73; 55 – 63, 2007. 
Sriraksa, N.; Wattanathorn, J.; Muchimapura, S.; Tiamkao, S.; Brown, K.; 
Chaisiwamongkol, K. Cognitive-enhancing effect of quercetin in a rat model of 
Parkinson’s disease induced by 6-hydroxydopamine. Evidence-based  
Complementary and Alternative Medicine. 2012. 
Soares, J. C.; Chen, G.; Dippold, C. S.; Wells, K. F.; Frank, E.; Kupfer, D. J.; Manji, H. 
K.; Mallinger, A. G. Concurrent measures of protein kinase C and phosphoinositides 
in lithium-treated bipolar patients and healthy individuals: a preliminary study. 
Psychiatry Research. v. 95; 109 – 118, 2000. 
41 
 
   
 
Souza, G. C.; Gomes, J. A. S.; Queiroz, A. I. G.; Araújo, M. M.; Cavalcante, L. M.; 
Machado, M. J. S.; Monte, A. S.; Lucena, D. F.; Quevedo, J.; Carvalho, A. F.; Macêdo, 
D. Preclinical evidences for an antimanic effect of carvedilol. Neural Plasticity. 2015. 
Souza, F. G. M. Tratamento de manutenção no transtorno bipolar. Revista Debates 
em Psiquiatria. 1 (5); 5, 2011. 
Suganthy, N.; Devi, K. P.; Nabavi, S. F.; Braidy, N.; Nabavi, S. M. Bioactive effects of 
quercetin in the central nervous system: focusing on the mechanisms of actions. 
Biomedicine & Pharmacotherapy. v. 84; 892 – 908, 2016. 
Swanson, J.; Baler, R. D.; Volkow, N. D. Understanding the effects of stimulant 
medications on cognition in individuals with attention-deficit hyperactivity disorder: a 
decade of progress. Neuropsychopharmacology. v. 36(1); 207 – 226, 2011. 
Szabo, S. T.; Machado-vieira, R.; Yuan, P.; Wang, Y.; Wei, Y.; Falke, C.; Cirelli, C.; 
Tononi, G.; Manji, H. K.; Du, J. Glutamate receptors as targets of protein kinase C in 
the pathophysiology and treatment of animal models of mania. Neuropharmacology. 
56 (1): 47 – 55, 2009. 
Tan, W. S. D.; Liao, W.; Zhou, S.; Wong, W. S. F. Is there a future for andrographolide 
to be an anti-inflammatory drug? Deciphering its major mechanisms of action. 
Biochemical Pharmacology. 2017. 
Tan, W. S. D.; Peh, H. Y.; Liao, W.; Pang, C. H.; Chan, T. K.; Lau, S. H.; Chow, V. T.; 
Wong, W. S. F. Cigarette smoke-induced lung disease predisposes to more severe 
infection with nontypeable Haemophilus Influenzae: protective effects of 
andrographolide. Journal of Natural Products. v. 79(5); p. 1308-1315, 2016. 
Tapia-Rojas, C.; Schüller, A.; Lindsay, C. B.; Ureta, R. C.; Mejías-reyes, C.; Hancke, 
J.; Melo, F.; Inestrosa, N. C. Andrographolide activates the canonical Wnt signaling 
pathway by a mechanism that implicates the non-ATP competitive inhibition of GSK-
3b: autoregulation of GSK-3b in vivo. Biochemical Journal. v. 466(2):415-30, 2015. 
Trede, K.; Salvatore, P.; Baethge, C.; Gerhard, A.; Maggini, C.; Baldessarini, R. J. 
Manic-depressive illness: evolution in Kraepelin’s textbook, 1883-1926. Harvard 
Review of Psychiatry. v. 13(3); p. 155-178, 2005. 
Trein, L. T. Efeito da quercetina em parâmetros comportamentais tipo maníacos 
induzidos por anfetamina em ratos machos e fêmeas. 2017. 32f. Dissertação 
(Mestrado em Farmacologia) - Departamento de Farmacologia, Universidade Federal 
do Paraná, Curitiba, 2017. 
Tufik, S.; Lindsey, C. J.; Carlini, E. A. Does REM sleep deprivation induce a 
supersensitivity of dopaminergic receptors in the rat brain? Pharmacology. 16(2); 98 
– 105, 1978. 
Valvassori, S. S.; Cararo, J. H.; Peper-nascimento, J.; Ferreira, C. L.; Gava, F. F.; Dal-
pont, G. C.; Andersen, M. L.; Quevedo, J. Protein kinase C isoforms as a target for 
manic-like behaviors and oxidative stress in a dopaminergic animal model of mania. 
Progress in Neuro-psychopharmacology & Biological Psychiatry. 2020. 
Valvassori, S. S.; Resende, W. R.; Dal-Pont, G.; Sangaletti-Pereira, H.; Gava, F. F.; 
Peterle, B. R.; Carvalho, A. F.; Varela, R. B.; Dal-Pizzol, F.; Quevedo, J. Lithium 
ameliorates sleep deprivation-induced mania-like behavior, hypothalamic-pituitary-
42 
 
   
 
adrenal (HPA) axis alterations, oxidative stress and elevations of cytokine 
concentrations in the brain and serum of mice. Bipolar Disorders. v. 19(4): 246-258, 
2017. 
Valvezan, A. J.; Klein, P. S. GSK-3 and Wnt signaling in neurogenesis and bipolar 
disorder. Frontiers In Molecular Neuroscience. v. 5(1), 2012. 
Wang, H. Y.; Friedman, E. Enhanced protein kinase C activity and translocation in 
bipolar affective disorder brains. Biological Psychiatry. 40; 568 – 575, 1996. 
Ward, K.; Citrome, L. Lisdexamfetamine: chemistry, pharmacodynamics, 
pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge 
eating disorder. Expert Opinion on Drug Metabolism & Toxicology. v. 14(2); 229 – 
238, 2018. 
Way, K. J.; Chou, E.; King, G. L. Identification of PKC-isoform-specific biological 
actions using pharmacological approaches. Trends in Pharmacological Sciences. 
21 (5); 181 – 187, 2000. 
Wendler, E.; De Souza, C. P.; Dornellas, A. P. S.; Dos Santos, L. E.; Ferreira, T. S.; 
Galduróz, J. C. F.; Wöhr, M.; Schwarting, R. K. W.; Andreatini, R. Mania-like elevated 
mood in rats: enhanced 50-kHz ultrasonic vocalizations after sleep deprivation. 
Progress in Neuropsychopharmacology & Biological Psychiatry. v. 88, 142 - 150, 
2019. 
Wendler, E.; De Souza, C. P.; Vecchia, D. D.; Kanazawa, L. K. S.; Hocayen, P. A. S.; 
Wöhr, M.; Schwarting, R. K. W.; Andreatini, R. Evaluation of 50-kHz ultrasonic 
vocalizations in animal models of mania: ketamine and lisdexamfetamine-induced 
hyperlocomotion in rats. European Psychopharmacology. v. 26(12); p. 1900-1908, 
2016. 
Wetsel, W. C.; Khan, W. A.; Merchenthaler, I.; Rivera, H.; Halpern, A. E.; Phung, H. 
M.; Negro-vilar, A.; Hannun, Y. A. Tissue and cellular distribuition of the extended 
family of protein kinase C isoenzymes. Journal of Cell Biology. 117 (1); 121 – 133, 
1992. 
Williams, R. J.; Spencer, J. P. E.; Rice-evans, C. Flavonoids: antioxidants or signalling 
molecules? Free Radicals Biology and Medicine. 36, 838 – 849, 2004. 
Wintink, A. J.; Brudzynski, S. M. The related roles of dopamine and glutamate in the 
initiation of 50-kHz ultrasonic calls in adult rats. Pharmacology, Biochemistry and 
Behavior. v. 70(2-3); p. 317-323, 2001. 
Wöhr, M.; Schwarting, R. K. W. Affective communication in rodents: ultrasonic 
vocalizations as a tool for research on emotion and motivation. Cell Tissue Research. 
v. 354(1): 81 – 97, 2013. 
Wright, J. M.; Dobosiewicz, M. R.; Clarke, P. B. α- and β-adrenergic receptors 
differentially modulate the emission of spontaneous and amphetamine-induced 50-
kHz ultrasonic vocalizations in adult rats. Neuropsychopharmacology. v. 37(3); 808-
821, 2012. 
Young, S. L.; Taylor, M.; Lawrie, S. M. “First do no harm”, a systematic review of the 
prevalence and management of antipsychotic adverse effects. Journal of 
Psychopharmacology. v. 29(4); p. 353-362, 2015. 
43 
 
   
 
Young J. W., Henry B. L., Geyer M. A. Predictive animal models of mania: hits, misses 
and future directions. British Journal of Pharmacology. v. 164, n. 4, p. 1263-1284, 
2011. 
Zarate, C. A.; Singh, J. B.; Carlson, P. J.; Quiroz, J.; Jolkovsky, L.; Luckenbaugh, D. 
A.; Manji, H. K. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of 
acute mania: a pilot study. Bipolar Disorders. v. 9; 561 – 570, 2007. 
Zhang, Z.; Lai, D.; Wang, L.; Yu, P.; Zhu, L.; Guo, B.; Xu, L.; Zhou, L.; Sun, Y.; Lee, 
S. M.; Wang, Y. Neuroprotective effects of the andrographolide analogue AL-1 in the 
MPP/MPTP-induced Parkinson’s disease model in vitro and in mice. Pharmacology, 
Biochemistry and Behavior. v. 122: 191-202, 2014. 
Zhang, H.; Zhang, H.; Zhang, Y.; Ng, S. S.; Ren, F.; Wang, Y.; Duan, Y.; Chen, L.; 
Zhai, Y.; Guo, Q.; Chang, Z. Dishevelled-DEP domain interacting protein (DDIP) 
inhibits Wnt signaling by promoting TCF4 degradation and disrupting the TCF4/beta-










   
 
CHAPTER 2 
Overview of the effects of andrographolide on disorders of the Central Nervous 
System 
Kanazawa, L. K. S.a; Nelissen, E. b, Prickaerts, J.b Andreatini, R.a 
a Laboratory of Physiology and Pharmacology of the Central Nervous System, Department of 
Pharmacology, Federal University of Paraná, Centro Politécnico, 81540-990 Curitiba, PR, Brazil 
b Department of Psychiatry and Neuropsychiatry, School for Mental Health and Neuroscience (MHeNS), 
Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands 
 
ABSTRACT 
Andrographolide (ANDRO) is the major bioactive constituent of the plant Andrographis 
paniculata. This plant has been widely used for centuries for its several therapeutic 
properties. Preclinical studies show that ANDRO possesses anti-inflammatory and 
antioxidant properties, and is capable of inducing neurogenesis. In addition, ANDRO 
exhibits neuroprotective and antiapoptotic effects. These effects are mechanistically 
linked to increased expression of several neuroprotective proteins such as BDNF and 
Akt, as well as the inhibition of several anti-neuroplasticity proteins, such as GSK3β. 
These effects and mechanisms of actions have been linked to the attenuation of 
symptoms of several diseases and disorders. As for disorders of the central nervous 
system, many pre-clinical studies indeed demonstrate therapeutic potential of ANDRO 
for Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and depression. 
ANDRO is also already being tested in first clinical trials which makes it an even more 
interesting drug for further studies on its exact mechanism of action and to determine 
its potential efficacy for the management of neurodegenerative and neuropsychiatric 
disorders. 
Key words: Andrographis paniculata, andrographolide, anxiety, central nervous 
system, depression, mood, neurodegenerative diseases, psychiatric disorders. 
 
1. INTRODUCTION 
The plant Andrographis paniculata (Burm.f.) Wall. ex Nees (Acanthaceae) has 
been used for centuries mainly in Asian traditional medicine. It is native to India, China 
and Sri Lanka, but can also be found in other Asian countries such as Taiwan, Malasia, 
Thailand, Pakistan and Indonesia, and in tropical areas of America and some countries 
in Africa (Hossain et al., 2014; Okhuarobo et al., 2014; Jayakumar et al., 2013). The 
genus Andrographis comprises more than 40 species of plants and A. paniculata is 
the most used in popular medicine. A. paniculata is an annual herbaceous plant that 
is branched, with an erect dark green stem, growing about 30 – 110 cm tall. It has 
white flowers with purple spots on the petals and it is known as “King of Bitters”, due 
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to its bitter taste (Gupta et al., 2017; Tan et al., 2017; Lim et al., 2012). The whole 
plant has been used in Ayurvedic medicine for the treatment of several ailments such 
as dyspepsia, dysentery, influenza, and for snakebites and stings from insects 
(Okhuarobo et al., 2014). More specifically, the roots have been used as antihelmintic, 
antipyretic and stomachic, while the aerial parts have been used for the treatment of 
common cold, hypertension and urinary tract infection, among other ailments 
(Okhuarobo et al., 2014; Saxena et al., 1998). The leaves of the plant have been used 
to treat common cold, fever, gastrointestinal disorders, respiratory infections, and 
sores (Okhuarobo et al., 2014; Saxena et al., 1998).  
The leaves of A. paniculata comprise the highest concentration of the major 
bioactive constituent of the plant: andrographolide (ANDRO), although it is also found 
in lesser concentrations in other parts of the plant (Jayakumar et al., 2013). ANDRO 
is a labdane diterpenoid lactone from the isoprenoid family that has the chemical 
formula C20H30O5 (Islam et al., 2018). ANDRO was first isolated in a pure crystalline 
state, as the active constituent of A. paniculata by Gorter in 1911. In 1951, as reported 
in the Indian Medical Gazette, Chakravarti and Chakravarti described the usage of the 
roots and leaves of A. paniculata in cases of loss of appetite, bowel disorders and as 
febrifuge and antihelmintic, and they also elucidated the chemical structure of ANDRO 
((3-[decahydro-6-hydroxy-5-hydroxymethyl)-5,8a-dimethyl-2-methylene-1-
napthalenyl]ethylidene-4-hydroxy-2(3H)-furanone) (Chakravarti and Chakravarti, 
1951). In 1984, laboratory tests were performed for the first time to evaluate the 
biological effects of ANDRO. In these tests, ANDRO was capable of reducing hepatic 
microsomal lipid peroxidation (LPO) induced by carbontetrachloride administration in 
male rats and also in vitro (Choudhury and Poddar, 1984). Ever since, several in vitro, 
in vivo and clinical studies have confirmed various pharmacological activities of A. 
paniculata extracts as well as ANDRO. In recent times, commercial preparations of 
this plant extract are also available as herbal supplements for health promotion 
(Hossain et al., 2014; Jarukamjorn and Nemoto, 2008). 
 
  
2.  EFFECTS OF ANDRO ON DISORDERS OF THE NERVOUS SYSTEM 
Neurodegenerative disorders involve progressive dysfunction of neurons, 
oligodendrocytes or Schwann’s cells among others, which lead to disease-specific 
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symptoms as a consequence of impairments in the central nervous system (CNS) or 
peripheral nervous system (PNS) (Radi et al., 2014). ANDRO is known to possess 
anti-inflammatory and antiapoptotic properties, as well as offering protection against 
oxidative stress, which can all be very beneficial in the context of neurodegenerative 
disorders (Graverini et al., 2018; Yang et al., 2017). 
 
2.1 Effects of ANDRO on brain oxidative stress 
Due to various chemical reactions from diverse signaling pathways constantly 
occurring, the brain is susceptible to oxidative stress (Cobley et al., 2018). Glucose 
metabolism, glutamatergic neurotransmission, neurotransmitter auto-oxidation, 
microglial activation, and imbalanced mitochondrial activity increase the accumulation 
of reactive oxygen and nitrogen species (ROS and RNS, respectively) and oxidative 
stress (Cobley et al., 2018). The excessive production of ROS and RNS is involved in 
several acute and chronic pathological processes, including neurodegenerative 
diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and 
Huntington’s disease (HD) (Liguori et al., 2018). The vulnerability of the brain to 
oxidative stress can be due to its deficient endogenous antioxidant defense, high 
levels of polyunsaturated fatty acids, and high consumption of O2 (Das et al., 2009). 
Therefore, antioxidant therapy may be helpful in the attenuation of oxidative damage 
(Liguori et al., 2018).  
Lindsay et al. (2020) demonstrated that ANDRO significantly reduced the total 
amyloid- (Aβ) levels, as well as astrogliosis and IL-6 levels in the brains of aged 
Octodon degus, used as models of AD as this is the only rodent that naturally develops 
AD-like pathology with age. ANDRO also reduced the levels of the oxidative stress 
markers 4-hydroxynonenal and N-tyrosine adducts in the hippocampus. 
ANDRO (2.5 mg/kg p.o.) decreased blood glucose levels and also reduced the 
catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GPx) 
activities in the hypothalamus, hippocampus, cerebellum and cerebral cortex of 
diabetic Sprague Dawley rats (Naik et al., 2017). ANDRO (250 mg/kg/day for 7 days 
i.p.) was capable of reversing nicotine-induced inhibition of mitochondrial electron 
transport chain complexes (I, II, III), overproduction of nitric oxide (NO) and 
suppression of mitochondrial oxidative stress scavenger system (CAT, glutathione 
reductase (GR), glutathione-S-transferase (GST) and glutathione (GSH), for example) 
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in different rat brain regions, such as the cerebral hemisphere, cerebellum and 
diencephalon (Das et al., 2009). The incubation of primary astrocyte cultures with 
50µM ANDRO also upregulated the antioxidant molecule heme oxygenase-1 (HO-1) 
expression and potently activated its transcription factor, the nuclear factor erythroid 
2 (Nrf2). This is related to ANDRO’s effect on astrocyte-mediated antioxidant and anti-
inflammatory responses and supports the potential of ANDRO as a therapeutic agent 
for neurological conditions that involve oxidative stress and neuroinflammation (Wong 
et al., 2016a).  
 
2.2 Effects of ANDRO on neuroinflammation and apoptosis 
Neuroinflammation has been implicated as a pathological factor in many 
neurodegenerative diseases. Overactivation of glial cells’ pro-inflammatory activity 
may lead to increased cytokine release and ROS, which may result in CNS injury 
(Schain and Kreisl, 2017). Therefore, the anti-inflammatory effects of ANDRO could 
be beneficial for inflammation-related neurodegenerative disorders (Yang et al., 2017).  
Pre- and post-treatment with ANDRO exhibited a significant protective effect 
against lipopolysaccharide (LPS)-induced neurotoxicity in mixed neuron-glia cultures, 
by attenuating LPS-induced microglial activation and production of ROS, TNF-α, NO, 
and prostaglandin E2 (PGE2). Furthermore, ANDRO dose-dependently attenuated 
LPS-induced inducible nitric oxide synthase (iNOS) and ciclooxigenase-2 (COX2) 
expression in BV-2 microglia (Wang et al., 2004). Wong et al. (2014) demonstrated 
that ANDRO pretreatment (30 and 50 M) of cultured rat primary astrocytes followed 
by incubation with IL-1β, attenuated the upregulation of the leukocyte chemoattractant 
chemokine C-C motif ligand 5 (CCL5). This effect could be related to ANDRO’s 
capacity of reducing the phosphorylation of NF-κB, p65, and IκBα after IL-1β 
stimulation. Chemokines are divided into four main families (C-C, C-X-C, C-X3-C and 
C) and they are upregulated and secreted by primary microglia and astrocytes after 
IL-1β or TNF-α release during an inflammatory response (Ransohoff and Brown, 2012; 
de Haas et al., 2007). Despite the essential function of chemokines, dysregulation in 
their levels is implicated in neurological diseases and disorders such as AD, multiple 
sclerosis (MS) and traumatic brain injury (TBI) (Gyoneva and Ransohoff, 2015; Liu et 
al., 2014; Kerstetter et al., 2009). Thus, the anti-inflammatory effect of ANDRO in the 
context of inhibiting the upregulation and release of chemokines in the brain can be 
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beneficial for neurological disorders. Wong et al. (2016b) demonstrated that oral 
administration of ANDRO (25 or 50 mg/kg) 1h after intraperitoneal injection of LPS 
was also capable of attenuating mouse cortical C-C (CCL-2 and CCL-5) and C-X-C 
(CXCL-1, CXCL-2 and CXCL-9) chemokine levels. Also, 48h-incubation with ANDRO 
4h before (10, 30 or 50 M) or 4h after (50 M) LPS incubation, caused abrogation of 
LPS-induced chemokines mRNA upregulation, as well as TNF-α in rat astrocytes 
(Wong et al., 2016b). 1h pre-treatment with ANDRO (5-10 M) significantly protected 
primary microglia and BV-2 microglial cells against Aβ(1-42) toxicity and attenuated the 
release of TNF-α, IL-1β, NO, and PGE2 by inhibiting the nuclear translocation of NF-
kB by affecting IkB phosphorylation. It also downregulated the protein levels of iNOS 
and COX2 in microglial cells (Yang et al., 2017). In addition, cerebral endothelial cells 
of C57/BL6 mice were stimulated with LPS which subsequently increased the 
expression of pro-inflammatory enzymes, such as COX2 and iNOS. However, co-
treatment with ANDRO markedly decreased the levels of both enzymes (Chang et al., 
2014). 
Apoptosis is a selective cell deletion process that is necessary for homeostasis. 
However, dysfunctions in the cell death program play a role in several human 
diseases, including neurodegenerative disorders such as AD, PD and HD, as a 
consequence of tissue damaged caused by increased apoptosis (Radi et al., 2014). 
Caspases play a pivotal role in apoptosis, as cytochrome c induces cleavage and 
activation of pro-caspase-9, which stimulates caspase-3 to induce degradation of 
several proteins and programmed cell death (Riedl and Shi, 2004). One of the main 
families of proteins involved in apoptosis is the Bcl-2 family, which comprises anti-
apoptotic (Bcl-2, Bcl-XL, Mcl-1) or pro-apoptotic (Bid, Bax, and Bad) proteins (Cory 
and Adams, 2002).  
Tzeng et al. (2012) showed that ANDRO and its derivative 14-deoxy-11,12-
didehydroandrographolide reduced pro-inflammatory cytokines (IL-1, IL-6 and TNF-
) levels, oxidative stress and chondroitin sulfate proteoglycans (CSPG) in H2O2-
treated pheochromocytoma cell line 12 (PC12) cells in a TNF-α stimulated astrocyte 
conditioned medium. ANDRO (20 M) administration is also capable of protecting and 
rescuing PC12 cells from Aβ(1-42)-induced cell death and restoring alterations in 
nuclear morphology (Gu et al., 2018). In this study, ANDRO reduced the level of lactate 
dehydrogenase, malondialdehyde (MDA), intracellular ROS, NO, Bax and p-tau in 
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PC12 cells after Aβ(1-42) incubation. In addition, ANDRO administration increased the 
levels of the autophagy-related proteins beclin-1, p62, Atg (autophagy-related gene) 
5 and 7 and AMBRA1 (a beclin-1 regulator). Finally, ANDRO increased the levels of 
Nrf2, which plays an important role in cell protection against oxidants, and also of p21, 
an anti-apoptotic protein.  
The anti-inflammatory and antiapoptotic effects of ANDRO are corroborated by 
the results of Das et al. (2017). They showed that in vitro administration of ANDRO (1 
g/mL in Dulbecco’s modified Eagle medium) in microglial cell culture, or in vivo, in 
BALB/c mice (1 mg/kg 3 times/week for one week i.p.), inhibited LPS-induced 
overexpression of high-mobility group box-1 protein (HMGB1), toll-like receptor 4 
(TLR4), NFκB, COX2, iNOS and nitrite expression. Also, it decreased LPS-induced 
overexpression of protein markers like protein kinase C (PKC), p-CREB, Aβ, amyloid 
precursor protein (APP), p-tau, Bax, caspase-1 and -3, NLRP3. It also decreased the 
levels of TFN-α, IL-6, TGF-β and IL-1β, while increasing the levels of IL-10 and Bcl-2. 
In addition, ANDRO increased the levels of synapsin and post synaptic density-95 
(PSD-95). Seo et al. (2017) showed that ANDRO (5 or 10 M) increased the levels of 
Nrf2, nuclear Nrf2 and HO-1 in immortalized mouse hippocampal HT22 cell lines 
transfected with Aβ42 plasmids. In addition, in murine microglial BV-2 cells, ANDRO 
(1, 5 or 10 M) decreased intracellular levels of Aβ42, IL-6, IL-1β, PGE2, NO, iNOS, 
COX-2 and p-NF-kB. This can be due to the ability of ANDRO of inducing the 
expression and translocation of Nrf2 from the cytoplasm to the nucleus, enhancing 
HO-1 expression, as previously mentioned. Taken together, all these effects of 
ANDRO demonstrate its beneficial potential in the management of neurodegenerative 
diseases and psychiatric disorders with neuroinflammatory background, such as AD. 
 
2.3 ANDRO and Alzheimer’s disease 
AD is the most prevalent neurodegenerative disorder and it is characterized by 
progressive cognitive impairment and its pathophysiology involves increased levels of 
amyloid-β and tau proteins (Kumar and Singh, 2015). An important model of AD is the 
use of APPswe/PS1ΔE9 transgenic mice, which display amyloidosis and, 
consequently, a progressive inflammatory response (Ruan et al., 2009). Serrano et al. 
(2014) showed that in vivo, ANDRO (2 mg/kg i.p.) prevents changes in neuropathology 
by reducing Aβ aggregates, tau phosphorylation and p-Tyr216-GSK3β (the active form 
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of the enzyme) in the brain of 7-month-old AβPPswe/PS1 mice. ANDRO also 
increased the levels of PSD-95, GluA2, Shank and GluN2B. In the hippocampus and 
cortex, ANDRO increased the levels of p-Ser9-GSK3β, as well as the levels of total 
and activated -catenin. ANDRO recovered cognitive function of AβPPswe/PS-1 mice, 
in behavioral tests such as the memory flexibility test and the Morris water maze test. 
In vitro experiments showed that 10µM ANDRO increased synaptic transmission and 
protected LTP against Aβ oligomers (1 M) in hippocampal slices. Also, ANDRO was 
capable of recovering the capacity of AβPPswe/PS1 mice hippocampal slices to 
induce LTP in comparison to AβPPswe/PS1 controls. This was seen as ANDRO 
increases slope of field excitatory postsynaptic potentials (fEPSP) in the CA1 region 
of hippocampal slices. The in vitro experiments also showed that in the hippocampal 
slices, ANDRO decreased the levels of p- Tyr216-GSK3β and increased the levels of 
p-Ser9-GSK3β and β-catenin, as well as inhibiting LTD induction.  
In regards to the latter mechanism of action, several studies show that multiple 
beneficial effects of ANDRO may be related to the inhibitory activity of ANDRO on 
GSK3β. Tapia-Rojas et al. (2015), for example, showed that ANDRO treatment in both 
primary rat hippocampal neurons or HEK293 cells causes specific inhibition of GSK3β, 
as indicated by the increase in the inhibited form of the enzyme (p-Ser9) and the 
decrease in the active form (p-Tyr216). This correlates with an accumulation of β-
catenin in a concentration-dependent manner. In vivo tests show that chronic ANDRO 
administration (2 mg/kg) in rats significantly decreased the level of phosphorylated β-
catenin in Ser33, Ser37 and Thr41 (phosphorylation in these epitopes leads β-catenin 
for ubiquitination and proteasomal degradation), at the same time increasing the levels 
of the inactive form of GSK3β (p-Ser9) (Tapia-Rojas et al., 2015). The inhibition of 
GSK3β may be correlated to several pathways involved in neuronal survival and 
neuroprotection, such as protection against the damages caused by Aβ oligomers 
(Silva-Alvarez et al., 2013). The presence of A oligomers induces an increase in 
GSK3, and this facilitates LTD and the internalization of AMPA receptors from the 
postsynaptic region, consequently reducing the synaptic strength. However, ANDRO 
induces GSK3 inhibition, which, in turn, reduces PSD-95 phosphorylation, preventing 
the internalization of AMPA receptors and hindering the effect of A oligomers on 
synaptic depression (Serrano et al., 2014). ANDRO also induces the translocation of 
β-catenin to the nucleus and the transcription of Wnt target genes (Tapia-Rojas et al., 
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2015). In addition, studies demonstrate that the Wnt signaling, which can be activated 
after GSK3β by lithium, for example, reduces spatial memory impairment and 
neurodegeneration (Toledo and Inestrosa, 2010). In this context, Cisternas et al. 
(2018) showed that in vitro (50 M) and in vivo (2 mg/kg i.p.) administration of ANDRO 
activates Wnt signaling and improves glucose utilization by increasing the expression 
and/or activity of hexokinase, phosphofructokinase and also the ATP and glycolytic 
rate levels in the brains of APPswe/PS1ΔE9 transgenic mice. In addition, in behavioral 
tests, ANDRO improved locomotor activity in the large open-field test, and improved 
spatial and recognition memory in the novel object recognition, novel object 
localization and memory flexibility tests with APPswe/PS1ΔE9 transgenic mice.  
Varela-Nallar et al. (2015), also evaluated the effects of ANDRO (2 mg/kg i.p.) 
in APPswe/PS1ΔE9 transgenic mice. ANDRO increased neural progenitor cell 
proliferation (Nestin+/Ki67+ cells) and neurogenesis (BrdU+ and Ki67+ cells) in the 
subgranular zone of mice. Moreover, ANDRO increased cell proliferation and the 
density of immature neurons in the dentate gyrus. In addition, ANDRO induced the 
activation of the Wnt signaling pathway in the hippocampus of wild-type and 
APPswe/PS1ΔE9 mice, increasing the levels of β-catenin and of NeuroD1, a Wnt 
target gene involved in neurogenesis. Tapia-Rojas et al. (2016) showed that ANDRO, 
activating Wnt signaling reduces the levels of Aβ(1-42) increases Aβ40 levels, and 
reduces the Aβ42/Aβ40 ratio. These protective effects of ANDRO are related to 
activation of the Wnt pathway, from which ANDRO increased the levels of β-catenin 
and calcium/calmodulin-dependent protein kinase type IV (CAMKIV). 
ANDRO sulfonate (2.5 or 5 mg/kg/day), given to the APP/PS1 transgenic mice 
in their drinking water for 7 months before the onset of Aβ plaque, prevented cognitive 
decline in spatial memory test. ANDRO increased the time in the target quadrant and 
decreased escape latency in the Morris water maze. ANDRO also increased the time 
in the new arm in the Y maze, as well as the time in the central area in the open-field 
test. In addition, ANDRO increased BDNF, synaptopodin, GDNF and NGF levels. 
Regarding oxidative stress factors, ANDRO increased SOD, CAT and decreased MDA 
levels. Finally, ANDRO increased ATP production and attenuated mitochondria 
swelling (Geng et al., 2017). 
Without using transgenic mice, Rivera et al. (2016) showed that the beneficial 
effects of ANDRO were reproducible in Octodon degus. ANDRO (2 or 4 mg/kg i.p.) 
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was administered in aged degus (56-month-old) for 3 months and it led to recovery of 
spatial memory and learning performance in the novel local/object recognition and 
Barnes maze test. In addition, ANDRO led to recovery of synaptic basal transmission 
by reversing impaired hippocampal synaptic plasticity. Moreover, ANDRO increased 
the levels of GluN2A, VGluT1, PSD95 and decreased the levels of phosphorylated 
tau, Aβ40, Aβ42 and amyloid plaques in aged degus. 
Another important aspect of AD is that cholinergic neurotransmission is 
severely decreased (Waite, 2015). Acethylcholinesterase (AchE) inhibitors, such as 
tacrine, donepezil, rivastigmine and galantamine are employed for the management 
of AD, as they increase acetylcholine levels. However, these drugs do not stop 
neuronal loss and the deterioration of cognitive function in AD patients (Godyn et al., 
2016). Therefore, the research for new therapeutic strategies for the management of 
AD is necessary. In this context, Thakur et al. (2016) demonstrated that A. paniculata 
leaf extract (50, 100 or 200 mg/kg) or ANDRO (15, 30 and 60 mg/kg) oral 
administration in STZ-induced diabetic rats were capable of attenuating cognitive 
deficits, as seen by reductions in the escape latency in the Morris water maze test. 
Treatment with A. paniculata extract or ANDRO also reduced AchE activity in both 
pre-frontal cortex (PFC) and hippocampus, as seen by a photometric method using 
acetyltiocholine as a substrate. In addition, the treatments attenuated oxidative stress 
in the PFC and hippocampus of diabetic rats, by decreasing LPO levels and increasing 
CAT and SOD activity. 
Taken together, these results indicate that ANDRO may have a beneficial effect 
for AD, as its mechanism of action attenuated important detrimental factors in AD 
pathophysiology. 
 
2.4 ANDRO and Parkinson’s disease 
PD is a progressive neurodegenerative disorder characterized by the 
degeneration of dopaminergic neurons from the nigroestriatal pathway and the 
presence of Lewy bodies (Connolly and Lang, 2014; Deumens et al., 2002). The 
available pharmacological therapies, such as levodopa, monoamine oxidase inhibitors 
or dopamine agonists act mainly by counteracting the consequences of the loss of 
dopamine (Connolly and Lang, 2014). These drugs can improve quality of life for 
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patients, but they do not alter the underlying neurodegenerative process (Connolly 
and Lang, 2014). Thus, an alternative therapy for PD would be of great relevance. 
In this context, Zhang et al. (2014) showed that the ANDRO-lipoic acid 
conjugate AL-1 significantly prevented 1-methyl-4-phenylpyridinium (MPP)-induced 
neurotoxicity in SH-SY5Y cells and primary cerebellar granule neurons. In a mouse 
model of PD, AL-1 rescued 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-
induced loss of tyrosine hydroxylase-positive neurons. It also counteracted the MPTP-
induced impairments of locomotor activity and gait and postural patterns, as seen in 
the open-field and Catwalk tests. AL-1 administration also elevated the striatal levels 
of dopamine and its metabolite 3,4-dihydroxyphenylacetic acid. Furthermore, AL-1 
remarkably lowered the NO and MDA levels and increased the SOD level in the 
substantial nigra of MPTP-treated mice. AL-1 also scavenged free radicals such as 
*OH, O2*-, ONOO- and DPPH-, suggesting an attenuating effect of AL-1 on oxidative 
stress. The immunoblotting data showed that AL-1 significantly ameliorated the 
decreased expression of tyrosine hydroxylase (TH) protein in the substantia nigra and 
inhibited the up-regulation of phosphorylated NF-κB p65 in vitro and in vivo. Thus, 
ANDRO or its conjugates could be interesting to protect the nigrastiatal system from 
oxidative stress and attenuate its dopaminergic cell loss. 
 
2.5 ANDRO and stroke 
Ischemic brain injury inflicted by stroke is among the leading causes of death 
and disability worldwide (Soares et al., 2016). Cerebral ischemia is characterized by 
an interruption of the brain blood flow and decreased oxygen and glucose supply to 
the neurons, leading to neuronal death and the pathogenesis involves complex 
oxidative stress-related pathways, such as the Nrf2 and HO-1 pathways (Soares et 
al., 2016; Yen et al., 2013). 
Du et al. (2018) demonstrated that 10µM ANDRO reduced cell apoptosis in 
hypoxia-injured mouse cortical astrocytes (C8-D1A). ANDRO was capable of reducing 
the levels of Bax as well as the ratio of pro/cleaved caspases 3 and 9, while increasing 
the levels of Bcl-2, which demonstrates an attenuation of apoptosis of hypoxic 
astrocytes. In addition, ANDRO increased the levels of pro-autophagic Beclin-1 and 
LC3-II, and lowered the levels of p62, showing that ANDRO promoted autophagy in 
hypoxic astrocytes. Autophagy (or type II programmed cellular death) involves 
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degradation of cellular components when homeostasis is disturbed (Mizushima and 
Komatsu, 2011). Thus, by promoting autophagy, ANDRO plays a protective role (Du 
et al., 2018). The neurotrophic factor S100B expression was upregulated after ANDRO 
administration as well as proteins from the JNK pathway, which regulates autophagy 
(Du et al., 2018). 
Within this framework, Chan et al. (2010) demonstrated by histological analysis 
that i.p. administration of ANDRO in rats, 1 h after permanent middle cerebral artery 
occlusion (pMCAO), reduced infarct volume. In correlation, neurological deficits were 
also reduced by ANDRO. Treatment with ANDRO also significantly reduced pMCAO-
induced activation of microglia and elevation of TNF-α, IL-1β and PGE2 levels in the 
ischaemic brain areas. In addition, ANDRO suppressed the translocation of p65 from 
cytosol to nucleus, indicating by reduced NF-κB activation. These neuroprotective 
effects exhibited by ANDRO may have therapeutic value in the treatment of stroke. 
Chern et al. (2011) showed that treatment of mice that have undergone cerebral 
ischemic/reperfusion (CI/R) injury with ANDRO (10 or 100 g/kg i.v.) ameliorated CI/R-
induced oxidative/nitrosative stress (increased ROS production and increased protein 
nitrosylation), brain infarction, and neurological deficits in the mice, and enhanced their 
survival rate. ANDRO reversed the enhanced expression of NOX2, iNOS, and the 
infiltration of CD11b cells due to activation of NF-κB and hypoxia-inducible factor 1-
alpha (HIF-1 α). In vitro, ANDRO was capable of reversing oxygen-glucose 
deprivation-induced ROS and NO overproduction caused by upregulation of NOX2 
and iNOS via the PI3K/Akt-dependent NF-κB and HIF-1α pathways in BV-2 cells. 
Wang et al. (2020) showed that rats submitted to the cerebral hypoperfusion-induced 
hippocampal neuronal damage model and treated with ANDRO showed decreased 
levels of caspase-3, p-PTEN and increased levels of p-Akt, when compared to 
controls, suggesting a neuroprotective property of ANDRO. 
10 µM ANDRO modulated the MAPK-Nrf2-HO-1 signaling cascade in primary 
cerebral endothelial cells (CECs) from C57/BL6 mice. Moreover, it provided protection 
against middle cerebral artery occlusion (MCAO)-induced ischemic stroke in Wistar 
rats. Furthermore, ANDRO increased HO-1 protein and mRNA expressions, Nrf2 
phosphorylation, and nuclear translocation in CECs. In addition, HO-1 knockdown 
attenuated the protective effect of ANDRO against oxygen-glucose deprivation-
induced CEC death. In vivo, ANDRO (0.1 mg/kg) significantly suppressed free radical 
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formation, blood-brain barrier disruption, and brain infarction in MCAO-insulted rats. 
The mechanism is attributable to HO-1 activation, as directly evidenced by ANDRO-
induced pronounced HO-1 expression in brain tissues. These findings provide strong 
evidence that ANDRO could be a therapeutic agent for treating ischemic stroke (Yen 
et al., 2013). 
 
2.6 ANDRO and traumatic brain injury 
One of the main factors involving brain ischemia after TBI is neuronal cell death 
and inflammation, which relates to excessive NO and/or cytokines release (Mauler et 
al., 2003). ANDRO treatment (0.5, 1 or 2 mg/kg i.p.) effectively reduced neuronal cell 
death and alleviated neurobehavioral disorders and brain edema in rats after 
intracerebral hemorrhage (ICH) induced by secondary brain injury. It also reduced the 
levels of IL-1, LDH, NLRP3, p20, GSDMD-N and CASP-1. In vitro, ANDRO (1, 3, 10 
or 30 M) ameliorated microglia activation-induced neuronal cell death by 
oxyhemoglobin and also decreased cytokine levels, TNF-α and IL-6 due to the 
inhibition of NF-κB signaling pathway activation. Meanwhile, ANDRO decreased the 
levels of IL-1β and LDH as well as microglia pyroptosis induced by ICH by suppressing 
the assembly of the NLRP3 inflammasome (Li et al., 2018). 
After ANDRO (1 mg/kg i.p.) administration, neurological effects were 
attenuated, and both cerebral edema and apoptosis in brain tissues were decreased 
following TBI induced by a weight drop model in Sprague-Dawley rats. ANDRO 
decreased brain water content, albumin levels in the peri-contusive cortex and the 
modified neurological severity score (mNSS) score after 24h of TBI. ANDRO inhibited 
both microglial activation and the expression of pro-inflammatory cytokines induced 
by TBI (TNF- IL-1 and IL-6). It also suppressed NF-κB p65 subunit translocation to 
the nucleus and expression levels of phosphorylated ERK and p38 MAPK after TBI 
(Tao et al., 2018).  
Overall, these results demonstrate the relevance of ANDRO in the context of 






   
 
2.7 ANDRO and multiple sclerosis 
Xu et al. (2016) demonstrated that ANDRO treatment (1.5625, 3.125 or 6.25 
M) of RSC96 Schwann cells enhanced DNA content, which marks enhanced cell 
proliferation. ANDRO also promoted gene expression of BDNF and S100β, a specific 
Schwann cell marker. By hematoxylin‑eosin staining, it was shown that ANDRO 
maintained the Schwann cell phenotype. Therefore, ANDRO accelerated proliferation 
of RSC96 cells in vitro, while maintaining the Schwann cell phenotype; which could for 
example be beneficial for peripheral nerve injury (Xu et al., 2016). ANDRO also 
possesses immunomodulatory properties, as tested in a preclinical model of 
autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein 
(MOG) injection, which leads to chronic spinal cord demyelination and paralysis. 
ANDRO (4 mg/kg i.p.) suppressed T-cell function and IL-2 release in neural tissue 
stimulated by a mix lymphocyte reaction between C57BL/6 and BALB/c mice 
splenocytes. ANDRO also suppressed maturation process of dendritic cells and direct 
response of antibody to myelin antigens, by reducing IFN-, IL-2 and anti-MOG IgG 
(Iruretagoyena et al., 2005).  
In addition, clinical studies with A. paniculata extracts or ANDRO tablets are 
being performed or have been completed in order to evaluate their effects on different 
diseases, such as MS (Phase I, NCT02280876). A pilot clinical trial, by Ciampi et al. 
(2020) showed that 140 mg ANDRO (p.o.) given twice daily for 24 months in patients 
with not active primary or secondary progressive MS led to reduction in brain atrophy 
and disability progression, compared to placebo. 
 
2.8 ANDRO and brain cancer 
Khan et al. (2018) showed that ANDRO inhibited colon cancer cell proliferation 
and migration, arrested cell cycle at G2/M phase and induced apoptosis through 
caspase independent pathway in HT-29 cells. Kumar et al. (2012) demonstrated that 
ANDRO suppresses breast tumor growth in an orthotopic NOD/SCID mice model and 
this was correlated with down-regulation of the PI3K/Akt signaling pathway and 
inhibition of expression of pro-angiogenic molecules such as osteopontin (OPN) and 
vascular endothelial growth factor (VEGF). Among all types of malignant brain primary 
tumors, glioblastomas are the most common. Li et al. (2012) showed that glioblastoma 
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U251 and U87 cells incubated with ANDRO (10 – 100 M) had decreased proliferation 
levels in the MTT essay. ANDRO (50 and 70 M) induced G2/M phase arrest in both 
glioblastoma cell lines, as determined by flow cytometry. Some studies suggest that 
the inactivation of PI3K/Akt signaling has been implicated as an important target for 
the treatment of glioblastoma, as Akt is overactivated in 70% of the cases (Gharbi et 
al., 2007; Koul et al., 2006). ANDRO downregulated the levels of Cdk1 and Cdc25C 
proteins, as well as the activity of PI3K/Akt signaling, in both cell lines, as the levels of 
p-PI3K, p-Akt, p-mTOR and p-p70s6k decreased. All these findings underline that 
ANDRO possesses an antitumor activity. 
 
2.9 Effects of ANDRO on anxiety and mood 
The antidepressant-like effects of ANDRO were shown in the study of Geng et 
al. (2019), where depressive-like behavior was induced by chronic unpredictable mild 
stress (CUMS) in C57BL/6 mice. The administration of ANDRO (5 mg/kg) markedly 
decreased immobility time in the forced swim test and reversed the anhedonic 
behavior induced by CUMS on the sucrose preference test. Additionally, ANDRO 
reversed the increase in immobility time in the tail suspension test induced by CUMS. 
Treatment with ANDRO was also able to reverse the reduction in the levels of BDNF, 
glial cell-derived neurotrophic factor (GDNF) and nerve growth factor (NGF) induced 
by CUMS. These neurotrophins are important for the maintenance and regeneration 
of neurons in the brain. All these antidepressant-like effects of ANDRO were similar to 
the effects of the selective serotonin reuptake inhibitor fluoxetine on these same tests. 
In this study, the possible mechanism of action of ANDRO seems to be related to its 
anti-inflammatory properties (Geng et al., 2019). 
Zhang et al. (2019) also demonstrated the antidepressant-like effect of ANDRO 
(10, 20 and 50 mg/kg i.p.) as it reversed the increased immobility time in both the 
forced swim and tail suspension tests in naïve mice and mice submitted to the CUMS 
protocol. All these effects were similar to the effects of fluoxetine. Additionally, ANDRO 
was able to increase the levels of BDNF, pTrkB, pERK1 and 2, p-Akt and pCREB in 
the hippocampus of naive mice and mice submitted to CUMS. Zhang et al. (2019) also 
showed that CUMS induced a reduction in the number of DCX+ cells and NeuN+/BrdU+ 
co-labelled cells in the dentate gyrus, and both ANDRO and fluoxetine reversed this 
reduction. Taken together, these results indicate that the antidepressant-like effects of 
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ANDRO possibly involve the BDNF pathway in the hippocampus, and also the 
promotion of hippocampal neurogenesis. It is known that the pathophysiology of 
depression involves a reduction in BDNF synthesis and in hippocampal neurogenesis 
(Dean and Keshavan, 2017). Indeed, the mechanism of action of several 
antidepressants involve stimulation of neurogenesis (Kraus et al., 2017). Some studies 
have attested the capacity of ANDRO of enhancing BDNF expression and inducing 
neurogenesis in the hippocampus (Xu et al., 2016; Varela-Nallar et al., 2015; Adlam 
and Zaman, 2013), which makes ANDRO an interesting object of study due to its 
antidepressant-like effects. 
Another aspect regarding the pathophysiology of depression is 
neuroinflammation. The anti-inflammatory properties of pure ANDRO and an A. 
paniculata extract were also related to its antidepressant-like and anti-stress effects in 
the study of Thakur et al. (2014a), in chronic foot shock stressed rats. A 21-day 
pretreatment with ANDRO (30 and 60 mg/kg p.o.) and the A. paniculata extract 
decreased the number of escape failures and the immobility time of stressed rats in 
the learned helplessness test and behavioral despair test, respectively. ANDRO and 
the A. paniculata extract also reversed the increase expression of TNF-, IL-10 and 
IL-1 in the blood and brain tissue of stressed rats. Thus, this is another indication that 
ANDRO can modulate behavioral alterations by regulating cytokine homeostasis 
(Thakur et al., 2014a). 
As previously mentioned, the antioxidant properties of ANDRO have beneficial 
effects on neurological disorders (Naik et al., 2017; Wong et al., 2016a; Das et al., 
2009). Thakur et al. (2014b) showed that the administration of an A. paniculata extract 
reversed the decreased immobility time and escape failures in the behavioral despair 
and learned helplessness tests, respectively, in type-2 diabetic rats. These effects 
were similar to the effects of antidepressant imipramine. The A. paniculata extract 
increased SOD and CAT levels, while lowering LPO in the frontal cortex of diabetic 
rats. The extract also normalized the levels of monoamines (norepinephrine, 
dopamine and serotonin) in the hippocampus of diabetic rats. The modulation of 
neurotransmitter levels by ANDRO or the A. paniculata extract was also depicted in 
Thakur and Kumar (2018). In this study, ANDRO and the A. paniculata extract 
reversed the decrease in head twitches after 5-hydroxytryptophan administration and 
the decrease in behavior score after L-dopa injection in diabetic Swiss mice. These 
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effects were similar to the effects of imipramine. The study implies that both ANDRO 
and the A. paniculata extract are involved in the modulation of dopaminergic and 
serotonergic neurotransmission and that this activity is related to their antidepressant-
like effect in diabetic mice.  
ANDRO also seems to possess an anxiolytic-like effect, as demonstrated by 
Thakur et al. (2014c), in which ANDRO was able to reverse stress (repeated foot 
shocks)-induced hyperthermia in a manner similar to anxiolytic drug diazepam. 
Additionally, ANDRO was able to potentiate pentobarbital hypnosis, as it prolonged 
the duration of sleep induced by pentobarbital in stressed animals. The study suggests 
that ANDRO exhibits an adaptogenic potential of normalizing stress-triggered thermal 
alterations and other physiological responses. 
Overall, ANDRO is shown to stimulate hippocampal neurogenesis, enhance 
BDNF expression, inhibit neuroinflammation and brain oxidative stress, which are all 
aspects of the pathophysiology of several affective disorders.  
 
3.  DISCUSSION 
The wide variety of biological effects of ANDRO have been shown in several 
papers describing both pre-clinical and clinical tests. These biological effects of 
ANDRO include its anti-inflammatory, antioxidant, antimicrobial, antihyperglycemic, 
hepatoprotective and anticancer properties, for example. ANDRO was shown to 
counteract neuroinflammation and apoptosis in models of AD, PD, stroke and TBI, 
among other aspects of the pathophysiology of these disorders. The lack of effective 
therapies without a large side-effect profile for the management of disorders such as 
AD and PD makes it important to search for new therapeutic agents. This review 
demonstrates the potentially beneficial effects of ANDRO treatment on the 
pathophysiology and symptomatology of disorders of the CNS. Interestingly, ANDRO 
could possibly be beneficial not only for neurodegenerative diseases, but also for 
psychiatric disorders. Throughout the review, several studies showing the effects and 
possible mechanisms of action of ANDRO in disorders of the CNS were described. 
Yet, more studies are necessary to elucidate its therapeutic potential and to state its 
efficacy for the management of these disorders.  
However, it is noteworthy that ANDRO has a potential for becoming a 
pharmacological intervention. This is corroborated by the fact that ANDRO is already 
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sold and consumed worldwide as dietary supplement as A. paniculata pills (powdered 
plant) or Kalmegh pills, mainly for its anti-inflammatory, antioxidant and antimicrobial 
properties (Kataky and Handique, 2010). In addition, scientific research involving 
ANDRO does not rely solely upon pre-clinical tests, but several clinical studies have 
already been performed and are still being developed. In a randomized, double-blind, 
placebo-controlled trial, the therapeutic efficacy of tablets of A. paniculata extract (170 
mg of A. paniculata containing 85 mg of ANDRO) was evaluated in subjects with 
relapsing-remitting MS receiving interferon therapy significantly improved MS-
associated fatigue (following the Fatigue Severity Scores), in 44% compared to the 
placebo group (Bertoglio et al., 2016). A phase II randomized double-blind placebo-
controlled clinical study for the evaluation of A. paniculata oral tablets in patients with 
MS was completed in 2015 (NCT02280876), but the results are yet to be published. 
Other clinical studies with A. paniculata or ANDRO are starting to develop. In 2017, a 
clinical study for the evaluation of the effects of a mixture of magnesium, partenium, 
Andrographis, co-enzyme Q10 and riboflavin on migraine disorders, started recruiting 
subjects (NCT03190044). At the end of 2018, the evaluation of a dietary supplement 
with A. paniculata (with 40 mg of ANDRO) and Withania somnifera for cognitive 
impairment in elderly subjects began (NCT03780621). Thus, there are great 
perspectives for the research on ANDRO and its therapeutic effects on the CNS. 
 
4. CONCLUSIONS 
Overall, several pre-clinical studies show therapeutic effects of ANDRO in 
neurodegenerative and neuropsychiatric diseases, such as AD, PD, MS, and 
depression. Its mechanisms of action appear to involve the induction of hippocampal 
neurogenesis, the attenuation of neuroinflammation and brain oxidative stress, the 
increased expression of several neuroprotective proteins such as BDNF and Akt, as 
well as the inhibition of several anti-neuroplasticity proteins, such as GSK3. The fact 
that ANDRO is also already being tested in first clinical trials makes it an even more 
interesting drug to be further studied for its exact mechanism of action and to 
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Andrographolide prevents sleep deprivation- and methylphenidate-induced 
manic-like behavior mediated via GSK3 inhibition 
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PR, Brazil 
ABSTRACT 
The pathophysiological aspects of bipolar disorder (BD) are not yet completely 
elucidated. However, studies indicate that it involves increased activity of the enzyme 
glycogen synthase kinase 3 beta (GSK3β) in the brain. Inhibition of GSK3β activity 
has been shown to reduce manic symptoms, with the antimanic effects of lithium, a 
GSK3β inhibitor, as a clear example. Andrographolide (ANDRO), the major bioactive 
compound of the plant Andrographis paniculata, is also an inhibitor of GSK3β and, 
therefore, might possess antimanic-like properties. Thus, we aimed to investigate the 
effect of a 21 days chronic treatment with 0.5 mg/kg or 2 mg/kg ANDRO or 100 mg/kg 
lithium on mice submitted to different models of mania: 24-h paradoxical sleep 
deprivation (SD) and acute administration of 5 mg/kg methylphenidate (s.c.). Both 
models are known to induce hyperlocomotion and increased activity of GSK3β The 
results showed that SD induced hyperlocomotion in mice, which was reversed by 
chronic treatment with lithium and both doses of ANDRO. We also found that SD 
decreased Ser9 phosphorylation of GSK3β in the prefrontal cortex (PFC) of these 
mice, indicative of increased GSK3β activity. Chronic treatment with lithium or 2.0 
mg/kg ANDRO was able to reverse this SD-induced decrease in p-Ser9-GSK3β. In 
addition, chronic administration of lithium as well as 0.5 mg/kg and 2.0 mg/kg ANDRO 
reduced methylphenidate-induced hyperlocomotion. Methylphenidate induced 
decreased Ser9 phosphorylation of GSK3β in the striatum, which was prevented by 
lithium and 2.0 mg/kg ANDRO. These results indicate that ANDRO has antimanic-like 
properties that may be mediated by inhibiting GSK3β activity in the frontostriatal 
system. 
Key words: andrographolide, bipolar disorder, glycogen synthase kinase 3 
beta, mania, methylphenidate, sleep deprivation. 
Abbreviations: ANDRO, andrographolide; BD, bipolar disorder; GSK3β, 








   
 
CHAPTER 4 
Andrographolide prevents increases in 50-kHz ultrassonic vocalizations, 
hyperlocomotion and oxidative stress induced by lisdexamfetamine in rats, an 
animal model of mania 
Kanazawa, L. K. S.a; Radulski, D. R.b; Pereira, G. S.b; Prickaerts, J.c; Schwarting 
R.K.W.d; Acco, A.b; Andreatini, Ra. 
a Laboratory of Physiology and Pharmacology of the Central Nervous System, Department of 
Pharmacology, Federal University of Paraná, Centro Politécnico, 81540-990 Curitiba, PR, Brazil 
b Laboratory of Pharmacology and Metabolism, Department of Pharmacology, Federal University of 
Paraná, Centro Politécnico, 81540-990, Curitiba, PR, Brazil 
c Department of Psychiatry and Neuropsychiatry, School for Mental Health and Neuroscience (MHeNS), 
Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands 
d Behavioural Neuroscience, Experimental and Biological Psychology, and Center for Mind, Brain and 
Behavior (CMBB), Philipps-Universität Marburg, 35032 Marburg, Germany 
 
ABSTRACT 
In rats, lisdexamfetamine (LDX) induces manic-like behaviors such as 
hyperlocomotion and increase in appetitive 50-kHz ultrasonic vocalizations (USVs), 
which are prevented by antimanic drugs, such as lithium. Inhibition of glycogen 
synthase kinase 3 beta (GSK3β) has been associated with antimanic effect. Thus, the 
aim of the present study was to evaluate the possible antimanic-like effect of 
andrographolide (ANDRO), a GSK3β inhibitor, on LDX-induced hyperlocomotion and 
50-kHz USVs increase. In addition, the effect of ANDRO was studied on LDX-induced 
oxidative stress. Lithium was used as positive control. Adult Wistar rats were treated 
with vehicle, lithium (100 mg/kg i.p.) or ANDRO (2.0 mg/kg i.p.) 3 times a week for 21 
days. On the test day, either 10 mg/kg LDX or saline was administered i.p. and USV 
calls and locomotor activity were recorded. LDX administration increased the number 
of 50-kHz calls as well as locomotor activity. Repeated treatment with lithium or 
ANDRO prevented these effects of LDX on 50-kHz USVs and locomotor activity. LDX 
increased lipid peroxidation (LPO) levels in rat striatum and both lithium and ANDRO 
prevented this effect. LPO levels in rat striatum were positively correlated with 
increases in 50-kHz USV emission as well as hyperlocomotion. In conclusion, the 
present results indicate that ANDRO has antimanic-like and antioxidant effects in an 
animal model of mania. 
 
Key words: andrographolide, bipolar disorder, glutathione, GSK3β, 
lisdexamfetamine, lipid peroxidation, mania, oxidative stress, ultrassonic vocalizations 
Abbreviations: ANDRO: andrographolide; GSH: reduced glutathione; 
GSK3β  glycogen synthase kinase-3β LDX: lisdexamfetamine; LPO: lipid 









   
 
CHAPTER 5 
Quercetin reduces manic-like behavior and brain oxidative stress induced by 
paradoxical sleep deprivation in mice 
Luiz K. S. Kanazawa,a Débora D. Vecchia,a Etiéli M. Wendler,a Palloma de A. S. 
Hocayen,a Francislaine A. dos Reis Lívero,b Maria Carolina Stipp,b Inara M. R. 
Barcaro,a Alexandra Acco,b Roberto Andreatinia,* 
a Laboratory of Physiology and Pharmacology of the Central Nervous System, Department of 
Pharmacology, Federal University of Paraná, Centro Politécnico, 81540-990, Curitiba, PR, Brazil 
b Laboratory of Pharmacology and Metabolism, Department of Pharmacology, Federal University of 




Quercetin is a known antioxidant and protein kinase C (PKC) inhibitor. Previous 
studies have shown that mania involves oxidative stress and an increase in PKC 
activity. We hypothesize that quercetin affects manic symptoms. In the present study, 
manic-like behavior (hyperlocomotion) and oxidative stress were induced by 24 h 
paradoxical sleep deprivation (SD) in male Swiss mice. Both 10 and 40 mg/kg 
quercetin prevented SD-induced hyperlocomotion. Quercetin reversed the SD-
induced decrease in glutathione (GSH) levels in the prefrontal cortex (PFC) and 
striatum. Quercetin also reversed the SD-induced increase in lipid peroxidation (LPO) 
in the PFC, hippocampus, and striatum. Pearson’s correlation analysis revealed a 
negative correlation between locomotor activity and GSH in the PFC in sleep-deprived 
mice and a positive correlation between locomotor activity and LPO in the PFC and 
striatum in sleep-deprived mice. These results suggest that quercetin exerts an 
antimanic-like effect at doses that do not impair spontaneous locomotor activity, and 
the antioxidant action of quercetin might contribute to its antimanic-like effects. 
 
Key words: Bipolar disorder, mania, oxidative stress, paradoxical sleep deprivation, 
protein kinase C, quercetin. 
Abbreviations: BD, bipolar disorder; CAT, catalase; CMC, carboxymethylcellulose; 
CNS, central nervous system; DPPH, 2,2-diphenyl-1-picrylhydrazyl; DTNB, 5,5’-
dithiobis-(2-nitrobenzoic acid); GPx, glutathione peroxidase; GSH, reduced 
glutathione; GSK-3, glycogen synthase kinase-3; LPO, lipid peroxidation; PFC, 







   
 
1. INTRODUCTION 
Bipolar disorder (BD) is a chronic disease that is characterized by recurrent 
episodes of depression and mania (Abrial et al., 2015). It is a common, disabling, and 
recurrent mental health condition that has various levels of severity (Price and 
Marzani-Nissen, 2012) and prevalence of 1-3% worldwide (Merikangas et al., 2007). 
Bipolar patients experience both symptoms of the disease and also impaired 
functioning, compromised quality of life, and stigma (Michalak et al., 2011). Lithium is 
the main pharmacological treatment for BD. Other treatments include the 
anticonvulsants valproate, carbamazepine, and lamotrigine and atypical 
antipsychotics quetiapine, risperidone, olanzapine, and aripiprazole (Chiu et al., 2013; 
Miklowitz and Johnson, 2006; Müller-Oerlinghausen et al., 2002). The currently 
available treatments for BD have many side effects (Price and Marzani-Nissen, 2012), 
such as xerostomia, polydipsia, polyuria, weight gain, insulin resistance, 
extrapyramidal symptoms, and sexual dysfunction, among others (Kemp et al., 2014; 
Chiu et al., 2013; Price and Marzani-Nissen, 2012; Müller-Oerlinghausen et al., 2002). 
The great number of side effects results in low treatment adherence (Miklowitz and 
Johnson, 2006; Sajatovic et al., 2004), and more than one-third of BD patients do not 
respond to treatment, even when it is adequate (Perlis et al., 2006; Judd et al., 2005). 
The pathophysiology that underlies BD involves alterations in neurotransmitter 
levels (Lahera et al., 2013; Hashimoto et al., 2007), increases in the activity of protein 
kinase C (PKC) (Manji et al., 2000), and increases in oxidative stress (Berk et al., 
2011; Andreazza et al., 2008). Studies have shown that chronic treatment with lithium 
and valproate at therapeutic concentrations exert robust antioxidant effects in vitro by 
inhibiting glutamate-induced DNA fragmentation, lipid peroxidation (LPO), and protein 
oxidation (Shao et al., 2005). Souza et al. (2014) reported an increase in oxidative 
stress in rats that exhibited ouabain-induced hyperlocomotion (i.e., an animal model 
of mania). Lithium also prevented manic-like behavior in rats and the ouabain-induced 
increase in superoxide dismutase (SOD) activity and decreases in catalase (CAT) and 
glutathione peroxide (GPx) activity in the cerebral cortex and hippocampus. 
Another relevant mechanism of action of lithium is its inhibitory effect on the 
enzyme PKC, which can be related to its antimanic actions (Wang and Friedman, 
1989). Wang and Friedman (1996) showed that post-mortem brains of BD patients 
had increases in the translocation of PKC and PKC to the membrane, which 
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indicates higher levels of the active form of these enzymes. Similarly, some of the 
pharmacological activities of flavonoids, such as the flavonol quercetin, have been 
postulated to result from inhibitory activity on kinases, such as PKC (Gamet-Payrastre 
et al., 1999). However, quercetin is best known for its antioxidant properties (Dajas et 
al., 2015; Lakhanpal et al., 2007). It appears to be one of the most powerful flavonoids 
with regard to protecting the body against reactive species that are produced during 
normal oxygen metabolism or induced by exogenous damage (De Groot, 1994; Grace, 
1994). Quercetin is able to increase the levels or activity of antioxidants, such as 
glutathione (GSH), CAT, and SOD, and decrease in LPO (Rinwa and Kumar, 2013). 
Manic patients experience sleep disturbances (Streck et al., 2015), and the 
model of paradoxical sleep deprivation (SD) is considered a non-pharmacological 
animal model of mania that induces manic-like behavior (i.e., hyperlocomotion) (Abrial 
et al., 2015; Streck et al., 2015; Gessa et al., 1995; Tufik et al., 1978) and increases 
in oxidative stress (Streck et al., 2015; Ghosh et al., 1976). 
Considering the relationship between manic symptoms and increases in PKC 
activity and oxidative stress in BD, the objective of the present study was to evaluate 
the effects of the antioxidant and PKC inhibitor quercetin on manic-like behavior and 
oxidative stress in mice that were subjected to SD-induced hyperlocomotion. 
 
2. MATERIALS AND METHODS 
2.1. Animals 
The experiments were conducted using male Swiss mice (30-40 g) housed at 
22C ± 2C (6-8/cage) under a 12 h/12 h light/dark cycle (lights on at 7:00 AM). The 
animals were kept in polypropylene cages (41 cm  34 cm  16 cm) with food and 
water available ad libitum. All of the experiments were approved by the Committee of 
Animal Experimentation of the Federal University of Paraná (CEUA/BIO-UFPR, 
protocol no. 733). 
 
2.2. Drugs 
The mice were treated with saline (0.9% NaCl; 10 ml/kg i.p.), lithium carbonate 
(Eurofarma, Itapevi, Brazil; positive control; 100 mg/kg i.p., dissolved in saline, with 
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the pH adjusted to 7.4 with HCl), or quercetin (Sigma, St. Louis, MO, USA; 10 or 40 
mg/kg i.p., suspended in 0.5% carboxymethylcellulose [CMC]). All of the drugs were 
administered in a volume of 10 ml/kg of body weight. The doses were based on data 
from the literature (Silva et al., 2004) and previous studies by our research group 
(Bhutada et al., 2010; Sabioni et al., 2008). 
 
2.3. Paradoxical sleep deprivation protocol 
Prior to SD, basal spontaneous locomotor activity was measured in an 
automated activity box for 20 min. Based on the animals’ basal locomotor activity, they 
were divided by stratified randomization into sleep-deprived and non-sleep deprived 
groups and further subdivided into vehicle, lithium, and 10 and 40 mg/kg quercetin 
groups. The mice were treated with the respective drugs and sleep-deprived for 24 h 
according to an adaptation of the multiple platform protocol (Ghosh et al., 1976). 
Briefly, in the SD procedure, groups of six animals were placed in polypropylene 
cages (41 cm  34 cm  16 cm). Each cage contained 12 platforms (3 cm diameter, 5 
cm height), surrounded by water up to 1 cm below the surface of the platforms. The 
animals could move freely, jumping from one platform to another. Food and water were 
available during the entire procedure. 
Thirty minutes before the end of the deprivation period (i.e., 23.5 h after 
beginning the SD period), the animals were treated again with the respective drugs. 
After the deprivation period of 24 h, the animals were immediately placed in the 
automated activity box for 20 min to evaluate locomotor activity (Figure 1). 
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Fig 1. Timeline of the paradoxical sleep deprivation protocol. 
 
2.4. DPPH assay 
The DPPH (2,2-diphenyl-1-picrylhydrazyl) assay is used to evaluate the free 
radical scavenging activity of antioxidants. The assay is based on the principle that 
DPPH, upon accepting a hydrogen atom from a scavenger molecule (e.g., an 
antioxidant), is reduced, and the purple color of the solution changes to yellow, 
concomitant with a decrease in absorbance (Pereira et al., 2011). 
Following the protocols described by Blois (1958) and Chen et al. (2004), with 
minor modifications, different concentrations of either quercetin or lithium (0.001, 
0.003, 0.01, 0.03, 0.1, 0.3 and 1 g/ml) were mixed with DPPH methanolic solution 
(10 g/ml). Ascorbic acid (50 g/ml) was used as a positive control. Distilled water with 
0.5% CMC was used as a negative control. Absorbance was measured at 517 nm 
using a multi-mode microplate reader (BioTek Synergy HT, BioTek Instruments, 






   
 
2.5. Evaluation of oxidative stress parameters in the mouse brain 
2.5.1. Brain samples 
The mice were euthanized by decapitation immediately after being exposed to 
the automated activity box. The prefrontal cortex (PFC), hippocampus, and striatum 
were dissected, frozen in liquid nitrogen, and stored at -80ºC until further analysis. The 
brain samples were homogenized in potassium phosphate buffer (0.1 M, pH 6.5) in a 
1:10 dilution. One part of the homogenate was used to determine GSH levels, and the 
other was centrifuged at 9000  g in a micro-high-speed refrigerated centrifuge (VS-
15000 CFNII, Vision Scientific, Daejeon, South Korea) for 20 min. The supernatant 
was used to evaluate LPO. 
 
2.5.2. Evaluation of GSH levels 
To evaluate GSH levels, 100 l of the homogenate was mixed with 80 l of 
12.5% trichloroacetic acid and centrifuged at 6000 rotations per minute (rpm) for 15 
min at 4ºC. Afterwards, 20 l of the supernatant was mixed with 280 l of Tris buffer 
(0.4 M, pH 8.9) and 5 l of DTNB (5,5’-dithiobis-[2-nitrobenzoic acid] or Ellman’s 
reagent; 0.01 M) according to the protocol that was originally described by Sedlak and 
Lindsay (1968), with minor modifications. Absorbance was read at 415 nm using a 
multi-mode microplate reader (BioTek Synergy HT, BioTek Instruments, Highland 
Park, VT, USA). The individual values were interpolated in a standard curve of GSH 
(0.375-3 g) to verify the linearity of the reaction (r2 must be > 0.99), and the values 
were divided by a correction factor. The results are expressed as g/g of tissue, 
representing the quantity of GSH (g) in the tissue (g). 
 
2.5.3. Evaluation of LPO levels 
LPO was measured according to the method described by Jiang et al. (1992), 
with minor modifications. First, 100 l of the supernatant was suspended in 100 l of 
methanol, vortexed, and centrifuged at 5000 rpm for 5 min at 4ºC. Afterwards, 100 l 
of the supernatant was added to 900 l of FOX2 reagent (Wolff’s reagent; 4 mM BHT, 
250 µM FeSO4, 250 mM H2SO4, and 100 mM xylenol orange). The samples were then 
vortexed and incubated for 30 min at room temperature in the dark. Absorbance was 
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read at 560 nm using a multi-mode microplate reader (BioTek Synergy HT, BioTek 
Instruments, Highland Park, VT, USA). The results are expressed as mmol of 
hydroperoxides/mg of tissue. 
 
2.6. Statistical analysis 
For all of the experiments, two-way analysis of variance (ANOVA) was used, 
with the exception of the DPPH assay, followed by the Newman-Keuls post hoc test if 
significant main effects or interactions were found in the ANOVA. The DPPH assay 
data were analyzed using one-way ANOVA followed by the Newman-Keuls post hoc 
test. The data are expressed as mean ± SEM. Values of p < 0.05 were considered 
statistically significant. Pearson’s correlation analysis was performed to identify 
possible relationships between the behavioral and oxidative stress parameters (all 
mice, n = 38-42). 
 
3. RESULTS 
3.1 Effect of quercetin on 24 h SD-induced hyperlocomotion 
The two-way ANOVA revealed significant main effects of SD (F1,50 = 4.21, p < 
0.05) and treatment (F3,50 = 19.52, p < 0.001) and a SD  treatment interaction (F3,50 
= 4.80, p < 0.01). The Newman-Keuls post hoc test revealed that SD increased 
locomotor activity compared with the control group (non-sleep-deprived + vehicle; p < 
0.001) and all of the other groups (all p < 0.01; Figure 2). Treatment with lithium and 
10 and 40 mg/kg quercetin blocked SD-induced hyperlocomotion (p < 0.001). Sleep-
deprived mice that were treated with 40 mg/kg quercetin exhibited a decrease in 
locomotor activity compared with control mice (p < 0.05). Non-sleep-deprived mice 
that were treated with 40 mg/kg quercetin exhibited a tendency toward a decrease in 
locomotor activity (p = 0.055). 
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Fig 2. Effect of acute quercetin (Q; 10 and 40 mg/kg i.p.) and lithium (Li; 10 mg/kg i.p.) administration 
on 24 h SD-induced hyperlocomotion. Control: non-deprived mice. SD: sleep-deprived mice. Veh, 
vehicle. The data are expressed as the mean ± SEM number of beam breaks over 20 min. n = 7-8 
mice/group. *p < 0.05, (*) 0.05 < p < 0.10, compared with non-sleep-deprived mice treated with vehicle; 
#p < 0.05, compared with sleep-deprived mice treated with vehicle (two-way ANOVA followed by 
Newman-Keuls post hoc test). 
 
3.2. Oxidative stress 
3.2.1. DPPH assay 
The one-way ANOVA of the free radical scavenging activity of lithium and 
quercetin in the DPPH assay revealed an antioxidant effect (F8,18 = 137.39, p < 0.001, 
and F8,18 = 52.07, p < 0.001, respectively; Figure 3A, B). The post hoc comparisons 
showed that all concentrations of lithium, quercetin (except 0.001 and 0.003 µg), and 





   
 
Fig 3. Effects of lithium (A), quercetin (B), vehicle (C; negative control), and ascorbic acid (AA; positive 
control) on free radical scavenging activity in the DPPH assay. The data are expressed as mean ± SEM. 
The tests were performed in triplicate. *p < 0.001, compared with control (C). #,p < 0.05, compared with 
all other groups; MW: Li2CO3=42.39 (1 µg=23.6 nmol); Quercetin (C15H10O7): 302.24 (1 µg=3.3 nmol). 
 
3.2.2. Effect of acute administration of quercetin on glutathione levels 
after SD 
The two-way ANOVA revealed an effect of treatment (F3,31 = 16.93, p < 0.001) 
on GSH levels in the PFC and a SD  treatment interaction (F3,31 = 12.11, p < 0.001). 
In the hippocampus, there was an effect of treatment (F3,31 = 3.33, p < 0.05) on GSH 
levels. The two-way ANOVA also revealed significant effects of SD (F1,30 = 8.72, p < 
0.001) and treatment (F3,30 = 12.26, p < 0.001) on GSH levels in the striatum and a 
SD  treatment interaction (F3,30 = 8.70, p < 0.001). The post hoc tests revealed that 
SD decreased GSH levels in the PFC (Figure 4A) and striatum (Figure 4C) compared 
with non sleep deprived mice (p < 0.05, PFC; p < 0.01, striatum). 
Treatment with 10 and 40 mg/kg quercetin and lithium blocked the SD-induced 
decrease in GSH levels in the PFC (p < 0.001; Figure 4A). The post hoc comparisons 
revealed that mice treated with 10 and 40 mg/kg quercetin (non deprived + deprived) 
exhibited an increase in GSH levels in the hippocampus (Figure 4B) compared with 
the vehicle group (non deprived + deprived; p < 0.05). The post hoc comparisons 
revealed that sleep-deprived mice that were treated with 10 mg/kg quercetin exhibited 
an increase in GSH levels in the striatum compared with the sleep deprived mice that 
were treated with vehicle (p < 0.001; Figure 4C). Sleep-deprived mice that were 
treated with lithium exhibited lower GSH levels in the striatum compared with the 
control group (p < 0.001) and non-sleep-deprived mice that were treated with lithium 
(p < 0.05). Sleep-deprived mice that were treated with 40 mg/kg quercetin did not differ 
from either group that was treated with vehicle (p > 0.05). 
 
3.2.3. Effect of acute administration of quercetin on LPO after SD 
The two-way ANOVA revealed effects of SD (F1,34 = 44.15, p < 0.001) and 
treatment (F3,34 = 7.92, p < 0.001) on LPO in the PFC and a SD  treatment interaction 
(F3,34 = 4.53, p < 0.001). In the hippocampus, there were effects of SD (F1,34 = 64.48, 
p < 0.001) and treatment (F3,34 = 6.89, p < 0.001) on LPO. The two-way ANOVA 
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revealed an effect of SD (F1,30 = 25.23, p < 0.001) on LPO in the striatum and a SD  
treatment interaction (F3,30 = 9.58, p < 0.001). 
SD increased LPO in the PFC (p < 0.05), hippocampus (p < 0.05), and striatum 
(p < 0.05) compared with non sleep deprived mice that were treated with vehicle. 
Sleep-deprived mice that were treated with lithium (p < 0.05), 10 mg/kg quercetin (p < 
0.001), and 40 mg/kg quercetin (p < 0.01) exhibited a decrease in LPO in the PFC 
compared with sleep-deprived mice that were treated with vehicle (Figure 5A). Sleep-
deprived mice that were treated with 10 mg/kg quercetin exhibited a significant 
increase in LPO compared with non-sleep-deprived mice that were treated with 10 
mg/kg quercetin (p < 0.05). Sleep-deprived mice that were treated with 10 mg/kg 
quercetin and lithium exhibited an increase in LPO compared with non sleep deprived 
mice that were treated with vehicle (p < 0.05). 
The post hoc comparisons showed that sleep-deprived mice that were treated 
with lithium (p < 0.05), 10 mg/kg quercetin (p < 0.001), and 40 mg/kg quercetin (p < 
0.05) exhibited a decrease in LPO in the hippocampus compared with sleep-deprived 
mice (Figure 5B). Sleep-deprived mice that were treated with lithium and 40 mg/kg 
quercetin exhibited an increase in LPO compared with the control group (p < 0.05) and 
non-sleep-deprived mice that were treated with the respective drugs (p < 0.01). 
The post hoc comparisons revealed that sleep-deprived mice that were treated 
with lithium (p < 0.01) and 10 mg/kg quercetin (p < 0.05) exhibited a decrease in LPO 
in the striatum compared with sleep-deprived mice that were treated with vehicle 
(Figure 5C). Treatment with 40 mg/kg quercetin did not affect the SD-induced increase 
in LPO (p > 0.05). 
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Fig 4. Effect of acute administration of quercetin (Q; 10 and 40 mg/kg i.p.) and lithium (Li; 100 mg/kg 
i.p.) on GSH levels in the PFC (A), hippocampus (B), and striatum (C) in mice subjected or not to 24 h 
SD. The data are expressed as mean ± SEM. n = 6 mice/group. *p < 0.05, compared with non-sleep-
deprived mice treated with vehicle; #p < 0.05, compared with sleep-deprived mice treated with vehicle; 
@p < 0.05, compared with non-sleep-deprived mice treated with the same drug; +p < 0.05, compared 
with sleep-deprived and non-sleep-deprived mice that were treated with vehicle. Control: non-deprived 




   
 
 
Fig 5. Effect of acute administration of quercetin (Q; 10 and 40 mg/kg i.p.) and lithium (Li; 100 mg/kg 
i.p.) on LPO in the PFC (A), hippocampus (B), and striatum (C) in mice that were or were not subjected 
to 24 h SD. The data are expressed as mean ± SEM. n = 6 mice/group. *p < 0.05, compared with non-
sleep-deprived mice treated with vehicle; #p < 0.05, compared with sleep-deprived mice treated with 
vehicle; @p < 0.05, compared with non-sleep-deprived mice treated with the same drug. Control: non-




   
 
3.2.4. Correlation between SD-induced hyperlocomotion and indices of 
oxidative stress 
The correlation analysis revealed a negative correlation between locomotor 
activity and GSH levels in the PFC in sleep-deprived mice (r = -0.76, p < 0.001) and a 
positive correlation between locomotor activity and LPO in the PFC (r = 0.53, p < 0.05) 
and striatum (r = 0.49, p < 0.05) in sleep-deprived mice (Table 1). 
When considering all of the animals together, a negative correlation was found 
between locomotor activity and GSH levels (r = -0.57, p < 0.001), and a positive 
correlation was found between locomotor activity and LPO (r = 0.44, p < 0.01) in the 
PFC. The correlation analysis also revealed a tendency towards a positive correlation 
between locomotor activity and LPO in the hippocampus (r = 0.30, 0.01 < p < 0.05) 
and striatum (r = 0.32, 0.01 < p < 0.05). In the sleep-deprived group, a tendency toward 
a positive correlation was found between locomotor activity and LPO in the 
hippocampus (r = 0.39, 0.01 < p < 0.05; Table 1). 
 
Table 1. Correlation coefficients (Pearson’s r) between SD-induced hyperlocomotion and GSH and LPO 
in the hippocampus, striatum, and PFC. 
 Hippocampus Striatum Prefrontal Cortex 
Locomotor Activity GSH LPO GSH LPO GSH LPO 
All mice (n = 38-42) -0.14 0.30(*) -0.14 0.32(*) -0.57*** 0.44** 
Sleep-deprived (n = 
17-22) 
-0.30 0.39(*) -0.15 0.49* -0.76*** 0.53* 
Non-sleep-deprived 
(n = 19-21) 
0.10 0.12 0.04 -0.10 -0.05 0.07 
*p < 0.05, **p < 0.01, ***p < 0.001, (*) 0.01 < p < 0.05. 
 
4. DISCUSSION 
The present study showed that 24 h sleep-deprived mice exhibited 
hyperlocomotion compared with control non-sleep-deprived mice. Acute treatment 
with quercetin at doses that did not impair spontaneous locomotor activity and acute 
treatment with lithium blocked SD-induced hyperlocomotion. Thus, our findings 
demonstrated a potential antimanic-like effect of quercetin, indicating that this 
flavonoid may be a promising therapeutic agent for the treatment of manic symptoms. 
Animal models of mania frequently focus on a specific aspect of the disorder, 
namely hyperactivity. This feature can be easily induced and monitored. Non-
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pharmacological or environmental methods, such as SD, are widely used to induce 
manic-like behavior in animals (Einat, 2006). Gessa et al. (1995) showed that SD 
results in a short period of hyperactivity that is responsive to lithium, which validates 
the model for screening novel antimanic drugs. In the clinical context, during a manic 
episode, 69-99% of patients experience a reduced need for sleep (Harvey et al., 
2009). Indeed, many studies have shown that BD patients present sleep disturbances 
(Rumble et al., 2015; Harvey et al., 2009), and SD can predict manic episodes 
(Colombo et al., 1999). An important validation of SD-induced manic-like symptoms 
as a model for the human condition is its sensitivity to lithium (Gessa et al., 1995). In 
the present study, the SD model was sensitive to lithium treatment, in which sleep-
deprived animals that were treated with lithium exhibited a reduction of 
hyperlocomotion compared with sleep-deprived animals that were treated with vehicle. 
Ghosh et al. (1976) reported that SD caused a marked increase in 
dopaminergic neurotransmission and concomitant increase in locomotor activity. In 
humans, amphetamine, which increases dopaminergic neurotransmission, was shown 
to increase motor activity in a human open field test (Minassian et al., 2016). Likewise, 
the increase in dopamine levels that is caused by SD is a source of oxidative stress in 
the brain, which might be related to the establishment of manic symptoms (Berk et al., 
2007; Rees et al., 2007). The central nervous system (CNS) is vulnerable to oxidative 
stress. The brain utilizes great amounts of oxygen, consequently promoting the 
formation of oxygen free radicals and reactive oxygen species. Corroborating the 
notion that oxidative stress may indeed be related to the pathophysiology of BD and 
manic-like behavior, Souza et al. (2014) showed that melatonin treatment decreased 
ouabain-induced hyperlocomotion in rats. Their study also showed a positive 
correlation between manic-like behavior and indices of oxidative stress in the PFC and 
hippocampus. 
In the present study, the antioxidant property of quercetin was demonstrated in 
the DPPH assay (Figure 3B). Our results also indicated that 10 mg/kg quercetin 
increased GSH levels in the PFC and striatum, attenuating the SD-induced decrease 
in GSH levels in these brain areas. Treatment with 40 mg/kg quercetin blocked the 
SD-induced decrease in GSH levels in the PFC. Lithium also exerts neuroprotective 
effects against oxidative stress (Frey et al., 2006), which is consistent with our DPPH 
assay results (Figure 3A). Our results showed that acute lithium treatment increased 
GSH levels in the PFC. However, in the striatum, sleep-deprived mice treated with 
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lithium exhibited a decrease in GSH levels after SD compared with the control group 
(non-sleep-deprived + vehicle) and non-sleep-deprived mice that were treated with 
lithium. Previous studies have shown that the antioxidant effect of lithium varies, 
depending on the specific brain region and treatment regimen (Frey et al., 2006; Bhalla 
and Dhawan, 2009). 
The present study found a negative correlation between locomotor activity and 
GSH levels in the PFC in sleep-deprived animals. When considering all of the animals 
together, a negative correlation was found between locomotor activity and GSH levels 
in the PFC. The CNS has a limited antioxidant capacity, and GSH is the main 
antioxidant in the brain (Jornada et al., 2011). Gawryluk et al. (2011) showed that the 
post mortem PFC in BD patients had lower levels of GSH, which can lead to higher 
susceptibility to neuronal oxidation, interfere with neuronal activity, and may contribute 
to the establishment of BD symptoms (Dringen, 2000). In the present study, SD-
induced hyperlocomotion was related to lower GSH levels in the PFC. Other studies 
have shown that the replenishment of GSH diminishes oxidative cellular damage and 
ameliorates the symptoms of BD (Magalhães et al., 2011; Dean et al., 2009). Our 
results also suggest that the hippocampus is less vulnerable to SD-induced GSH 
depletion compared with the PFC and striatum. 
Another parameter of oxidative stress that was analyzed in the present study 
was LPO. Lipids are the major components of cellular membranes and myelin sheaths 
that allow the conduction of neuronal signaling. LPO can dramatically compromise 
brain function (Joshi and Praticò, 2014). High levels of oxidative damage to membrane 
phospholipids or the aggregation of oxidized proteins alters fluidity, which can induce 
cell death by apoptosis (Mahadik et al., 2001). Under certain conditions, LPO causes 
structural disturbances, alterations in integrity, fluidity, and permeability, the functional 
loss of biomembranes, and the generation of potentially toxic products (Greenberg et 
al., 2008). Hydroperoxides are the major products of the free radical-mediated LPO of 
polyunsaturated fatty acids, and they are assumed to be pathogenic and contribute to 
the etiology of many diseases, including neurodegenerative diseases (Niki, 2009; 
Sultana et al., 2006). Previous studies have reported that uncompensated oxidative 
stress increases LPO throughout the course of BD (Andreazza et al., 2007; Machado-
Vieira et al., 2007). In the present study, acute lithium administration and 10 and 40 
mg/kg quercetin reversed the increases in LPO in the PFC, hippocampus, and striatum 
that were induced by SD. These findings demonstrate the antioxidant and 
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neuroprotective effects of both lithium and quercetin, suggesting antimanic-like effects 
of both drugs. 
In the present study, a positive correlation was found between locomotor activity 
and LPO in the PFC and striatum in sleep-deprived mice. Considering all of the 
animals together, a positive correlation was found between locomotor activity and LPO 
in the PFC. Our findings indicate that SD-induced hyperlocomotion is correlated with 
higher LPO in the PFC and striatum. Brüning et al. (2012) also reported a positive 
correlation between hyperlocomotion and indices of LPO. 
Other studies have shown that antioxidant substances, such as a-lipoic acid 
and N-acetyl-cysteine, are capable of reducing levels of oxidative stress, manic-like 
behavior and manic symptoms (Pereira et al., 2014; Andreatini et al., 2013). Our 
research group has shown that the flavonoid myricitrin, which possesses antioxidant 
and PKC-inhibiting activities, is capable of reducing levels of oxidative stress and 
manic-like behavior (Pereira et al., 2014; Andreatini et al., 2013). However, Valvassori 
et al. (2014) reported that tamoxifen reduced levels of oxidative stress, although it 
does not possess antioxidant properties. Furthermore, trials have assessed well-
known antioxidant agents, such as vitamin E, have reported either negative or 
controversial results (La Fata et al., 2014; Bjelakovic and Gluud, 2007. This indicates 
that different mechanisms are involved in the lower levels of oxidative stress, which 
does not necessarily require antioxidant effects. Therefore, we can only hypothesize 
that the antioxidant effect of quercetin might be responsible for the reduction of the 
SD-induced increase in LPO levels. Likewise, it is only possible to imply that the 
antioxidant effect of this flavonoid might contribute to its antimanic-like effect. 
Our results indicate that quercetin decreases SD-induced hyperlocomotion and 
displays an antimanic-like effect. Our results also indicated an antioxidant effect of 
quercetin, which may be related to its antimanic-like effect. Similar results were found 
for lithium, which is currently the treatment of choice for BD. The antioxidant and PKC 




Overall, the present study showed that quercetin prevented SD-induced 
hyperlocomotion in mice at doses that did not impair locomotor activity, suggesting an 
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antimanic-like effect. This flavonoid also reversed the SD-induced decrease in GSH 
levels in the PFC and striatum and SD-induced increase in LPO in the PFC, 
hippocampus, and striatum. These behavioral and neurochemical effects appeared to 
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Increases in protein kinase C (PKC) and oxidative stress have been related to mania. 
Drugs with antioxidant effects or inhibitory actions on PKC may have antimanic effects. 
The flavonoid quercetin has antioxidant and PKC-inhibiting effects that resemble those 
of lithium, the first-line treatment for mania in bipolar disorder. We hypothesized that 
quercetin may have antimanic-like effects in an animal model. In the present study, 
we investigated the effects of acute and chronic treatment with quercetin (2.5, 5, 10, 
and 40 mg/kg i.p.) in male Swiss mice that were subjected to methylphenidate (5 
mg/kg i.p.)-induced hyperlocomotion, an animal model of mania. Lithium (100 mg/kg 
i.p.) and diazepam (5 mg/kg i.p.) were used as positive and negative controls, 
respectively. We also evaluated the effects of these treatments on methylphenidate-
induced oxidative stress in the brain by measuring reduced glutathione (GSH) and 
lipid peroxidation (LPO) levels in the prefrontal cortex, hippocampus, and striatum. 
Acute and chronic (21-day) treatment with lithium and diazepam reduced 
methylphenidate-induced hyperlocomotion. Chronic but not acute treatment with 
quercetin (10 and 40 mg/kg) blocked methylphenidate-induced hyperlocomotion. 
These effects of lithium and quercetin occurred at doses that did not alter spontaneous 
locomotor activity, whereas diazepam reduced spontaneous locomotor activity. 
Chronic treatment with lithium and quercetin blocked the methylphenidate-induced 
increase in LPO levels in the striatum. These results suggest that chronic quercetin 
treatment has antimanic-like and antioxidant effects, thus encouraging further studies 
of quercetin as a putative new antimanic drug. 
 
Key words: Bipolar disorder, hyperlocomotion, mania, oxidative stress, protein kinase 
C, quercetin. 
Abbreviations: BD, bipolar disorder; CMC, carboxymethylcellulose; DTNB, 5,5’-
dithiobis-(2-nitrobenzoic acid); GSH, reduced glutathione; LPO, lipid peroxidation; 




   
 
1. INTRODUCTION 
Manic episodes in bipolar disorder (BD) are treated with mood stabilizers (e.g., 
lithium), atypical antipsychotics (e.g., risperidone), and anticonvulsants (e.g., sodium 
valproate), but their management in clinical settings remains a challenge (Hoertel et 
al., 2013; Nivoli et al., 2012). Mania has been related to oxidative stress (Berk et al., 
2011; Andreazza et al., 2008) and increased activity of protein kinase C (PKC) (Armani 
et al., 2014; Manji and Lenox, 2000). Lithium and sodium valproate, which are the 
most frequently used antimanic drugs, exert antimanic effects via PKC inhibition 
and/or antioxidant activity (Abrial et al., 2015; Armani et al., 2014; Macêdo et al., 2012; 
Frey et al., 2006 Wang and Friedman, 1989).  
One animal model that is employed to induce manic-like behavior involves the 
administration of psychostimulants, such as methylphenidate. The pharmacological 
induction of manic-like behavior (e.g., hyperlocomotion) is relatively easy to generate 
and test and has reliability and validity. Locomotor activity is known to increase in 
manic patients (Young et al., 2011). Mines et al. (2013) showed that methylphenidate, 
which blocks dopamine and noradrenaline transporters (DAT and NET respectively) 
enhancing dopamine and norepinephrine synaptic levels, increased locomotor activity 
in mice, and this effect was blocked by sodium valproate, carbamazepine, and lithium 
at doses that did not impair spontaneous locomotor activity (Nogoceke et al., 2016; 
Souza et al., 2016; Arunagiri et al., 2014; Tonelli et al., 2013; Barbosa et al., 2011; 
Pereira et al., 2011). 
Quercetin is a flavonoid that possesses antioxidant properties (Dajas et al., 
2015) and inhibits PKC (Gamet-Payrastre et al., 1999). We hypothesized that 
quercetin might also have antimanic-like effects. A previous study found that acute 
administration of quercetin blocked both hyperlocomotion and oxidative stress that 
were induced by sleep deprivation (Kanazawa et al., 2016). However, this previous 
study administered quercetin only acutely and employed only one model, which may 
have resulted in false-positive results. Quercetin has already been tested in a clinical 
trial of its anti-inflammatory effects (Boots et al., 2011), indicating its therapeutic utility. 
The objective of the present study was to evaluate the effects of acute and chronic 
quercetin administration on methylphenidate-induced hyperlocomotion and oxidative 




   
 
2. MATERIALS AND METHODS 
2.1. Animals 
The study included male Swiss mice, weighing 30-40 g, that were housed at 
22ºC ± 2ºC under a 12 h/12 h light/dark cycle (lights on at 7:00 AM). The animals were 
kept in polypropylene cages (41 cm x 34 cm x 16 cm) with food and water available 
ad libitum. All of the experiments were approved by the Committee of Animal 
Experimentation of the Federal University of Paraná (CEUA/BIO-UFPR, protocol no. 
733) and conducted in accordance with the Guide for the Care and Use of Laboratory 
Animals (National Institutes of Health). 
 
2.2. Drugs 
Mice were treated with saline (0.9% NaCl; 10 ml/kg i.p.), lithium carbonate 
(Eurofarma, Itapevi, Brazil; positive control; 100 mg/kg i.p. dissolved in saline, with the 
pH adjusted to 7.4 with hydrochloric acid), diazepam (Cristália, Itapira, Brazil; 5 mg/kg 
i.p., dissolved in distilled water), or quercetin (Sigma, St. Louis, MO, USA; 2.5, 5, 10, 
or 40 mg/kg i.p., suspended in 0.5% carboxymethylcellulose [CMC]). Methylphenidate 
(Novartis, São Paulo, Brazil) was dissolved in saline and administered subcutaneously 
(s.c.) at a dose of 5.0 mg/kg. The drugs were administered in a volume of 10 ml/kg of 
body weight. The doses were based on data from the literature (Bhutada et al., 2010) 
and previous studies by our research group (Kanazawa et al., 2016; Pereira et al., 
2011; Sabioni et al., 2008). Chronic treatment with lithium, diazepam, and quercetin 
was performed once per day for 21 days. 
 
2.3. Methylphenidate-induced hyperlocomotion protocol 
In the acute treatment protocol, the animals were pretreated with lithium, 
diazepam, quercetin, or vehicle 15 min before the administration of either vehicle or 
methylphenidate (Figure 1, top). In the chronic treatment protocol, the animals were 
pretreated with lithium, diazepam, quercetin, or vehicle once per day for 21 days. On 
the test day, vehicle or methylphenidate was administered 15 min after the last 
administration of lithium, diazepam, quercetin, or vehicle (Figure 1, bottom). 
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Twenty minutes after vehicle or methylphenidate administration, the animals 
were individually placed in an automated activity box (40 cm x 20 cm x 26 cm) that 
was constructed from wood with a wire mesh floor. The box had three photoelectric 
sensors (10 cm apart) on the two longer lateral walls. The number of crossings was 
cumulatively recorded by photoelectric sensors over a 20 min period. The number of 
crossings was considered an index of locomotor activity. An increase in the number of 
crossings after methylphenidate administration indicated a stimulant effect. The 
blockade of the stimulant effect of methylphenidate at a dose that did not decrease 
spontaneous locomotor activity indicated an antimanic-like effect (Sabioni et al., 2008; 
Gould et al., 2001). 
 
 
Fig 1. Timeline of treatment schedule and methylphenidate-induced hyperlocomotion model of mania 
in mice. 
 
2.5. Evaluation of oxidative stress parameters in the mouse brain 
2.5.1. Brain samples 
The mice were euthanized by decapitation immediately after being exposed to 
the automated activity box. The prefrontal cortex (PFC), hippocampus, and striatum 
were dissected, frozen in liquid nitrogen, and stored at -80ºC until further analysis. The 
samples were homogenized in potassium phosphate buffer (0.1 M, pH 6.5) in a 1:10 
dilution. One part of the homogenate was used to evaluate reduced glutathione (GSH) 
levels, and the other part was centrifuged at 9700 rotations per minute (rpm) in a micro-
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high-speed refrigerated centrifuge (VS-15000 CFNII, Vision Scientific, Daejeon, South 
Korea) for 20 min. The supernatant was used to evaluate lipid peroxidation (LPO) 
levels. 
 
2.6. Evaluation of GSH levels 
To evaluate GSH levels, 100 µl of the homogenate was mixed with 80 µl of 
12.5% trichloroacetic acid and centrifuged at 6000 rpm for 15 min at 4ºC. Afterwards, 
20 µl of the supernatant was mixed with 280 µl of Tris buffer (0.4 M, pH 8.9) and 5 µl 
of 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB; 0.01 M) according to the protocol of 
Sedlak and Lindsay (1968), with minor modifications. Absorbance was read at 415 nm 
using a multi-mode microplate reader (BioTek Synergy HT, BioTek Instruments, 
Winooski, VT, USA). The individual values were then interpolated in a standard curve 
of GSH (0.375-3 µg) to verify the linearity of the reaction (r2 must be > 0.99), and the 
values were divided by a correction factor. The results are expressed as µg of GSH 
per g of tissue. 
 
2.7. Evaluation of LPO levels 
LPO levels were measured according to the method of Jiang et al. (1992), with 
minor modifications. Initially, 100 ml of the supernatant was suspended in 100 µl of 
methanol, vortexed, and then centrifuged at 5000 rpm for 5 min at 4ºC. Afterward, 100 
ml of the supernatant was added to 900 µl of FOX2 reagent (4 mM BHT, 250 µM 
FeSO4, 250 mM H2SO4, and 100 mM xylenol orange). The samples were vortexed 
and incubated in the dark for 30 min at room temperature. Absorbance was read at 
560 nm using a multi-mode microplate reader (BioTek Synergy HT, BioTek 
Instruments, Winooski, VT, USA). The results are expressed as mmol of 
hydroperoxides per mg of tissue. 
 
2.9. Statistical analysis 
For all of the experiments, two-way analysis of variance (ANOVA) was used. 
Significant main effects or interactions in the ANOVA were followed by the Newman-
Keuls post hoc test. The Pearson correlation coefficient (r) was performed to measure 
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the correlation between locomotor activity and oxidative stress parameters. The data 
are expressed as mean ± SEM. Values of p < 0.05 were considered statistically 




3.1. Behavioral test 
3.1.1. Effect of acute quercetin administration on methylphenidate-
induced hyperlocomotion 
There are significant main effects of methylphenidate (F1,42 = 127.56, p < 
0.0001) and acute treatment (F6,42 = 17.24, p < 0.0001) and a methylphenidate ´ acute 
treatment interaction (F6,42 = 3.85, p < 0.01). Lithium and diazepam blocked the effects 
of methylphenidate (p < 0.05). Diazepam alone reduced spontaneous locomotor 
activity (p < 0.05, compared with vehicle + vehicle). No effect of quercetin was 
observed at any dose tested (Figure 2). 
 
3.1.2. Effect of chronic quercetin treatment on methylphenidate-induced 
hyperlocomotion 
There are significant main effects of methylphenidate (F1,42 = 131.90, p < 0.001) 
and chronic treatment (F6,42 = 14.90, p < 0.001) and a methylphenidate chronic 
treatment interaction (F6,42 = 9.96, p < 0.001). Methylphenidate increased locomotor 
activity compared with the control (vehicle + vehicle; p < 0.01; Figure 4). Treatment 
with lithium, diazepam, and 10 and 40 mg/kg quercetin blocked methylphenidate-
induced hyperlocomotion (all p < 0.05). Treatment with 2.5 and 5 mg/kg quercetin 
attenuated methylphenidate-induced hyperlocomotion (p < 0.05, compared with 
vehicle + vehicle and vehicle + methylphenidate). No effect of lithium or quercetin on 
spontaneous locomotor activity was observed. Treatment with diazepam alone 
significantly reduced spontaneous locomotion (p < 0.001). 
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Fig 2. Effect of acute (A) and chronic (21-day) (B) treatment with quercetin (Q; 2.5-40 mg/kg i.p.), lithium 
(Li; 100 mg/kg i.p.), and diazepam (DZ; 5 mg/kg i.p.) on methylphenidate-induced hyperlocomotion. 
Veh, vehicle; MPH, methylphenidate (5.0 mg/kg i.p.). The data are expressed as the mean ± SEM 
number of beam breaks over 20 min. n = 4 mice/group (acute) and n = 10-12 mice/group (chronic). *p 
< 0.05, compared with vehicle+vehicle; #p <0.05, compared with vehicle+methylphenidate; +p < 0.05, 
compared with same drug+vehicle; (+)0.05 < p < 0.10, compared with same drug+vehicle (Two-way 
ANOVA followed by Newman-Keuls test). 
 
3.2. Oxidative stress 
3.2.1. Effect of acute administration of quercetin on GSH levels after 
methylphenidate-induced hyperlocomotion 
There are significant effects of methylphenidate (F1,42 = 75.73, p < 0.001) and 
acute treatment (F6,42 = 5.72, p < 0.001) on GSH levels in the PFC and a 
methylphenidate x acute treatment interaction (F6,42 = 9.54, p < 0.001). 
Methylphenidate increased GSH levels compared with the vehicle + vehicle group (p 
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< 0.001). Lithium and 2.5, 5.0, and 40 mg/kg quercetin also increased GSH levels (p 
< 0.05, compared with vehicle + vehicle). None of the treatments affected the 
methylphenidate-induced increase in GSH levels (Table 1). 
There are significant effects of methylphenidate (F1,40 = 19.95, p < 0.001) and 
acute treatment (F6,40 = 4.70, p < 0.01) but no methylphenidate x acute treatment 
interaction (F6,40 = 1.22, p > 0.05; Table 1). Independent of treatment, methylphenidate 
increased GSH levels (p < 0.01). Quercetin (2.5 and 5.0 mg/kg) increased GSH levels 
independent of methylphenidate treatment (both p < 0.05). 
There is a significant main effect of methylphenidate (F1,33 = 9.45, p < 0.05) but 
no effect of acute treatment (F6,33 = 1.42, p > 0.05) and no methylphenidate x acute 
treatment interaction (F6,33 = 0.13, p < 0.05; Table 1). Methylphenidate decreased GSH 
levels independent of treatment (p < 0.01). 
 
Table 1. Effects of acute quercetin (Q: 2.5-40 mg/kg i.p.), lithium (Li: 100 mg/kg i.p.) and diazepam (DZ: 
5 mg/kg i.p.) administration on LPO levels in the PFC, hippocampus, and striatum in mice in the 
methylphenidate-induced hyperlocomotion model. 
Index Area  
Treatment 
Veh Li DZ Q 2.5 Q 5 Q 10 Q 40 
GSH 
Hippocampus 
Veh 23 ± 1 32 ± 3 23 ± 4 29 ± 2 2 37 ± 3 2 24 ± 4 30 ± 3 
MPH 31 ± 2 34 ± 4 28 ± 2 41 ± 2 2 40 ± 2 2 38 ± 4 36 ± 3 
PFC 
Veh 81 ± 6 286 ± 24 153 ± 9 242 ± 11* 182 ± 18* 130 ± 13 168 ± 27* 
MPH 302 ± 36* 250 ± 22* 358 ± 6* 298 ± 19* 202 ± 20* 255 ± 25* 281 ± 36* 
Striatum 
Veh 33 ± 3 32 ± 1 30 ± 1 32 ± 2 31 ± 1 33 ± 1 28 ± 2 
MPH 30 ± 1 29 ± 1 27 ± 3 30 ± 1 29 ± 2 28 ± 1 25 ± 3 
LPO 
Hippocampus 
Veh 12 ± 1 14 ± 1 14 ± 1 15 ± 2 22 ± 2* 22 ± 2* 19 ± 2* 
MPH 22 ± 1* 15 ± 1# 15 ± 1# 19 ± 1* 22 ± 1* 27 ± 2* 18 ± 1* 
PFC 
Veh 32 ± 1 28 ± 1 49 ± 2 35 ± 4 45 ± 4 40 ± 3 2 43 ± 1 2 
MPH 39 ± 5 29 ± 3 51 ± 5 39 ± 1 37 ± 2 45 ± 5 2 59 ± 4 2 
Striatum 
Veh 14 ± 1 16 ± 1 15 ± 1 18 ± 1 15 ± 2 14 ± 2 14 ± 1 
MPH 15 ± 1 16 ± 2 18 ± 1 16 ± 2 15 ± 2 15 ± 1 17 ± 1 
Veh, vehicle; Q, quercetin (2.5-40 mg/kg i.p.); Li, lithium (100 mg/kg i.p.); DZ, diazepam (5 mg/kg i.p.).; 
MPH: methylphenidate. The data are expressed as mean + SEM. n = 4 mice/group. 
* p < 0.05, compared with vehicle + vehicle 
# p < 0.05, compared with vehicle + methylphenidate 
1 p < 0.05, compared with vehicle (independent of acute treatment factor) 





   
 
3.2.2. Effect of acute quercetin treatment on LPO levels after 
methylphenidate-induced hyperlocomotion 
There are significant main effects of methylphenidate (F1,41 = 10.32, p < 0.01) 
and acute treatment (F6,41 = 13.13, p < 0.001) but no methylphenidate x acute 
treatment interaction (F6,41 = 1.11, p > 0.05; Table 1). Independent of treatment, 
methylphenidate increased LPO levels (p < 0.01). Quercetin (10 and 40 mg/kg) 
increased LPO levels independent of methylphenidate treatment (both p < 0.01). 
 There are significant main effects of methylphenidate (F1,41 = 16.14, p < 0.001) 
and acute treatment (F6,41 = 13.28, p < 0.001) and a significant methylphenidate x 
acute treatment interaction (F6,41 = 3.92, p < 0.001). Methylphenidate increased LPO 
levels compared with the vehicle + vehicle group (p < 0.001). Treatment with 5.0, 10, 
and 40 mg/kg quercetin alone increased LPO levels (5 and 10 mg/kg, p < 0.001; 40 
mg/kg, p < 0.05) but did not block the methylphenidate-induced increase in LPO levels. 
Lithium and diazepam blocked the effect of methylphenidate (p < 0.05; Table 1). 
There is no significant effect of methylphenidate (F1,41 = 1.61, p > 0.05) or acute 
treatment (F6,41 = 0.88, p > 0.05) and no methylphenidate x acute treatment interaction 
(F6,41 = 0.84, p > 0.05; Table 1). 
 
3.2.3. Effect of chronic quercetin treatment on GSH levels after 
methylphenidate-induced hyperlocomotion 
There is a significant effect of chronic treatment (F6,42 = 18.65, p < 0.001) but 
no effect of methylphenidate (F1,42 = 2.92, p > 0.05) and no methylphenidate x chronic 
treatment interaction (F6,42 = 1.18, p > 0.05; Figure 3). Lithium and 5.0 and 40 mg/kg 
quercetin increased GSH levels independent of methylphenidate administration. 
There are significant effects of methylphenidate (F1,40 = 42.78, p < 0.001) and 
chronic treatment (F6,40 = 4.77, p < 0.001) but no methylphenidate x chronic treatment 
interaction (F6,40 = 2.18, p = 0.064; Figure 3). Independent of treatment, 
methylphenidate increased GSH levels (p < 0.001). No significant difference was 
observed between vehicle and any other treatment in chronic treatment factor. 
There are significant effects of methylphenidate (F1,40 = 71.38, p < 0.001) and 
chronic treatment (F6,40 = 5.03, p < 0.001) and a methylphenidate chronic treatment 
interaction (F6,40 = 7.35, p < 0.001). The post hoc test indicated that the vehicle + 
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methylphenidate group exhibited a tendency toward a decrease in GSH levels 
compared with the vehicle + vehicle group (p = 0.06). Chronic treatment with 2.5 mg/kg 
quercetin increased GSH levels in the striatum compared with the vehicle + vehicle 
group (p < 0.05). The 2.5 mg/kg quercetin + methylphenidate group exhibited a 
decrease in GSH levels compared with the vehicle + vehicle group (p < 0.05). The 
methylphenidate + quercetin groups exhibited a reduction of striatal GSH levels 
compared with the vehicle + quercetin group at all quercetin doses tested, except for 
the 5.0 mg/kg dose (all p < 0.05; Figure 3). 
 
Fig 3. Effects of chronic quercetin (Q; 2.5-40 mg/kg i.p.), lithium (Li; 100 mg/kg i.p.), and diazepam (DZ; 
5 mg/kg i.p.) administration on GSH levels in the PFC (A), hippocampus (B), and striatum (C) in mice 
in the methylphenidate-induced hyperlocomotion model. The data are expressed as mean ± SEM. n = 
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4 mice/group. *p < 0.05, compared with vehicle+vehicle; #p < 0.05, compared with 
vehicle+methylphenidate; (*)0.05 < p < 0.10, compared with vehicle+vehicle; (#)0.05 < p < 0.10, 
compared with vehicle+methylphenidate; +p < 0.05, compared with same drug+vehicle (Two-way 
ANOVA followed by Newman-Keuls test). 
 
3.2.4. Effect of chronic quercetin treatment on LPO levels after 
methylphenidate-induced hyperlocomotion 
There are significant effects of methylphenidate (F1,41 = 41.49, p < 0.001) and 
chronic treatment (F6,41 = 3.96, p < 0.01) but no methylphenidate x chronic treatment 
interaction (F6,41 = 1.93, p > 0.05; Figure 4A). Independent of treatment, 
methylphenidate increased LPO levels (p < 0.001). Quercetin (40 mg/kg) increased 
LPO levels independent of methylphenidate treatment (p < 0.05). 
 There are significant effects of methylphenidate (F1,41 = 16.89, p < 0.001) and 
chronic treatment (F6,41 = 3.59, p < 0.01) and a methylphenidate x chronic treatment 
interaction (F6,41 = 4.77, p < 0.001). The post hoc test indicated that methylphenidate 
increased LPO levels in the hippocampus compared with the vehicle + vehicle group 
(p < 0.05). No dose of quercetin blocked the methylphenidate-induced increase in LPO 
levels in the hippocampus. Treatment with diazepam alone increased LPO levels 
compared with vehicle + vehicle (p < 0.05), whereas the diazepam + methylphenidate 
group did not differ from the vehicle + vehicle group (Figure 4B). 
There are significant effects of methylphenidate (F1,39 = 33.88, p < 0.001) and 
chronic treatment (F6,39 = 8.22, p < 0.001) and a methylphenidate x chronic treatment 
interaction (F6,41 = 3.24, p < 0.05). The post hoc test indicated that methylphenidate 
increased LPO levels compared with the vehicle + vehicle group (p < 0.001). 
Treatment with lithium, diazepam, and 2.5, 5.0, 10, and 40 mg/kg quercetin decreased 





   
 
 
Fig 4. Effects of chronic quercetin (Q; 2.5-40 mg/kg i.p.), lithium (Li; 100 mg/kg i.p.), and diazepam (DZ; 
5 mg/kg i.p.) administration on LPO levels in the PFC (A), hippocampus (B), and striatum (C) in mice in 
the methylphenidate-induced hyperlocomotion model. The data are expressed as mean ± SEM. n = 4 
mice/group. *p < 0.05, compared with vehicle+vehicle; #p < 0.05, compared with 
vehicle+methylphenidate; +p < 0.05, compared with same drug+vehicle; (+)0.05 < p < 0.10, compared 




   
 
3.2.5. Correlation between methylphenidate-induced hyperlocomotion 
and GSH and LPO levels in the hippocampus, striatum, and PFC 
Considering all animals from the acute treatment protocol, a positive correlation 
was found between hyperlocomotion and LPO levels in the PFC (r =  0.48, p < 0.001) 
and hippocampus (r = 0.56, p < 0.001), and a positive correlation was found between 
hyperlocomotion and GSH levels in the PFC (r = 0.32, p < 0.05) and hippocampus (r 
= 0.46, p < 0.001) (Table 2). 
Considering all animals from the chronic treatment protocol, a positive 
correlation was found between hyperlocomotion and GSH levels in the hippocampus 
(r = 0.37, p < 0.01), and a positive correlation was found between hyperlocomotion 
and LPO levels in the PFC (r = 0.26, p < 0.05) and striatum (r = 0.32, p < 0.05). A 
negative correlation was found between hyperlocomotion and GSH levels in the 
striatum (r = -0.36, p < 0.01) (Table 2). 
 
Table 2. Correlation coefficients (Pearson’s r) between methylphenidate-induced hyperlocomotion and 
GSH and LPO levels in the hippocampus, striatum, and PFC. 
  Hippocampus   Striatum     Prefrontal cortex 
Locomotor activity GSH LPO   GSH LPO   GSH LPO 
         
Acute treatment         
All mice (n = 47-56) 0.46* 0.56***  -0.17 -0.01  0.38** 0.48*** 
         
Chronic treatment         
All mice (n = 53-56) 0.37*** 0.09  -0.36** 0.32*  -0.03 0.26*** 
         
*p < 0.05, **p < 0.01, ***p < 0.001, (*) 0.01 < p < 0.05. 
 
4. DISCUSSION 
The present study showed that chronic but not acute treatment with 10 and 40 
mg/kg quercetin blocked methylphenidate-induced hyperlocomotion. Both acute and 
chronic lithium treatment blocked methylphenidate-induced hyperlocomotion, which is 
consistent with its clinical antimanic effect. These effects were seen at doses that did 
not alter spontaneous locomotor activity. The results with lithium indicate the sensitivity 
and validity of the procedure. The effects of quercetin on methylphenidate-induced 
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hyperlocomotion indicated an antimanic-like effect of chronic quercetin administration. 
Diazepam was used as a negative control, but acute and chronic diazepam treatment 
also blocked methylphenidate-induced hyperlocomotion. However, in both 
experiments, diazepam alone reduced locomotor activity, suggesting a sedative effect 
instead of an antimanic-like effect of diazepam (Young et al., 2011). 
Psychostimulant-induced hyperlocomotion is the most frequently used animal 
model of mania (Einat, 2006). This pharmacological induction of manic-like behavior 
is reliable and has face, construct, and predictive validity (Einat, 2006; Machado-Vieira 
et al., 2004). Psychostimulants that are able to increase the levels of dopamine induce 
behavioral effects that resemble mania, such as hyperlocomotion (Huey et al., 1981). 
Mania has been related to an increase in dopaminergic activity (Cousins et al., 2009). 
A reduction of dopaminergic activity ameliorates the symptoms of mania (Post et al., 
1980). Lithium is able to decrease dopaminergic transmission (Dziedzicka-
Wasylewska et al., 1996). Methylphenidate, which blocks dopamine reuptake, was 
shown to induce hyperlocomotion, which was prevented by lithium, valproate 
carbamazepine, and antipsychotic drug administration (Nogoceke et al., 2016; Souza 
et al., 2016; Arunagiri et al., 2014; Tonelli et al., 2013; Barbosa et al., 2011; Pereira et 
al., 2011). Moreover, methylphenidate can induce manic-like symptoms in humans 
(Ekinci et al., 2016; Chakraborty and Grover, 2011; Huey et al., 1981; Smith and Davis, 
1977). 
However, other factors are also involved in manic-like behavior that is induced 
by methylphenidate, such as oxidative stress. Burrows et al. (2000) reported that the 
administration of psychostimulants that increase dopaminergic neurotransmission can 
also cause oxidative stress. Shanthakumar et al. (2013) showed that mice that were 
treated with methylphenidate exhibited hyperlocomotion and increased oxidative 
stress, which were blocked by lithium treatment. 
The main antioxidant molecule in the brain is GSH, which participates in many 
cellular reactions. Reduced glutathione is involved in the regulation of lipid, glucose, 
and amino acid utilization. It is also involved in several chemical reactions that are 
associated with liver function, immunity, cellular physiology, and biosignaling 
pathways. However, the main function of GSH is its antioxidant activity. It effectively 
scavenges free radicals and other reactive oxygen species, removing hydrogen and 
lipid peroxides and preventing the oxidation of biomolecules (Wu et al., 2004). 
Therefore, the depletion of GSH levels may have deleterious effects. Gawryluk et al. 
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(2011) found lower levels of GSH in the post mortem PFC of BD patients compared 
with brain samples from individuals with no psychiatric illnesses. Macêdo et al. (2013) 
found that lisdexamphetamine dimesylate induced manic-like behavior in rats and 
decreased GSH content in the PFC, hippocampus, and striatum in rats, and these 
effects were reversed by lithium. 
In the present study, methylphenidate increased GSH levels in the PFC and 
hippocampus but decreased GSH levels in the striatum. Pearson’s correlation 
indicated a negative correlation between hyperlocomotion and GSH levels in the 
striatum in all of the animals that were subjected to the chronic treatment protocol. The 
heterogeneous effects of methylphenidate on GSH levels are not unusual or 
uncommon. Other research groups also reported diverse results regarding the effects 
of drugs that depend on dose, brain site, the specific oxidative stress parameter 
(Shanthakumar et al., 2013; Jornada et al., 2011; Bhalla and Dhawan, 2009; Frey et 
al., 2006). Our results showed that quercetin did not reverse the methylphenidate-
induced decrease in GSH levels, but in some cases quercetin increased GSH levels 
compared with controls (vehicle + vehicle). 
Emerging data indicate that oxidative stress may play a role in psychiatric 
illnesses, including BD. Low levels of free radicals or reactive oxygen/nitrogen species 
are considered normal, but high levels can damage and oxidize nucleic acids, 
carbohydrates, and lipids (Joshi and Praticò, 2014). Lipids are the major components 
of cell membranes, including neuronal membranes, and their peroxidation and 
alterations that generate hydroperoxides can greatly affect brain function (Joshi and 
Praticò, 2014). The levels of LPO increase during manic episodes. Lithium, which is 
used to treat mania in bipolar disorder, inhibits LPO and protein oxidation, suggesting 
that it has neuroprotective effects against oxidative stress that may be related to its 
antimanic effect (Cui et al., 2007). LPO that results from uncompensated oxidative 
stress is an important finding in BD, regardless of the stage of the illness (Andreazza 
et al., 2007; Machado-Vieira et al., 2007). Macêdo et al. (2013) also found an increase 
in LPO levels in the PFC, hippocampus, and striatum in rats in an animal model of 
psychostimulant-induced hyperlocomotion. Lithium treatment blocked this increase in 
oxidative stress. 
In the present study, the effects of methylphenidate on oxidative stress were 
heterogeneous. Pearson’s correlation indicated a positive correlation between 
hyperlocomotion and LPO levels in the PFC and hippocampus. Overall, 
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methylphenidate administration increased LPO levels in the PFC, hippocampus, and 
striatum. Acute lithium administration blocked the methylphenidate-induced increase 
in LPO only in the hippocampus. Acute diazepam administration blocked the 
methylphenidate-induced increase in LPO in the hippocampus, although at a dose that 
also decreased spontaneous locomotor activity. Chronic treatment with 10 mg/kg 
quercetin blocked the methylphenidate-induced increase in LPO levels in the PFC. 
Chronic treatment with lithium, diazepam, and all doses of quercetin blocked the 
methylphenidate-induced increase in LPO levels in the striatum. These results suggest 
that treatments that prevent methylphenidate-induced hyperlocomotion also have 
antioxidant effects. 
However, such effects have been inconsistent. Arunagiri et al. (2014) showed 
that methylphenidate decreased GSH levels and increased LPO levels in whole brain 
homogenates, and lithium treatment restored GSH levels and reduced LPO levels. 
Various other studies reported heterogeneous results concerning the effects of drugs 
on oxidative stress in the brain (Shanthakumar et al., 2013; Jornada et al., 2011; Bhalla 
and Dhawan, 2009; Frey et al., 2006). The results have varied, depending on the 
treatment protocol, drug, dose, and brain site, among other factors. Martins et al. 
(2006) found that methylphenidate administration reduced LPO levels in the PFC and 
striatum in rats. At lower doses, methylphenidate decreased LPO levels in the 
hippocampus. At higher doses, methylphenidate increased LPO levels in the 
hippocampus. Although our study found heterogeneous results, chronic treatment with 
lithium and quercetin reduced antimanic-like behavior and reduced LPO levels in the 
striatum. The present and previous findings reinforce the putative role of oxidative 
stress in mania. 
Overall, the present results indicated that chronic quercetin decreased 
methylphenidate-induced oxidative stress and hyperlocomotion, whereas acute 
treatment did not. This partially agrees with previous data that showed that acute 
quercetin treatment attenuated the increase in oxidative stress that was induced by 
sleep deprivation, which also led to an increase in locomotor activity (Kanazawa et al., 
2016). The disagreement between these studies may be related to the different animal 
models of mania that were used, which reinforces the importance of using more than 
one model to evaluate the potential antimanic-like effects of drugs. Altogether, these 
data indicate an acute and chronic effect of quercetin on manic-like behavior. 
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Previous studies have shown that increases in dopaminergic transmission and 
consequent hyperlocomotion involve the activation of signaling pathways that are 
related to such enzymes as PKC (Abrial et al., 2015). Both lithium and quercetin exert 
antioxidant effects, and both are known to exert inhibitory effects on the activity of PKC 
(Manji and Lenox, 2000). Our research group showed that myricitrin, a flavonoid that 
has antioxidant and PKC-inhibitory actions, blocked oxidative stress and manic-like 
behavior (Pereira et al., 2014; Andreatini et al., 2013). The pathophysiology of mania 
in bipolar disorder involves increases in both PKC activity and oxidative stress 
(Andreazza et al., 2007; Machado-Vieira et al., 2007; Friedman et al., 1993). We 
hypothesized that quercetin might have antimanic properties. Indeed, chronic 
treatment with 10 and 40 mg/kg quercetin blocked methylphenidate-induced 
hyperlocomotion. In some cases, quercetin also restored GSH levels and decreased 
LPO levels after methylphenidate administration, similar to the effects of lithium. This 
indicates that the antimanic-like effect of quercetin may be linked to a decrease in 
oxidative stress.  
PKC regulates several potential targets related to mood disorders, such as 
DAT, SERT, GSK3β, adenylate cyclase, NMDA receptors, GAP-43, BDNF and 
neurogenesis (Abrial et al., 2015). Specifically to dopamine system, PKC regulates 
DAT trafficking to cell surface, modulating dopamine neurotransmission (Vaughan and 
Foster, 2013; Chen et al., 2009) Moreover, PKC also affects drug induced dopamine 
efflux (Mikelman et al., 2016) Thus, an increase in PKC activity is associated with 
enhanced dopaminergic activity. It was proposed that dopamine transmission is 
increased in mania (Cousins et al., 2009), which can result in an augment in dopamine 
metabolism, generating dopamine metabolites rising. Quinone oxidative products of 
dopamine metabolites can generate toxic effects and increase oxidative stress 
(Segura-Aguilla et al., 2014). In this line, psychostimulants (amphetamine and 
fenproporex) act by augmenting dopamine transmission and they induce 
hyperlocomotion and oxidative stress increasing (Model et al., 2014; Young et al., 
2011). Thus, quercetin can exert its antimanic-like effect reducing oxidative stress and 
PKC activity. 
Quercetin has already been tested in clinical trials with regard to its anti-
inflammatory effect. The effective dose range in the present study was within the dose 




   
 
5. CONCLUSION 
Chronic quercetin treatment blocked methylphenidate-induced 
hyperlocomotion in mice, indicating an antimanic-like effect. Moreover, chronic 
quercetin treatment blocked the methylphenidate-induced increase in oxidative stress 
indices. These results corroborate previous data that indicated that quercetin may 
have antimanic-like effects that are associated with an antioxidant effect. Furthermore, 
the present findings extend previous data that showed that no tolerance to this effect 
develops after repeated administration, which is an important issue for the treatment 
of mania. The putative anti-inflammatory and antioxidant effects of quercetin have 
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The reduced number of efficient and safe pharmacological options for the 
management of bipolar disorder (BD) makes the research for alternative drugs 
necessary. Considering that lithium as the gold standard antimanic drug inhibits the 
enzyme glycogen synthase kinase 3 beta (GSK3β), we hypothesized that GSK3β 
inhibitor andrographolide (ANDRO), a component of the plant Andrographis 
paniculata, could possess antimanic-like properties. Moreover, considering that brain 
oxidative stress plays a pivotal role in several psychiatric disorders including BD, and 
that lithium shows antioxidant effects, we hypothesized that the flavonoid and 
antioxidant quercetin could also possess antimanic-like properties. 
Our findings show that chronic treatment with 0.5 and 2.0 mg/kg ANDRO and 
100 mg/kg lithium prevented 24h sleep deprivation (SD)- and methylphenidate-
induced hyperlocomotion. These are, respectively, non-pharmacological and 
pharmacological models of induction of manic-like behavior. The induction of SD and 
the administration of methylphenidate are considered to be valid animal models of 
mania, as they show face, construct and predictive validity (Einat, 2006; Machado-
Vieira et al., 2004). After 24h SD, animals show insomnia, hyperactivity, irritability, 
aggressiveness, hypersexuality, and stereotypy, which are behaviors also seen in 
humans after SD (Pereira et al., 2014; Gessa et al., 1995), and increases in the 
emission of 50-kHz ultrassonic vocalizations (USVs) (Wendler et al., 2019). 
Methylphenidate administration in animals mimic the effects of psychostimulant 
administration in humans, which induce manic behavior in healthy humans and BD 
patients, such as decreased need for sleep, elevated mood, hypersexuality, affecting 
sensorimotor function, and learning and memory (Corp et al., 2014; Cousins et al., 
2009; Berk et al., 2007; Asghar et al., 2003; Jacobs and Silverstone, 1986). This 
underlines the face validity of both models of mania. 
The 24h SD model also involves several neurochemical alterations, such as 
increase in the expression of D2 receptors in the striatum and supersensibility of 
dopaminergic receptors, leading to increased dopaminergic signaling in animals, 
which is also seen in BD patients (Lima et al., 2007; Tufik et al., 1978). 
Methylphenidate administration affects several neurotransmitter systems, as it 
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increases synaptic dopamine and norepinephrine through inhibition or reversing 
reuptake mechanisms, which is in line with the fact that these neurotransmitters are 
affected in patients with BD. This shows the construct validity of both models (Beyer 
and Freund, 2017; Berk et al., 2007). 
Lithium and valproate, which are drugs frequently used in the therapy of BD, 
can attenuate the SD- and methylphenidate-induced mania-relevant behavior, 
showing predictive validity of the models (Einat, 2006; Machado-Vieira et al., 2004; 
Gessa et al., 1995). Thus, the fact that ANDRO treatment prevented SD- and 
methylphenidate-induced hyperlocomotion denotes that ANDRO appears to possess 
antimanic-like properties.  
In parallel, we evaluated the effects of ANDRO on the levels of GSK3β and p-
GSK3β in the prefrontal cortex (PFC) and striatum of mice submitted to SD- or 
methylphenidate-induction of hyperlocomotion. Our results showed that SD decreased 
Ser9 phosphorylation of GSK3β in the PFC of mice, indicative of increased GSK3β 
activity. Chronic treatment with lithium or 2.0 mg/kg ANDRO were able to reverse this 
SD-induced decrease in p-Ser9-GSK3β. Methylphenidate induced decreased Ser9 
phosphorylation of GSK3β in the striatum, which was prevented by 2.0 mg/kg ANDRO 
and lithium. 
GSK3β is also considered to be a proinflammatory molecule, stimulating the 
production of various inflammatory cytokines and tumor necrosis factors. The inhibition 
of GSK3β has been proven to be beneficial in many inflammatory conditions (Jope et 
al., 2007). The impact of GSK3β on neurotransmission is unclear, but studies show 
that GSK3β interferes with neurotransmission as it affects the functioning of calcium 
and potassium channels. It is also involved in the phosphorylation of clock proteins 
and the regulation of the periodicity of the endogenous clock mechanism (Luca et al., 
2016). Higher levels of GSK3β have been reported in blood among patients 
experiencing manic episodes compared to healthy subjects (Luca et al., 2016). After 
lithium treatment, the levels did not change, but the inhibitory Ser9-phosphorylation of 
GSK3β increased (Li et al., 2010). Li and Jope (2010) reported a dysregulated activity 
of GSK3β, in terms of hyperactivity, due to a lower inhibitory Ser9 phosphorylation 
among BD. Dal-Pont et al. (2019) showed that SD induced manic-like behaviors in 
mice and decreases in neurotrophic factors in the PFC and hippocampus, which were 
reversed by treatment with lithium or valproate. Xue et al. (2019) showed that SD 
inhibited the PI3K/Akt/GSK3β pathway, suggesting an activation of GSK3β, 
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neuroinflammation and oxidative stress. Acute psychostimulant administration 
activates GSK3β by reducing its inhibitory Ser9-phosphorylation in mouse striatum and 
cerebral cortex, which is required for certain behavioral effects of psychostimulants, 
such as increased locomotor activity (Enman and Unterwald, 2012). By ablating 
GSK3β in the striatum of mice using a CRISPR-Cas9 system, Kim et al. (2019) 
showed that it suppressed amphetamine-induced hyperlocomotion. Mines and Jope 
(2012) demonstrated that 8-day intraperitoneal administration of 2 mg/kg 
amphetamine or 20 mg/kg methylphenidate led to decreased levels of p-Ser9-GSK3β 
in the striatum of C57BL/6J mice, which is similar to our observation in the 
methylphenidate model. They also showed that the effects of psychostimulants are 
brain region-selective as was also shown by our divergent PFC effects. Clearly more 
research is needed into the effects of GSK3β and their link to the mechanism of action 
of ANDRO in order to explain its antimanic-like affect. 
In the present study, we also evaluated the antimanic-like effect of ANDRO by 
inducing manic-like behavior (hyperlocomotion) by lisdexamfetamine (LDX) 
administration, which also leads to increases in 50-kHz USVs. LDX is a long-acting d-
amphetamine prodrug (Ermer et al., 2016) and its administration can be used as a 
model for mania (Eger et al., 2016; Wendler et al., 2016). The emission of USVs can 
be analyzed as a reflection of hedonic states of the rats (Burgdorf et al., 2011). Studies 
show that SD induces hyperlocomotion and increases in rearings and 50-kHz USV 
emission in rats, which denotes manic-like behaviors, showing face validity of the 
model (Wendler et al., 2019). Psychostimulants seem to induce increased 50-kHz 
USVs by D1 and D2 receptor activation (Rippberger et al., 2015), and this agrees with 
the pivotal role of increased dopaminergic neurotransmission in mania (Ashok et al., 
2017). Intra-accumbens application of quinpirole, a D2 and D3 receptor agonist, 
induces increases in 50-kHz USV emission (Brudzynski et al., 2012). LDX 
administration induces manic-like behaviors by enhancing dopaminergic 
neurotransmission, as well as inducing oxidative stress, and both parameters are 
involved in the pathophysiology of BD, thus showing the construct validity of the LDX 
administration model of mania (Macêdo et al., 2013). LDX administration induces 
increases in the number of 50-kHz USVs, which can be prevented by lithium treatment 
(Wendler et al., 2016). Pereira et al. (2014) demonstrated that lithium reversed 
amphetamine-induced increases in 50-kHz USV emission, and these studies 
demonstrate the predictive validity of the model as a model of mania. In our study, 
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chronic treatment with 2.0 mg/kg ANDRO prevented LDX-induced increases in the 
number of USVs and in the total time of USVs, as did chronic treatment with lithium. 
Both drugs also prevented LDX-induced hyperlocomotion.  
In parallel to the effects of ANDRO on LDX-induced hyperlocomotion and 
increases in 50-kHz USVs, we also evaluated the antioxidant effects of ANDRO. It has 
also been reported that both ANDRO and lithium possess antioxidant properties. 
Lithium reduces the superoxide dismutase and catalase ratio, thus reducing oxidative 
stress. In addition, lithium seems to exert positive effects on mitochondrial 
dysfunctions and endoplasmic reticulum stress response (Machado-Vieira et al., 2009; 
Maurer et al., 2009). The inhibition of GSK3β due to lithium administration has been 
found to be responsible for the resistance of oxidative stress of murine hippocampal 
neuronal cells (Schäfer et al., 2004). Zhang et al. (2019) showed that bupivacaine 
increased the levels of reactive oxygen species and decreased reduced glutathione 
(GSH) levels in human neuroblastoma SH-SY5Y cells, which was prevented by 
preincubation with ANDRO. Thakur et al. (2016) showed that streptozotocin-induced 
diabetic rats had increased lipid peroxidation (LPO) levels in the PFC, and this was 
reduced by ANDRO treatment. In our study, LDX administration induced increases in 
LPO in rat striatum, which were prevented by repeated treatment with ANDRO and 
lithium. There was a positive correlation between increased LPO levels in rat striatum 
and hyperlocomotion as well as increases in 50-kHz USVs. 
We also evaluated the antimanic-like properties of the flavonoid quercetin, a 
powerful antioxidant molecule and a protein kinase C (PKC) inhibitor, similar to lithium. 
Several studies link oxidative stress and PKC activity to the pathophysiology of BD 
(Valvassori et al., 2020; Garzón-Niño et al., 2017; Saxena et al., 2017). Therefore, we 
hypothesized that the antioxidant and PKC inhibitor quercetin might possess 
antimanic-like properties. In the present study, treatment with 10 and 40 mg/kg 
quercetin prevented SD-induced hyperlocomotion, as did lithium, the positive control. 
In addition, quercetin reversed SD-induced decreases in GSH levels in the PFC and 
striatum of mice, as well as reversing SD-induced increases in LPO in the PFC, 
hippocampus and striatum of mice. We also tested the effects of the acute and chronic 
treatment with 2.5, 5, 10 and 40 mg/kg quercetin on mice after methylphenidate-
induced hyperlocomotion. Our findings showed that chronic (but not acute) treatment 
with 10 and 40 mg/kg quercetin reversed methylphenidate-induced hyperlocomotion. 
Quercetin also reversed methylphenidate-induced increases in LPO levels in the 
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striatum of mice. Arunagiri et al. (2014) showed that methylphenidate decreased GSH 
levels and increased LPO levels in whole brain homogenates, and lithium treatment 
restored GSH levels and reduced LPO levels. Various other studies reported 
heterogeneous results concerning the effects of drugs on oxidative stress in the brain 
(Minassian et al., 2016; Berk et al., 2007; Einat, 2006; Müller-Oerlinghausen et al., 
2002). The results have varied, depending on the treatment protocol, drug, dose, and 
brain site, among other factors. Martins et al. (2006) found that methylphenidate 
administration reduced LPO levels in the PFC and striatum in rats. At lower doses, 
methylphenidate decreased LPO levels in the hippocampus. At higher doses, 
methylphenidate increased LPO levels in the hippocampus. Although our study found 
heterogeneous results, chronic treatment with lithium and quercetin reduced 
antimanic-like behavior and reduced LPO levels in the striatum. The present and 
previous findings reinforce the putative role of oxidative stress in mania. 
Gawryluk et al. (2011) showed that the post mortem PFC in BD patients had 
lower levels of GSH, which can lead to higher susceptibility to neuronal oxidation, 
interfere with neuronal activity, and may contribute to the establishment of BD 
symptoms (Dringen, 2000). In the present study, SD-induced hyperlocomotion was 
related to lower GSH levels in the PFC. Other studies have shown that the 
replenishment of GSH diminishes oxidative cellular damage and ameliorates the 
symptoms of BD (Magalhães et al., 2011; Dean et al., 2009). High levels of oxidative 
damage to membrane phospholipids or the aggregation of oxidized proteins alters 
fluidity, which can induce cell death by apoptosis (Mahadik et al., 2001). Under certain 
conditions, LPO causes structural disturbances, alterations in integrity, fluidity, and 
permeability, the functional loss of biomembranes, and the generation of potentially 
toxic products (Greenberg et al., 2008). Previous studies have reported that such 
uncompensated oxidative stress increases LPO throughout the course of BD 
(Andreazza et al., 2007; Machado-Vieira et al., 2007). All of this underlines the need 
to further study the antioxidant effect of ANDRO.  
Despite the numerous pharmacological activities of ANDRO, poor solubility and 
relatively low potency are still the major drawbacks of ANDRO to achieve therapeutic 
effect (Sharma et al., 2017). Further modification of the chemical structure and 
optimization of delivery system could enhance the pharmacological activity and 
increase the therapeutic index of ANDRO and its derivatives (Dai et al., 2018).  
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With regards to quercetin, studies also report poor oral bioavailability, however 
some studies indicate that quercetin glycosides are converted into aglycones in the 
intestine, by β-glycosidases, and then are adequately absorbed (Walle et al., 2005). 
The use of quercetin in the pharmaceutical industry is limited because of its poor 
permeability, poor solubility in water and poor bioavailability. However, several studies 
demonstrate that these parameters can be improved by modifications in the quercetin 
molecular structure. New quercetin formulations have been created, such as 
quercetin-loaded nanoparticles and quercetin-loaded polymeric micelles, or 
combinations with ions, such as calcium-phosphate-quercetin nanocomplex (Xu et al., 
2019). Thus, there is a perspective for the usage of ANDRO and quercetin as drugs, 
as they are already used as supplements and other preparations by the general 
population worldwide, and their safety has been attested. 
In conclusion, chronic treatment with ANDRO prevented hyperlocomotion 
induced by SD, methylphenidate and LDX, while increasing the p-Ser9-
GSK3β/GSK3β  ratio in the PFC or striatum of mice. ANDRO also prevented the 
increases of 50-kHz USVs induced by LDX, while preventing LDX-induced 
hyperlocomotion and lipid peroxidation in rats. Quercetin also prevented SD- and 
methylphenidate-induced hyperlocomotion and decreases in GSH or increases in LPO 
levels (oxidative stress parameters) in mice. Thus, both ANDRO and quercetin appear 
to possess antimanic-like effects and are promising agents to be thoroughly 






   
 
REFERENCES 
Andreazza, A. C.; Cassini, C.; Rosa, A. R.; Leite M. C.; De Almeida, L. M.; Nardin, P.; 
Cunha A. B.; Ceresér, K. M.; Santin, A.; Gottfried, C.; Salvador, M.; Kapczinski F.; 
Gonçalves C. A. Serum 100B and antioxidant enzymes in bipolar patients. Journal of 
Psychiatric Research. 41(6); 523-529, 2007. 
Arunagiri, P.; Rajeshwaran, K.; Shanthakumar, J.; Tamilselvan, T.; Balamurugan, E. 
Combination of omega-3 fatty acids, lithium, and aripiprazole reduces oxidative stress 
in brain of mice with mania. Biological Trace Element Research. 160; 409 – 417, 
2014. 
Asghar, S. J.; Tanay, V. A. M. I.; Baker, G. B.; Greenshaw, A.; Silverstone, P. H. 
Relationship of plasma amphetamine levels to physiological subjective, cognitive and 
biochemical measures in healthy volunteers. Human Psychopharmacology: 
Clinical & Experimental. v. 18(4): 291-299, 2003. 
Ashok, A. H.; Marques, T. R.; Jauhar, S.; Nour, M. M.; Goodwin, G. M.; Young, A. H.; 
Howes, O. D. The dopamine hypothesis of bipolar affective disorder: the state of the 
art and implications for treatment. Molecular Psychiatry. v. 22: 666-679, 2017. 
Berk, M.; Dodd, S.; Kauer-sant'anna, M.; Malhi, G. S.; Bourin, M.; Kapczinski, F.; 
Norman, T. Dopamine dysregulation syndrome: implications for a dopamine 
hypothesis of bipolar disorder. Acta Psychiatrica Scandinavica Supplementum. v. 
434: 41-9, 2007. 
Beyer, D. K. E.; Freund, N. Animal models for bipolar disorder: from bedside to the 
cage. International Journal of Bipolar Disorders. v. 5(1); 2017. 
Brudzynski, S. M.; Komadoski, M.; Pierre, J. S. Quinpirole-induced 50 kHz ultrasonic 
vocalization in the rat: role of D2 and D3 dopamine receptors. Behavioural Brain 
Research. v. 226(2); 511-518, 2012. 
Burgdorf, J.; Panksepp, J.; Moskal, J. R. Frequency-modulated 50 kHz ultrasonic 
vocalizations: a tool for uncovering the molecular substrates of positive affect. 
Neuroscience & Biobehavioral Reviews. v. 35(9): 1831-1836, 2011. 
Corp, S. A.; Gitlin, M. J.; Altshuler, L. L. A review of the use of stimulants and stimulant 
alternatives in treating bipolar depression and major depressive disorder. Journal of 
Clinical Psychiatry. v. 75(9): 1010-1018, 2014. 
Cousins, D. A.; Butts, K.; Young, A. H. The role of dopamine in bipolar disorder. 
Bipolar Disorders. v. 11: 787-806, 2009. 
Dai, Y.; Chen, S. R.; Chai, L.; Zhao, J.; Wang, Y.; Wang, Y. Overview of 
pharmacological activities of Andrographis paniculata and its major compound 
andrographolide. Critical Reviews in Food Science and Nutrition. v. 59(suppl 1): 
S17-S29, 2018. 
Dal-Pont, G. C.; Jorio, M. T. S.; Resende, W. R.; Gava, F. F.; Aguiar-geraldo, J. M.; 
Possamai-della, T.; Peper-nascimento, J.; Quevedo, J.; Valvassori, S. S. Effects of 
lithium and valproate on behavioral parameters and neurotrophic factor levels in an 
animal model of mania induced by paradoxical sleep deprivation. Journal of 
Psychiatric Research. v. 119: 76-83, 2019. 
163 
 
   
 
Dean, O. M.; Van Den Buuse, M.; Bush, A. I.; Copolov, D. L.; Ng, F.; Dodd, S.; Berk, 
M. A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? 
Animal models and relevance to clinical practice. Current Medicinal Chemistry. 16; 
2965-2976, 2009. 
Dringen, R. Metabolism and functions of glutathione in brain. Progress in 
Neurobiology. 62; 649-671, 2000. 
Eger, G. A.; Ferreira, V. V.; Batista, C. R.; Bonde, H.; De Lima, D. D.; Wyse, A. T. S.; 
Da Cruz, J. N.; Rodrigues, A. F.; Dal Magro, D. D.; Da Cruz, J. G. P. Antioxidant effect 
of simvastatin through oxidative imbalance caused by lisdexamfetamine dimesylate. 
Annals of the Brazilian Academy of Sciences. v. 88(1); 335 – 348, 2016. 
Einat, H. Modelling facets of mania – new directions related to the notion of 
endophenotypes. Journal of Psychopharmacology. 20 (5); 714 – 22, 2006. 
Enman, N. M.; Unterwald, E. M. Inhibition of GSK3 attenuates amphetamine-induced 
hyperactivity and sensitization in the mouse. Behavioural Brain Research. v. 231(1); 
p. 217-225, 2012. 
Ermer, J. C.; Pennick, M.; Frick, G. Lisdexamfetamine dimesylate: prodrug delivery, 
amphetamine exposure and duration of efficacy. Clinical Drug Investigation. V. 36: 
341-356, 2016. 
Garzón-niño, J.; Rodríguez-muñoz, M.; Cortés-montero, E.; Sánchez-blázquez, P. 
Increased PKC activity and altered GSK3b/NMDAR function drive behavior cycling in 
HINT1-deficient: bipolarity or opposing forces. Scientific Reports. v.7: 43468, 2017. 
Gawryluk, J. W.; Wang, J. F.; Andreazza, A. C.; Shao, L.; Young, L. T. Decreased 
levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from 
patients with psychiatric disorders. International Journal of 
Neuropsychopharmacology. 14; 123-130, 2011. 
Gessa, G. L.; Pani, L.; Fadda, P.; Fratta, W. Sleep deprivation in the rat: an animal 
model of mania. European Neuropsychopharmacology. v. 5 Suppl: 89-93, 1995. 
Greenberg, M. E.; Li, X. M.; Gugiu, B. G.; Gu, X.; Qin, J.; Salomon, R. G.; Hazen, S. 
L. The lipid Whisker model of the structure of oxidized cell membranes. Journal of 
Biological Chemistry. 283; 2385-2396, 2008. 
Jacobs, D.; Silverstone, T. Dextroamphetamine-induced arousal in human subjects as 
a model of mania. Psychological Medicine. v. 16(2); p. 323-329, 1986. 
Jope, R. S.; Yuskaitis, C. J.; Beurel, E. Glycogen synthase kinase-3 (GSK3): 
inflammation, diseases, and therapeutics. Neurochemical Research. v. 32(4-5): 
577–595, 2007. 
Kim, W.; Won, S. Y.; Yoon, B. H. CRMP2 mediates GSK3beta actions in the striatum 
on regulating neuronal structure and mania-like behavior. Journal of Affective 
Disorders. v. 245: 1079-1088, 2019. 
Li, X.; Liu, M.; Cai, Z.; Wang, G.; Li, X. Regulation of glycogen synthase kinase-3 




   
 
Li, X.; Jope, R. S. Is glycogen synthase kinase-3 a central modulator in mood 
regulation. Neuropsychopharmacology. v. 35(11): 2143–2154, 2010. 
Lima, M. M. S.; Andersen, M. L.; Reksidler, A. B.; Vital, M. A. B. F.; Tufik, S. The role 
of the substantia nigra pars compacta in regulating sleep patterns in rats. PLoS ONE. 
2(6): e513, 2007. 
Luca, A.; Calandra, C.; Luca, M. Gsk3 signaling and redox status in bipolar disorder: 
evidence from lithium efficacy. Oxidative Medicine and Cellular Longevity. v. 2016, 
1-12, 2016. 
Macêdo, D. S.; De Lucena, D. F.; Queiroz, A. I. G.; Cordeiro, R. C.; Araújo, M. M.; 
Sousa, F. C.; Vasconcelos, S. M.; Hyphantis, T. N.; Quevedo, J.; Mcintyre, R. S.; 
Carvalho, A. F. Effects of lithium on oxidative stress and behavioral alterations induced 
by lisdexamfetamine dimesylate: revelance as an animal model of mania. Progress 
in Neuro-Psychopharmacology and Biological Psychiatry. v. 43, p. 230-237, 
2013. 
Machado-Vieira, R.; Manji, H. K.; Zarate Jr., C. A. The role of lithium in the treatment 
of bipolar disorder: convergent evidence for neurotrophic effects as a unifying 
hypothesis. Bipolar Disorders. v. 11(2): 92–109, 2009. 
Machado-Vieira, R.; Andreazza, A. C.; Viale, C. I.; Zanatto, V.; Ceresér, V., Jr.; Da 
Silva Vargas, R.; Kapczinski, F.; Portela, L. V.; Souza, D. O.; Salvador, M.; Gentil, V. 
Oxidative stress parameters in unmedicated and treated bipolar subjects during initial 
manic episode: a possible role for lithium antioxidant effects. Neuroscience Letters. 
421(1); 33-36, 2007. 
Machado-Vieira, R.; Kapczinski, F.; Soares, J. C. Perspectives for the development of 
animal models of bipolar disorder. Progress in Neuro-Psychopharmacology & 
Biological Psychiatry. 28(2); 209 – 224, 2004. 
Magalhães, P. V.; Dean, O. M.; Bush, A. I.; Copolov, D. L.; Malhi, G. S.; Kohlmann, 
K.; Jeavons, S.; Schapkaitz I.; Anderson-hunt, M.; Berk, M. N-acetylcysteine for major 
depressive episodes in bipolar disorder. Revista Brasileira de Psiquiatria. 33; 374-
378, 2011. 
Mahadik, S. P.; Evans, D.; Lal, H. Oxidative stress and role of antioxidant and omega-
3 essential fatty acid supplementation in schizophrenia. Progress in 
Neuropsychopharmacology and Biological Psychiatry. 25(3); 463-493, 2001. 
Martins, M. R.; Reinke, A.; Petronilho, F. C.; Gomes, K. M.; Dal-Pizzol, F.; Quevedo, 
J. Methylphenidate treatment induces oxidative stress in young rat brain. Brain 
Research. 1078; 189 – 197, 2006. 
Maurer, I. C.; Schippel, P.; Volz, H. P. Lithium-induced enhancement of mitochondrial 
oxidative phosphorylation in human brain tissue. Bipolar Disorders. v. 11 (5): 515– 
522, 2009. 
Minassian, A.; Young, J. W.; Cope, Z. A.; Henry, B. L.; Geyer, M. A.; Perry, W. 
Amphetamine increases activity but not exploration in humans and mice. 
Psychopharmacology. 233(2); 225-233, 2016. 
165 
 
   
 
Mines, M. A.; Jope, R. S. Brain region differences in regulation of Akt and GSK3 by 
chronic stimulant administration in mice. Cellular Signalling. v. 24(7): 1398-1405, 
2012. 
Müller-Oerlinghausen, B.; Berghöfer, A.; Bauer, M. Bipolar disorder. Lancet. 359; 241-
247, 2002. 
Pereira, M.; Andreatini, R.; Schwarting, R. K. W.; Brenes, J. C. Amphetamine-induced 
appetitive 50-kHz calls in rats: a marker of affect in mania? Psychopharmacology. v. 
231: 2567 – 2577, 2014. 
Rippberger, H.; Van Gaalen, M. M.; Schwarting, R. K. W.; Wöhr, M. Environmental 
and pharmacological modulation of amphetamine-induced 50-kHz ultrasonic 
vocalizations in rats. Current Neuropharmacology. v. 13: 220 – 232, 2015. 
Saxena, A.; Scaini, G.; Bavaresco, D. V.; Leite, C.; Valvassori, S. S.; Carvalho, A. F.; 
Quevedo, J. Role of protein kinase C in bipolar disorder: a review of the current 
literature. Molecular Neuropsychiatry. v. 3(2); 108-124, 2017. 
Schäfer, M.; Goodenough, S.; Moosmann, B.; Behl, C. Inhibition of glycogen synthase 
kinase 3β is involved in the resistance to oxidative stress in neuronal HT22 cells. Brain 
Research. v. 1005(1-2): 84–89, 2004. 
Sharma, V.; Sharma, T.; Kaul, S.; Kapoor, K. K.; Dhar, M. K. Anticancer potential of 
labdane diterpenoid lactone “andrographolide” and its derivatives: a semi-synthetic 
approach. Phytochemistry Reviews. v. 16: 513 – 526, 2017. 
Thakur, A. K.; Rai, G.; Chatterjee, S. S.; Kumar, V. Beneficial effects of Andrographis 
paniculata extract and ANDRO on cognitive function in streptozotocin-induced diabetic 
rats. Pharmaceutical Biology. v. 54(9):1528-38, 2016. 
Tufik, S.; Lindsey, C. J.; Carlini, E. A. Does REM sleep deprivation induce a 
supersensitivity of dopaminergic receptors in the rat brain? Pharmacology. 16(2); 98 
– 105, 1978. 
Valvassori, S. S.; Cararo, J. H.; Peper-nascimento, J.; Ferreira, C. L.; Gava, F. F.; Dal-
pont, G. C.; Andersen, M. L.; Quevedo, J. Protein kinase C isoforms as a target for 
manic-like behaviors and oxidative stress in a dopaminergic animal model of mania. 
Progress in Neuro-psychopharmacology & Biological Psychiatry. 2020. 
Xu, D.; Hu, M. J.; Wang, Y. Q.; Cui, Y. L. Antioxidant activities of quercetin and its 
complexes for medicinal application. Molecules. v. 24(6): 1123, 2019. 
Xue, R.; Wan, Y.; Sun, X.; Zhang, X.; Gao, W.; Wu, W. Nicotinic mitigation of 
neuroinflammation and oxidative stress after chronic sleep deprivation. Frontiers in 
Immunology. 2019. 
Walle, T.; Browning, A. M.; Steed, L. L.; Reed, S. G.; Walle, U. K. Flavonoid glucosides 
are hydrolyzed and thus activated in the oral cavity in humans. Journal of Nutrition. 
v. 135(1): 48-52, 2005. 
Wendler, E.; De Souza, C. P.; Dornellas, A. P. S.; Santos, L. E.; Ferreira, S. T.; 
Galduróz, J. C. F.; Wöhr, M.; Schwarting, R. K. W.; Andreatini, R. Mania-like elevated 
mood in rats: enhanced 50-kHz ultrassonic vocalizations after sleep deprivation. 




   
 
Wendler, E.; De Souza, C. P.; Vecchia, D. D.; Kanazawa, L. K. S.; Hocayen, P. A. S.; 
Wöhr, M.; Schwarting, R. K. W.; Andreatini, R. Evaluation of 50-kHz ultrasonic 
vocalizations in animal models of mania: ketamine and lisdexamfetamine-induced 
hyperlocomotion in rats. European Psychopharmacology. v. 26(12): 1900-1908, 
2016. 
Zhang, H.; Wang, W.; Du, Q. Andrographolide attenuates bupivacaine-induced 
cytotoxicity in SH-SY5Y cells through preserving Akt/mTOR activity. Drug Design, 









Increased activity of the enzyme glycogen synthase kinase 3 beta (GSK3β) is 
shown to play a pivotal role in the pathophysiology of several psychiatric disorders, 
including bipolar disorder (BD). Lithium, the prototype mood stabilizer, is an inhibitor 
of GSK3β. In animal models of mania, GSK3β inhibitors reproduce behaviors that 
mimic the effects of lithium. The pharmacological management of BD consists of 
administration of mood stabilizers or antipsychotics associated to antidepressants and 
it often involves a myriad of adverse effects or non-responsiveness, which affect 
medication adherence and quality of life. The search for new therapeutic agents for 
BD is therefore necessary. Considering that the inhibition of GSK3β activity may 
display antimanic-like effects, we tested the effects of andrographolide (ANDRO), the 
major bioactive compound isolated from Andrographis paniculata, which is an inhibitor 
of GSK3β. Studies showed that ANDRO possesses several therapeutic properties, 
including anti-inflammatory, antioxidant, antibacterial, hepatoprotective, 
neuroprotective, among others. Both ANDRO and lithium have been shown to 
decrease GSK3β levels and increase the levels of p-Ser9-GSK3β, the phosphorylated 
and inactive form of GSK3β  
Taking into consideration that GSK3β is an enzyme involved in the 
pathophysiology of BD and that GSK3β inhibition, such as induced by lithium, 
ameliorates manic symptoms, the effects of the chronic treatment with the GSK3β 
inhibitor ANDRO were tested in different animal models of mania, such as sleep 
deprivation (SD)-, methylphenidate- and lisdexamfetamine (LDX)-induced 
hyperlocomotion, increases in 50-kHz ultrassonic vocalizations (USVs) and oxidative 
stress. We also evaluated the effects of ANDRO in the levels of GSK3β  and p-Ser9-
GSK3β in the prefrontal cortex (PFC) and striatum of mice. A summary of the results 
is given below. 
SD resulted in hyperlocomotion and treatment with lithium, 0.5 mg/kg ANDRO, 
and 2.0 mg/kg ANDRO blocked SD-induced hyperlocomotion. SD decreased the p-
Ser9-GSK3β/GSK3β ratio in the PFC. Both lithium and 2.0 mg/kg ANDRO increased 
the p-Ser9-GSK3β/GSK3β ratio in the PFC.  
Methylphenidate administration increased locomotor activity compared to the 
control group and treatment with lithium, 0.5 mg/kg ANDRO, and 2.0 mg/kg ANDRO 
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blocked methylphenidate-induced hyperlocomotion. Methylphenidate reduced the p-
Ser9-GSK3β/GSK3β ratio in the striatum. Both lithium and 2.0 mg/kg ANDRO 
increased the p-Ser9-GSK3β/GSK3β ratio in the striatum. 
LDX increased locomotor activity in rats, which was prevented by chronic 
treatment with lithium or 2.0 mg/kg ANDRO. LDX administration increased the number 
of 50-kHz USVs, which was also prevented by chronic treatment with lithium or 2.0 
mg/kg ANDRO. Lithium and 2.0 mg/kg ANDRO also prevented LDX-induced 
increases in lipid peroxidation (LPO), an oxidative stress parameter in the striatum. 
There was a positive correlation between LDX-induced hyperlocomotion and LDX-
induced increases in 50-kHz USVs and LPO. 
Both 10 and 40 mg/kg quercetin prevented SD-induced hyperlocomotion. 
Quercetin reversed the SD-induced decrease in glutathione (GSH) levels in the PFC 
and striatum. Quercetin also reversed the SD-induced increase in LPO in the PFC, 
hippocampus, and striatum. Pearson’s correlation analysis revealed a negative 
correlation between locomotor activity and GSH in the PFC in sleep-deprived mice 
and a positive correlation between locomotor activity and LPO in the PFC and striatum 
in sleep-deprived mice.  
 Chronic but not acute treatment with quercetin (10 and 40 mg/kg) blocked 
methylphenidate-induced hyperlocomotion. Chronic treatment with lithium and 
quercetin blocked the methylphenidate-induced increase in LPO levels in the striatum. 
Overall, the results show that chronic treatment with ANDRO prevented 
hyperlocomotion induced by SD and methylphenidate, while increasing the p-Ser9-
GSK3β/GSK3β ratio in the PFC and striatum of mice, respectively. ANDRO also 
prevented LDX-induced hyperlocomotion and increases in the number of 50-kHz 
USVs, while also preventing LDX-induced LPO in the striatum of rats. Quercetin also 
prevented SD and methylphenidate-induced hyperlocomotion, while also preventing 
SD-induced decreases in GSH in the PFC and striatum, and LPO in the PFC, 
hippocampus and striatum. Quercetin also blocked methylphenidate-induced 
hyperlocomotion, and methylphenidate-induced increase in LPO levels in the striatum. 
Thus, both ANDRO and quercetin appears to possess antimanic-like effects and they 









Despite the numerous pharmacological options for bipolar disorder (BD), 
treatment still shows inadequate response in acute manic or depressive episodes or 
in long-term preventive maintenance treatment (Gitlin, 2006). Established first-line 
treatments include lithium, valproate and second-generation antipsychotics in acute 
mania, and lithium and valproate for maintenance treatment, as well as 
anticonvulsants. Combining multiple agents is the most commonly used clinical 
strategy, especially with antidepressants (López-Muñoz et al., 2018; Gitlin, 2006). 
Common adverse effects that result from the use of these drugs include weight gain, 
akathisia, nausea, vomiting, somnolence, tremors, dizziness, asthenia and blood 
dyscrasias, among many others (Bai et al., 2019; López-Muñoz et al., 2018).  These 
aspects, such as low self-efficacy for medication-taking behavior, fear of dependence 
on medications, concern about medication adverse effects affect treatment adherence 
in BD (Levin et al., 2020; Levin et al., 2016; Chang et al., 2015; Devulapalli et al., 
2010). 
In this perspective, the research for new alternative drugs is relevant. We 
investigated the possible antimanic-like effects of andrographolide (ANDRO) and 
quercetin. We hypothesized that ANDRO could possess antimanic-like properties as 
it shares common mechanisms of action as the mood stabilizer lithium, for instance, 
inhibitory activity over the enzyme glycogen synthase kinase 3 beta (GSK3β) and 
antioxidant properties. We also hypothesized that the flavonoid quercetin could exert 
antimanic-like properties as it also has similar mechanisms of action as lithium, such 
as inhibitory activity over protein kinase C (PKC) and antioxidant effects. 
ANDRO is already sold and consumed worldwide as dietary supplement as 
Andrographis paniculata pills (powdered plant) or Kalmegh pills, mainly for its anti-
inflammatory and antioxidant properties (Kataky and Handique, 2010). Safety has 
been widely tested preclinically. Bothiraja et al. (2012) showed that up to 5 g/kg or 500 
mg/kg oral doses of ANDRO given daily for up to 14 days and 21 days, respectively, 
had no observable adverse effects in rats. Handa and Sharma (1990) showed that the 
LD50 of ANDRO given via intraperitoneal injection to mice is 11.46 g/kg. Prakash and 
Manavalan (2011) showed that the acute administration of 2000 mg/kg ANDRO p.o. 
in mice did not alter body or liver weight, kidney and heart. It neither altered creatinine, 
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total cholesterol or blood sugar levels, nor hematological parameters, such as platelet 
counts, hemoglobin or red/white blood cells of mice treated with ANDRO when 
compared to the control group. Al Batran et al. (2013) showed that acute oral 
administration of 500 mg/kg ANDRO did not induce toxic effects in the liver or kidney 
in rats. These studies show that ANDRO appears to be relatively safe, and for this 
reason, there is an increasing interest in its therapeutic use (Lu et al., 2019; Tan et al., 
2017). 
In addition, scientific research involving ANDRO does not rely solely upon pre-
clinical tests, but several clinical studies have already been performed and are still 
being developed. In a randomized, double-blind, placebo-controlled trial, the 
therapeutic efficacy of tablets of A. paniculata extract (170 mg of A. paniculata 
containing 85 mg of ANDRO) was evaluated in subjects with relapsing-remitting 
multiple sclerosis receiving interferon therapy significantly improved multiple sclerosis-
associated fatigue (following the Fatigue Severity Scores), in 44% compared to the 
placebo group (Bertoglio et al., 2016). A phase II randomized double-blind placebo-
controlled clinical study for the evaluation of A. paniculata oral tablets in patients with 
multiple sclerosis was completed in 2015 (NCT02280876), but the results are yet to 
be published. Thus, there are great perspectives for the research involving ANDRO 
and its therapeutic effects. 
Quercetin is also taken as a dietary supplement as quercetin pills, due to its 
antioxidant properties (Vida et al., 2019). This flavonoid is widely distributed in nature 
in plants and vegetables as quercetin glycosides, while dietary supplements usually 
contain quercetin in its free form, as aglycones (Andres et al., 2017). In dietary 
supplements, recommended daily doses of quercetin aglycones can range up to 1000 
mg (Andres et al., 2017). Studies show that no adverse effects were reported by 
volunteers after repeated daily intake of 500 mg quercetin for 4-8 weeks (Javadi et al., 
2017), 730 mg quercetin for 4 weeks (Edwards et al., 2007), or 1000 mg for 5 days to 
12 weeks (Rezvan et al., 2017), showing the safety in the administration or intake of 
quercetin. Ferry et al. (1996) showed that 945 mg/m² intravenous quercetin injection 
was still a safe dose of quercetin, demonstrating its safety, although studies suggest 
that excessive consumption of quercetin, above the recommended daily intake, can 




   
 
Clinical trials are in course to test the therapeutic effects of quercetin. A 
randomized double-blind placebo-controlled trial has shown that the combination of 
quercetin (500, 1000 or 2000 mg), vitamin C (350 mg) and niacin (10 mg) is beneficial 
for patients with chronic obstructive pulmonary disease (NCT01708278). Another 
randomized double-blind placebo-controlled clinical study to evaluate the effects of 
quercetin on sarcoidosis is taking place at Maastricht University, the Netherlands, 
where the antioxidant and inflammatory status of the participants is analyzed after 24 
h from taking 1000 mg of quercetin (NCT00402623). Another research group is 
evaluating the effects of dietary supplement with luteolin (100 mg/capsule), quercetin 
(70 mg/capsule) and rutin (30 mg/capsule) on 50 children with autism spectrum 
disorders (NCT01847521). This shows a future perspective in the employment of 
quercetin as a drug in the management of various health problems. 
BD patients have increased risk of many general-medical disorders, with 
increased morbidity, disability and diminished longevity (Baldessarini et al., 2020). BD 
patients have more adverse clinical outcomes and diminished life-expectancy, with all-
cause mortality up to 15-times above general population rates (Ösby et al., 2018; 
Staudt-Hansen et al., 2019). Thus, it is very important to continue the research for new 
antimanic drugs that can be included in the pharmacological arsenal for the 
management of BD. Actually, our studies showed that ANDRO and quercetin exert 
antimanic-like effects and are promising candidates for further development and 
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